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Abstract
Background. A berrant m éthylation of CpG islands is associated w ith down- 
regulation or silencing of th e  associated gene, and it is th e re fo re  an a lternative  
mechanism to  DNA m utation for silencing tum our suppressor genes in cancer. 
M ethods. Using 'ICEAMP', a technique th a t utilises a m ethyl-binding-domain 
column to isolate m ethylated  DNA, DNA pooled from 36 ductal invasive 
carcinom as was screened for aberran t CpG island m éthylation. This screen did 
not identify any novel CpG island m éthylation, however, previous screens of 
pooled DNA from 128 b reast carcinom as had identified m éthylation a t th e  CpG 
islands of the  genes for heparan sulphate 3-0-sulphotransferase 3B (HS3ST3B) 
and heparan sulphate 3-0-sulphotransferase 1 (HS3ST1). L iterature and database 
in terrogation identified four o ther HS3ST genes, one of which does not have a 
CpG island (HS3ST5) and another (HS3ST2) th a t published da ta  indicated was 
m ethylated  in a high proportion of b reast, pancreatic , and colonic cancers. Using 
MS-PCR a cohort of 80 b reast tum ours was analysed for m éthylation a t six 
d ifferen t CpG islands associated with HS3ST genes. HS3ST3B has two separa te  
CpG islands, one associated with exon 1 (HS3ST3BE1) and one lying 3kb upstream  
from th e  prom oter (HS3ST3B). Results. HS3ST1 and HS3ST3A showed no CpG 
island m éthylation. HS3ST2 was m ethylated  in 45/80 cases, HS3ST4 in 34/80 
cases, HS3ST3B in 30/80 cases and HS3ST3BE1 in 15/80 cases. MSPCR sequencing 
confirm ed dense m éthylation of both HS3ST2 and HS3ST4 CpG islands in 10/10 
cases. Using a cell cu lture system and RTPCR, transcrip tional silence of HS3ST2 
and HS3ST4 was found to  co rre la te  with m éthylation of th e  respective gene. 
Déméthylation of the  CpG island using 5-aza-2-deoxycytidine lead to  re ­
expression of th e  associated gene. Statistical analysis showed th e re  w ere 
significant correlations betw een  HS3ST2 m éthylation sta tu s and grade (p=0.015), 
HS3ST3B m éthylation and lymphovascular invasion (p=0.028), and num ber of loci 
m ethylated and grade (p=0.04). Conclusions. Diverse p a tte rn s of prom oter 
m éthylation involving th e  HS3ST genes are observed in breast cancer. Some 
genes in this family are  frequently  m ethylated  and dow nregulated while two of 
th e  family, HS3ST1 and HS3ST3A, a re  never m ethylated . Individual HS3ST 
enzym es show substra te  specificity for oligomeric sequences in heparan sulphate 
glycosaminoglycan chains, and 3-0-sulphation of heparan sulphate constitu tes 
<5% of th e  sulfuryl groups in a heparan sulphate m olecule, this m eans it may be 
suited to  ac t as a m odulator of cell surface biological processes. 3-0-sulphation 
is essential for antithrom bin ilia functioning, endocytosis of HSV-1, and 
po ten tia tes  bFGF signal transduction. The d a ta  p resen ted  suggest th a t 3-0- 
sulphation of heparan sulphate could play a role in human b reast cancer. Further 
work is required to  determ ine th e  biological significance of the  dissim ilarity in 
m éthylation of th e  d ifferen t family m em bers.
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Preface
This thesis has been w ritten  with two people in mind. One is the  person who 
will have tim e and the  inclination to  read the  docum ent as a whole. The o ther 
is som eone w ithout as much free  tim e who requires an overview of th e  work. 
With the  la tte r  in mind a general discussion and overview section is included at 
th e  s ta rt of the  thesis.
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1 General Discussion and Overview
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This project was in itiated in 2002. There was a considerable body of work a t 
th a t tim e to  support the  idea th a t DNA méthylation a t CpG islands was critical 
for the  silencing of unm utated tum our suppressor genes in cancer. This was of 
particular im portance as therapeutic  reversal of m éthylation, using DNA 
m ethyltransferase inhibitors such as 5-azacytidine, had been dem onstrated in 
cell culture. It had also been docum ented th a t tumours differed in their 
m éthylation patterns, and the  number of abnormally m ethylated genes in a 
tum our type was high, estim ated to  be 600 genes on average (Costello, 
Fruhwald e t  al. 2000). Although many tum our suppressor genes, identified 
through familial studies and loss of heterozygosity analysis, had been shown to 
have a role in familial forms of cancer it was not known if méthylation events 
in sporadic cancers would frequently include these familial genes. This 
relatively novel field therefore offered considerable potential.
With this in mind, there  w ere th ree  aims for this project;
1. Isolate novel CpG islands m ethylated in breast cancer, but not in normal 
breast tissue.
2. Develop a ‘high-throughput' technique to  assess the  m éthylation status of 
these CpG islands.
3. Use this technique to  m easure th e  frequency of méthylation a t the loci in a 
larger cohort of breast cancers and correlate  this information with 
clinicopathological data.
As with all projects like this there  w ere other ancillary aims. The idea th a t 
certain  genes are ‘turned off’ by méthylation a t specific points in 
carcinogenesis was appealing and it was hoped th a t the  identity of some of 
these  genes would be discovered. In order to  do this it was the  intention to 
collect pre-invasive cancer tissue and also samples containing atypical
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hyperplasias in order to  com pare the ir méthylation profiles with known invasive 
cancers.
It was possible to  tackle these  th ree  primary aims as there  was access to  a 
technique for isolating m ethylated DNA, and there  was ethical approval to 
collect a cohort of breast tumours and access a tum our database located at 
Glasgow Royal Infirmary.
The technique for isolating m ethylated DNA uses the  methyl binding domain of 
th e  Rat MeCP2 protein and had previously been used by Professor Adrian Bird 
and Dr Sally Cross in Edinburgh to  isolate unm ethylated CpG islands. Latterly Dr 
Graeme Brock developed a subtractive hybridisation step. This additional step 
isolates novel CpG islands m ethylated in breast cancer, but not in normal 
b reast tissue. A CpG island isolated in this fashion. Heparan Sulphate 3-0- 
sulphotransferase (HS3ST3B), acts as a molecular marker th a t differentiates 
betw een different grades of both ovarian and breast carcinomas (both in 
collaboration with Dr Tim Huang, then a t the  University of Missouri). The 
technique therefore appeared to  be robust and a t least one of th e  sequences 
isolated correlated with a clinicopathological marker
At the  s ta rt of this p ro ject approximately 20 CpG islands had already been 
isolated in the  collaborative studies undertaken by Dr Brock, using pooled 
samples of DNA from 155 different breast carcinomas contributed by Dr Huang. 
Pooled DNA was used as it was reasoned this would maximise th e  likelihood of 
identifying frequently m ethylated loci of potential im portance in the  genesis of 
breast cancer.
The first step in this p ro ject was to  re-establish the  methyl binding domain 
column facility. This was necessary as the MBD columns, previously 
constructed by Dr Brock, have a limited lifetim e. Several columns w ere
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constructed, using th e  sam e m ethods established by Professor Bird and Dr 
Cross, as subsequently modified by Dr Brock in his previous work.
Despite stric t adherence to  the  established protocols in making th e  columns, 
very considerable difficulty was experienced isolating CpG islands. This phase 
of laboratory work continued over a period of about eight months, during which 
tim e approximately ten  different MBD columns w ere constructed. Each column 
took not less than a week to m anufacture. The failure of each column to 
isolate m ethylated CpG islands from the  pooled breast tum our DNA lead to 
repeated  cycles of discarding th a t column and building another one. The 
presumption was th a t th e  columns w ere somehow not functioning, but in 
re trospect this seems unlikely to  have been the case. Control experim ents 
using a plasmid containing an HMLH1 insert, which could be prepared in 
m ethylated, hem i-m ethylated and unm ethylated forms did show appropriate 
binding to  the  columns.
Why, then, was it so difficult to  isolate CpG islands from the  pooled tum our 
DNA samples, which had been passed over the columns? One theoretical 
possibility is th a t th e  pooled DNA samples being worked on did not contain 
significant numbers of m ethylated CpG loci. As an absolute sta tem en t, this 
appears unlikely, given the  known high frequency of epigenetic modification of 
DNA a t many different loci in many different cancers, including breast cancers.
Another possibility, which may be more likely, is th a t although DNA m ethylated 
a t CpG islands was indeed present in th e  pooled DNA samples, it was not 
p resent in sufficiently high proportion relative to  unm ethylated DNA. However, 
given th a t Dr Brock had been successful in identifying CpG islands using the 
sam e approach in pooled breast carcinoma DNA provided by Dr Huang, this 
explanation is not compelling. Another issue th a t only becam e apparent a fte r 
the  column phase of th e  p ro ject was abandoned was the  nature of the  pooled 
DNA th a t was being screened for aberran t CpG island m éthylation. Previously
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the  pooled tum our DNA had been from 155 different sources, and the pooled 
DNA used in this p ro ject was only from 36 different sources. This issue becam e 
apparent a fte r discussing th e  nature of the  samples th a t had been kindly gifted 
by Dr Huang. Unfortunately, there  had been some miscommunication over the  
exact nature of this pooled breast cancer DNA. It may be th a t this had a 
bearing on the lack of success.
One o ther possible significant difference in the  experim ental protocol concerns 
the  use of an HPLC system in previous work by Dr Brock, as opposed to  the 
open-column (non-pressurised) system, which was adopted in th e  laboratory for 
this work. This change was adopted to  avoid the  very pro tracted  protocols 
(lasting 2-3 days) necessitated  by the  HPLC system. In addition the  lab did not 
own an HPLC system and the  experim ent would have been subject to  another 
laboratory’s assent. In order to  c rea te  a library, it could occupy 2, or more 
weeks to  com plete one experim ent. Although plasmid separation experim ents 
showed th a t the  open system did perform comparably to  the HPLC system, the  
possibility th a t some degradation of perform ance may have been associated 
with this change cannot, ultim ately, be excluded.
After isolating tum our DNA fractions in which there  ought to  have been 
enrichm ent for m ethylated DNA, including m ethylated CpG islands, and 
carrying out subtractive hybridisation with m ethylated DNA from normal breast 
tissue, th e  isolated sequences w ere cloned in E. coli and the  colonies w ere 
hybridised with COT-1 placental DNA to remove repetitive elem ents. Remaining 
sequences w ere then digested with Hpall and HhaI to  determ ine their GC 
conten t and size.
As CpG islands are in the size range 500-1200 base pairs, it was anticipated tha t 
successful isolations would be in this size range. The reality was th a t the 
inserts were almost never > 200 base pairs long, and could not, therefore, 
represen t in tact CpG islands.
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About 90% of the isolates recovered w ere elim inated by COT-1 DNA 
hybridisation, COT-1 DNA hybridises repetitive CpG rich sequences th a t are not 
CpG islands, and these clones therefore  likely to  have been repetitive 
elem ents. This finding is was som ewhat consistent with the  expected ability of 
the  MBD columns to  isolate m ethylated DNA, as these repetitive elem ents are 
known to be densely m ethylated.
A question th a t has to  be asked is w hether the  purification steps intended to 
isolate the  CpG islands w ere in fact removing them. This seems unlikely 
because the  screening process was both positively and negatively controlled for 
by the  use of known clones containing repetitive elem ents and a known CpG 
island (BRCA1). These control experim ents gave the  expected results; if they 
did not (and this only happened once), th a t result was discarded. In to ta l over 
3,500 colonies w ere screened.
With hindsight, it is possible th a t g rea ter success in the  isolation of CpG islands 
from pooled carcinoma specimens might have been obtained with the HPLC- 
based column, but a t the  sam e tim e there  was no reason to  doubt the  efficacy 
of the  open system. It is also possible th a t there  might have had more success 
by reusing some of th e  DNA samples provided by Dr Huang, but again there  was 
no reason not to  proceed with the  samples to  which there  was access, and an 
independent data  set would have had advantages.
After 8 months of relatively fruitless effort it was tim e to  decide w hat to  do 
next. Further effort could be invested in trying to  get th e  column and 
screening protocols working, or change direction.
During the  same period described above, there  was work taking place in 
conjunction with Dr Graeme Brock on screening the  subtractive hybridisation 
libraries previously cloned using th e  HPLC system and the  DNA containing 155 I
pooled breast tumours.
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In the  course of this work, one of these libraries proved to be particularly rich 
in CpG islands. Two clones from this rich library w ere identified, by 
sequencing, to  belong to  th e  same gene family, viz. the Heparan Sulphate D- 
glycosaminyl-3-O-sulphotransferase (HS3ST) family. Review of the  litera ture  
showed th a t frequent prom oter m éthylation of a third m em ber of this family, 
HS3ST2, had been described in a variety of tumours, including breast cancer.
At this point searches of th e  Human Genome database revealed th a t there  
w ere th ree  o ther m embers of th e  HS3ST family (six in to tal), all possessing CpG 
islands, with the  exception of HS3ST5. There was data  pointing towards this 
family of extracellular matrix modifiers as being possibly involved in breast 
cancer. There was also published data  showing th a t one of them , HS3ST2, was 
very frequently m ethylated, and silenced, in breast cancer.
These genes w ere also interesting in th a t the  existence of six d ifferent genes, 
all encoding enzymes th a t carry out exactly the  same chemical reaction, but 
have slightly d ifferent substrate  specificities, suggests th a t there  is a 
regulatory function associated with 3-0-sulphation. This idea is further 
supported by th e  fact th a t 3-0-sulphation of heparan sulphates amounts to  <5% 
of all sulphation modifications of heparan sulphates. Additionally, it is known 
th a t 3-0-sulphation of heparan sulphate is required for dimérisation of FGF1 
receptor on the  cell surface and subsequent FGF1-R m ediated signal 
transduction, suggesting a possible mechanistic link with human breast cancer. 
HS3ST1 activity is required for th e  activation of antithrom bin Ilia and may 
therefore  have an indirect role in tum our coagulation, m etastasis and 
angiogenesis. Drosophila m elanogaster Hs3st-B is a com ponent of th e  Notch 
pathway. Reduction of Hs3st-B function by RNA interference has been shown to 
compromise Notch signalling, producing neurogenic phenotypes (Kamimura, 
Rhodes e t al. 2004). It is also known th a t levels of Notch protein on the  cell 
surface in this situation are markedly decreased suggesting Hs3st-B is involved 
in Notch signalling by affecting stability or intracellular trafficking of Notch
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protein. In light of this information it was surmised th a t 3-0-suLphation of 
heparan sulphates may be of im portance in breast cancer.
It was therefo re  decided to  refocus by adopting the HS3ST gene family as the 
prime ta rge t of investigation, with th e  hypothesis th a t this was a group of 
putative Tumour Suppressor Genes, suggested by the  high frequency of HS3ST2 
méthylation described in breast cancer. The aim was to look a t them  as a group 
and try to  determ ine possible interactions betw een them.
All five of the  HS3ST genes, HS3ST1, HS3ST2, HS3ST3A, HS3ST3B and HS3ST4, 
with CpG islands w ere examined in a series of 80 breast cancers for which 
there  was fresh, unfixed, frozen DNA available. This was an essentially 
unselected, representative, series of breast cancers. The technique of 
methylation-specific PCR (MSPCR) was used in all cases.
Successful MSPCR analysis was achieved a t all loci for all cases. All analyses 
w ere conducted in trip licate. In all but five of th e  experim ents carried out the 
3 analyses w ere com pletely concordant. In th e  5 cases w here there  w ere 
discordant analyses experim ents w ere repeated  until a clear analysis was 
achieved.
It was found th a t there  was indeed a high frequency of CpG island méthylation 
a t the  HS3ST2 locus (45/80) and also a t the  HS3ST4 (34/80) locus in breast 
cancer, but m éthylation was never found a t e ither locus in normal breast 
epithelial tissue. HS3ST1 and HS3ST3A w ere, in contrast, never m ethylated in 
breast cancer. This is of in te rest as HS3ST1 activity is an absolute requirem ent 
for antithrom bin Ilia activity.
HS3ST3B has two separate  CpG islands, one (HS3ST3B) upstream  of the 
prom oter region and one (HS3ST3B-E1) spanning the s ta rt of transcription and 
exon 1. The upstream  prom oter CpG island (HS3ST3B) was m ethylated in 30/80 
carcinomas and the o ther (HS3ST3B-E1) in 15/80 carcinomas.
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These data pointed to  th e  possibility of HS3ST gene silencing as a significant 
event in breast cancer. It is believed th a t gene silencing by prom oter region 
m éthylation is associated with dense m éthylation of CpG dinucleotides in the 
relevant CpG island. MSPCR alone did not allow this to  be inferred, as the 
m éthylation specific primers only recognise a small number of CpG 
dinucleotides.
The next step  therefore  was to  undertake sequencing following MSPCR in a 
representative subsets of cases. W here this was carried out, the intervening 
CpGs w ere shown to  be com pletely (i.e. densely) m ethylated, as expected in 
th e  case of a gene silenced by m éthylation. A to ta l of 20 cases w ere MSPCR 
sequenced for HS3ST2 and HS3ST4 (10 cases for each CpG island), all with the 
sam e result.
Although this was strong evidence for gene silencing, the  relationship betw een 
prom oter m éthylation and transcription for HS3ST2 and HS3ST4 was examined 
and using cell culture it was sought to  determ ine if reversal of méthylation in- 
v itro  could lead to  re-expression of these  genes. The possibility of therapeutic  
reversal of abnormal m éthylation was one of the  initial a ttractions of this area. 
These experim ents w ere carried out in cell culture using the  breast carcinoma 
cell line MCF7 and the  ovarian cell line A2780 grown in th e  presence of 2- 
deoxy-5-azacytidine. These cell lines w ere chosen from a Larger panel th a t was 
screened for the presence of HS3ST gene m éthylation.
It was shown th a t there  is expression of the  associated mRNA in those cell lines 
in which th e re  is no HS3ST2 or HS3ST4 gene méthylation, and th a t there  is gene 
silencing in cell lines in which th e re  is m éthylation of th e  respective HS3ST 
gene. Déméthylation of a CpG island using 2-deoxy 5 azacytidine was 
associated with expression of th e  respective gene
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It was also decided to  look a t associations betw een HS3ST gene méthylation 
status and conventional pathological features of tumours examined. This was 
carried in light of published data  suggesting an association betw een HS3ST2 
m éthylation status and tum our grade and it was hoped th a t it might lead to 
clues regarding the  pathology of tumours.
Statistical analysis was carried out on the  MSPCR data: There is a positive 
correlation betw een méthylation a t the  HS3ST3BE1 CpG island and méthylation 
a t HS3ST2 (p=0.009), HS3ST3B (p=0.04) and HS3ST4 (p=0.009). There is a 
correlation betw een HS3ST2 m éthylation and grade (p=0.015) and strangely 
th e re  is a very strong correlation betw een lack of HS3ST2 méthylation and 
nodal status unknown (p=0.009) and NPI status unknown (p=0.002). HS3ST3B 
m éthylation is correlated with lymphovascular invasion (p=0.028). HS3ST3BE1 
méthylation is correlated with age {p=0.04), NPI (p=0.047) and size (p=0.04). 
The number of loci m ethylated correlates with grade (p=0,04). The correlations 
th a t show a trend are as follows: th e re  is a trend for number of loci m ethylated 
to  be correlated with ER/PR negativity (p=0.054), NPI (p=0.06) and 
lymphovascular invasion (p=0.096).
The data  presented in this thesis suggest a role for the  HS3ST family genes in 
b reast carcinogenesis.
However, these data do not, as yet, give any mechanistic insights into w hat the 
actual role of the  HS3ST gene family might be in breast cancer, although what 
is known of their biochemical activities does allow for some speculation on 
possible roles, in particular, th e  ability of these gene products to  modify the 
extracellular m atrix in th e  vicinity of tum our cells could allow them  a role in 
th e  em ergence of invasive behaviour via interactions with the  extracellular 
matrix. Another possibility is the  potential for modification of cell signalling, 
e ither potentiating the  e ffec t of growth-stimulating signals or possibly by down 
regulating the e ffect of inhibitory or even cell-death signalling from the
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extracellular matrix. Other possibilities include interactions with angiogenesis; 
th e  known interaction with antithrom bin 111 may be relevant in this context.
It would be most helpful for further research if th e re  w ere reagents to  examine 
the  expression of these gene products, e ither by in situ hybridisation or in the 
form of monoclonal antibodies which could be exploited through 
immunohistochemistry. This would allow th e  expression to  be looked a t on a 
larger scale, e.g. in tissue arrays, allowing a much more robust statistical 
analysis of their relevance in respect of classical pathological param eters. It 
would also be im portant to  determ ine to  w hat ex ten t these  genes are 
expressed by th e  epithelial, or stromal elem ents of th e  tumour; and in 
addition, w hether and w here they are expressed. Unfortunately there  is no 
data indicating these antibodies have been raised and th e  high degree of 
homology betw een th e  enzymes may make this a very difficult task.
Clearly, it would be helpful if more data was available about substrate 
specificity and areas of overlap and redundancy betw een family members. This 
knowledge could enable a prediction of the  ability of a com plem ent of HS3ST 
enzymes to  synthesise specific binding sites for growth factors or sites 
necessary for growth factor - recep tor interactions. The context of this ability 
to  produce binding sites is also im portant - a binding site on an ECM GAG may 
sequester a growth factor in the ECM and prevent it from interacting with the 
receptor on the  cell surface and the  same binding site on th e  correct cell 
surface proteoglycan may lead to  growth factor receptor interaction and 
potentiation of growth factor signalling. HS3ST enzymes are the  last 
modification to act on heparan sulphates. They are constructed and modified in 
th e  endoplasmic reticulum and they are therefore dependent on the previous 
modifications to  generate  a substrate  for them . It would therefore be 
necessary to  know th e  cell’s com plem ent of all the  enzymes th a t modify 
heparan sulphate in order to build such a model.
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The finding th a t méthylation and down regulation of specific members of the  
HS3ST family takes place in breast cancer highlights the  im portance of the 
extracellular matrix in the  carcinogenic process. Heparan sulphates and their 
modification have specific biological roles th a t are being modified by the  cell 
through méthylation and silencing of genes. The precise nature and the  
subtleties of the  system are  as yet not understood, however the  advent of 
more powerful polysaccharide sequencing technology may offer the  next 
advancem ent in this area.
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2 Introduction
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Breast cancer is the  most common fem ale malignancy and, a fte r lung cancer, 
the  second most common cause of fem ale deaths due to  a malignancy 
(McPherson, Steel e t al. 2000). Based on current lifetim e incidence of the 
disease, one in nine fem ales in th e  United Kingdom will eventually develop 
breast cancer. Each year over 40,000 women in the  UK are diagnosed with 
breast cancer, and one-third of them will die of it (CRUK 2005).
2.1 The Normal Breast
2.1.1 Breast Development
The mammary glands are often regarded as modified sweat glands; they appear 
in a rudim entary form around the  fifth week of life when the  mammary line 
thickens in the  thoracic portion of the  embryo to  form the  mammary 
ridge(Rosai 2004). Subsequently this ridge invaginates, buds and then grows 
down into the  mesodermal tissue beneath (Rosai 2004). A small pit is left 
behind a t the  site  of this event; ju s t prior to birth this rises and forms the 
nipple. Each bud from th e  ridge develops into one lobe of the  future breast, 
dividing to  form arborising ducts and ultim ately individual lobules (Ross 1984). 
At eight months gestation the stem  of these buds canalises, under the  influence 
of oestrogen, forming th e  lactiferous ducts and th e  surrounding mesoderm 
develops into the  interlobar connective septa. Adipocytes infiltrate  the  breast 
around month five (Rosen 2004). The structure  of the  breast from this point on 
is not greatly altered  until m enarche when oestrogen and progesterone induce 
duct elongation, further branching morphogenesis, and ultim ately proliferation 
of the  term inal ducts to  form the glandular lobules(Vogel, Georgiade e t al. 
1981).
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2.1.2 The Adult Breast
The adult breast, although it varies in size, has certain constant features. It 
lies vertically from the  second to  th e  sixth ribs and extends transversely from 
the  border of th e  sternum  to the  mid axillary line (J.S .P .Lum ley). The muscles 
underlying the breast, pectoralis m ajor, serratus anterior and the  external 
oblique, are covered by the  superficial fascia which forms the  deep border of 
th e  breast (S.Chummy 2006). The breast extends into th e  axilla and the 
axillary tail may extend as far laterally as the  posterior axillary line 
(S.Chummy 2006). The nipple is found in the  cen tre  of the  breast and its 
position in relation to  th e  underlying structures varies with the  volume of 
breast tissue present(J.S .P .L um ley). The areola, a circular pigmented area 
surrounding the  nipple, harbours th e  prom inent sebaceous glands of 
Montgomery and a network of smooth muscle fibres beneath  th a t contract 
during suckling (Ross 1984; Rosen 2004).
Each ‘tr e e ’ of breast epithelium  is surrounded by a basem ent m em brane (Yoon, 
Herman e t  al. 2002). The nipple and the  mouth of the  ducts are lined by 
stratified  squamous epithelium , this changes abruptly to  a double layer of 
cuboidal epithelium /m yoepithelium  in the  distal duct(Rosai 2004). 
Peripherally, the  outer myoepithelial cells Lose their cuboidal morphology, 
becoming fla ttened  and elongated, but continue as an outer layer into the 
term inal duct lobular units(Rosen 2004).
2.1.3 Breast Changes of the Menstrual Cycle
There is a m enstrual cycle of the  b reast, as well as th e  endom etrium . It is a 
cycle dependent on the  hypothalam ic-pituitary axis: the hypothalamus releases 
gonadotrophin releasing hormone (GnRH), stimulating the  anterior pituitary to 
produce follicle stimulating hormone (FSH) and leuteinising hormone (LH).
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These hormones drive oocyte m aturation and ovulation. This part of the  cycle, 
up to  th e  point of ovulation, is term ed the  follicular phase and breast lobules 
are relatively quiescent a t this stage (Vogel, Georgiade e t al. 1981), unlike the 
endom etrium  which proliferates during this part of the  cycle (Ramakrishnan, 
Khan e t  al. 2002). During th e  luteal phase, following ovulation, FSH stim ulates 
granulosa cells of th e  Graafian follicle to  synthesise oestrogen and 
progesterone from precursors produced by ad jacen t thecal cells. The cuboidal 
lining cells of th e  term inal duct lobular unit (TDLU) respond to  oestrogen by 
undergoing mitosis, but it is not clear th a t those lining the  ducts proximal to 
th e  TDLU are affected  in the  same way(Vogel, Georgiade e t al. 1981; Longacre 
and Bartow 1986; Ramakrishnan, Khan e t  al. 2002). The num ber of acini in the 
breast are said to  increase as a result of cell proliferation (Nijhawan, 
Hemachandran e t al. 2002); cells becom e vacuolated and the  lobular stroma 
becomes oedematous(Rosai 2004). The sense of breast fullness experienced by 
some women in the  prem enstrual phase of th e  cycle may be explained by the 
increased stromal oedem a. If fertilisation of th e  oocyte does not take place 
oestrogen and progesterone levels fall, mitotic stimulation to  the  breast 
epithelium  is removed and there  is a wave of subsequent apoptosis. Stromal 
oedem a also subsides and there  is infiltration of the  intralobular stroma by 
lymphocytes (Longacre and Bartow 1986).
The to ta l number of m enstrual cycles a woman undergoes and her risk of 
developing breast cancer are directly related (MacMahon 2006). Exact reasons 
for this are  not clear however, it may be th a t proliferation and apoptosis of the  
breast epithelium  are dependent on th e  hormones of the m enstrual cycle, with 
continuing rounds of cell proliferation promoting the  developm ent of precursor 
lesions from which invasive cancer ultim ately em erges. Increased 
understanding of mammary stem  cell niches and hom eostatic control of 
differentiating epithelial cell populations in the  breast are also likely to  be 
im portant for understanding of these processes.
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2.1.4 Lactation-Associated Breast Changes
During pregnancy th e  breast is prepared for lactation by a sustained period of 
cell proliferation resulting in a substantial increase in th e  bulk of the  glandular 
tissue (Battersby and Anderson 1989). Overall gland size is increased with a 
relative reduction in the  parenchymal elem ents (Joshi, Ellis e t  al. 1986). 
Following parturition th e  lactating s ta te  is established: this is the  fully 
d ifferentiated  s ta te  of th e  human mammary gland. Subsequent suckling 
removes milk and an oxytocin-dependent feedback loop maintains the  lactating 
state(Joshi, Ellis e t al. 1986). Once suckling ceases a wave of involution 
follows, resulting in loss and remodelling of th e  glandular tissue with a return 
ultim ately towards the 'resting' state{Joshi, Ellis e t al. 1986).
2.1.5 The Postmenopausal Breast
Following the  m enopause, monthly cycles of stimulation and apoptosis 
associated with the  m enstrual cycle are a bsent and the  b reast undergoes 
gradual involution (TA 1989; Rosen 2004). The volume fraction of the  breast 
composed of glandular elem ents decreases and there  is a concom itant increase 
in connective tissue elem ents, mainly fa t, in th e  postmenopausal breast (TA 
1989) In old age th e  lobular elem ents of the  breast almost disappear entirely 
,however, hormone replacem ent therapy retards this process(TA 1989).
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2.2 Breast Cancer
2.2.1 The History of Breast Cancer
The earliest known recording of breast disease comes from a 5000-year-old 
papyrus, bought in Luxor in 1820 by Edwin Smyth, which describes eight cases 
of tum ours and ulcers of the  breast (Weisman 1956). There are sporadic 
references in historical documents from then on, mainly descriptions of the 
disease{Rosen 2004). Hippocrates mentions breast cancer briefly in 400 BC, to 
note th a t he does not advocate any trea tm en t or medication. However, a t this 
tim e trea tm en ts w ere taking place: Herodotus states th a t a Persian physician 
living in G reece trea ted  and cured King Darius’ wife in 425 BC, but th e  exact 
surgery or medication is not revealed. Roman physicians perform ed extensive 
surgery, and the practice of surgery for breast cancer has continued from 
Roman tim es until present day, interspersed with periods w here physicians 
used chemical or physical cautery for fungating lesions (Donegan).
Efforts to  understand the  pathogenesis of breast cancer w ere made as tim e and 
knowledge progressed. Henri LeDran’s (1685-1770) postulate in 1757 th a t 
breast cancer originated in the  gland itself then spread through lymphatics to 
the  blood was a m ajor advance (HF.LeDran 1757; Cotlar, Dubose e t al. 2003). 
The idea is self evident in modern tim es, but prior to LeDran, René Descartes 
(1596-1650) had proposed ‘im pacted Lymph’ as the  cause of breast cancer. It 
serves as a rem inder th a t scientific facts are hard won and often run against 
th e  tide  of popular thinking. Just a fte r this Bernard Peyrilhe (1735-1804) w ent 
further and dem onstrated th e  m etastatic  potential of breast cancer 
experim entally, aspirating m aterial from a dog's mammary tum our and 
injecting it intraperitoneally (Co tlar, Dubose e t al. 2003). On opening the 
abdominal cavity a few weeks later, numerous m etastatic  deposits were 
observed over th e  peritoneum .
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Surgeons and patients a fte r 1846 benefited  greatly as general anaesthesia 
becam e available and experiences like th a t described by th e  author Fanny 
Burney (1752-1840), who underw ent a m astectom y in 1811, undertaken by the  
Napoleon's surgeon, th e  celebrated  Baron Larrey (1766-1842), and survived to 
w rite about it, w ere a thing of the  past. If there  is any doubt about the 
suffering involved in such an operation Burney depicts the  procedure 
graphically,
“ ..When th e  wound was m ade, and the  instrum ent was withdrawn, the  pain 
seem ed undiminished, for th e  air th a t suddenly rushed into those delicate parts 
fe lt like a mass of m inute but sharp and forked poinards, th a t w ere tearing the  
edges of the  wound but when again I fe lt th e  instrum ent - describing a curve - 
cutting against the  grain, if I may so say, while the  flesh resisted in a m anner 
so forcible as to  oppose and tire  th e  hand of the  operator, who was forced to 
change from the  right to  the  left - then indeed I thought I must have expired. I 
a ttem pted  no more to  open my eyes which remained herm etically shu t...."
Antisepsis (1867) and subsequently asepsis (1871 onwards) becam e accepted 
practice, further reducing m ortality and morbidity (Cotlar, Dubose e t al. 2003). 
As anaesthesia improved surgical trea tm en t of breast cancer becam e more 
aggressive, influenced by centrifugal theories of breast cancer spread. In 1867 
Charles Moore a t the  Middlesex Hospital, and la te r William Halsted (1852-1922) 
a t Johns Hopkins, described and championed radical m astectom y, advocating 
en bloc  removal of pectoralis m ajor and the  axillary nodes along with the 
breast. In the  middle of the  tw entie th  century, as operations becam e even 
more radical, surgeons audited more thoroughly the effectiveness of a 
procedure; ultim ately this saw th e  demise of such operations as the super­
radical m astectom y, as a m ortality ra te  of 12.5% and no increase in long-term 
survival sealed its fa te  (Robinson 1986).
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Assessment of surgical effectiveness, combined with the  understanding th a t 
breast cancer kills through m etastasis, not local recurrence, has Lead to  today 's 
more conservative approach. Surgery is tailored to ensure high-quality local 
control with very low local recurrence rates, achieved by e ith e r wide local 
excision and radiotherapy or simple mastectomy.
Surgical extirpation of a b reast tum our remains the single most im portant 
e lem ent in breast cancer trea tm en t (Levitt 1985), Radiotherapy is an im portant 
supplem entary trea tm en t; the  effectiveness of wide local excision combined 
with radiotherapy was shown as Long ago as the  1920s by the  pioneering studies 
of Geoffrey Keynes (1887-1982), but its acceptance into routine practice took 
many years(Veronesi, Luini e t al. 1993). Endocrine trea tm en ts (oophorectomy 
was first carried out by Beatson in 1896) and systemic chem otherapy reduce 
but do not entirely elim inate th e  risk of systemic relapse(Baum 1998; Rodger
2001).
Despite a large screening programme, access to  rapid diagnosis and surgery, 
adjuvant trea tm en ts, and increased understanding of its biology, breast cancer 
continues to  kill nearly 13,000 women every year in the  UK (CRUK 2005). In the 
last 10-15 years there  has, however, been a significant reduction in m ortality 
from breast cancer(CRUK 2005), probably due to system atic application of 
available trea tm en ts, i.e . optimal primary surgery and radiotherapy, and 
appropriate  use of chem otherapy and endocrine manipulations which reduce 
th e  risk of m etastatic  relapse. The im pact of screening for breast cancer 
remains a contentious issue (Elmore, Armstrong e t al. 2005; Gilbert 2005; 
Fryback, Stout e t al. 2006; Maraqa and Lansdown 2006). It is largely accepted 
th a t postmenopausal women benefit, but assessm ent of th e  benefits to  pre- 
and peri-menopausal women is difficult, and research is beset with 
confounding factors.
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The realisation th a t the  old fashioned, mutilating radical m astectom y is 
unnecessary is real progress. Sentinel node biopsy now offers b e tte r 
m anagem ent of th e  axilla, adjuvant therapy and trea tm en t of systemic disease 
prolong survival: these are m ajor advances. Five year survival for breast 
cancer in Scotland is now 77%, com pared to  18% for gastric cancer in women, 
colon and rectal carcinomas (48% and 50% respectively in fem ales), prostate 
cancer (60%) and bladder cancer (60% in fem ales). Also, when breast cancer 5 
year survival is examined over tim e, there  has been considerable improvement. 
For 1997-2001 five-year survival is 77%; for 1977-1981 it was 59.6% (NHSScotland 
2003).
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2.2.2 Clinical Presentation, Treatment and Prognosis of Breast 
Cancer
Breast cancer is subject to  a screening program in most developed countries 
and as a result many breast cancers diagnosed are asymptomatic, picked up by 
mammography and confirmed by FNA or biopsy (Elmore, Armstrong e t  al. 
2005). However, many cases also present with symptoms ranging from the  skin 
changes of Paget’s disease of the  nipple, abnormal secretions, a simple lump, 
to  neglected tumours th a t fungate and ulcerate  (Rosai 2004). The presentation 
of the  disease is therefore  varied and depends as much on psychosocial factors 
and cultural awareness: b reast cancer in Egypt often presents a t an advanced 
stage because many patients th e re  have little  awareness of b reast cancer(El- 
Monem 2003).
T reatm ent of breast cancer remains primarily surgical. The type of surgery 
depends on the  site and size of the  tumour, breast size and the  wishes of the 
patien t. Axillary clearance or sampling is required if there  is invasion in order 
to  stage disease. Due to  th e  morbidity associated with axillary surgery, 
particularly clearance, th e re  is a lot of research underway to  determ ine the 
need for com plete axillary clearance, the  value of intraoperative frozen 
sections on sentinel lymph nodes, and how the  lymph nodes should be 
processed. Sentinel node biopsy(Veronesi, Paganelli e t  al. 2003) has been 
shown to have a high specificity (100%) and sensitivity (>91%) for detecting 
axillary m etastasis, and may prove to be the  way forward(Fleissig, Fallowfield 
e t  al. 2005).
Adjuvant therapies for b reast cancer include hormone receptor antagonists like 
Tamoxifen and th e  newer arom atase inhibitors, radiotherapy, chem otherapy 
and more recently anti-Her2 agonists (Cole, Gelber e t al. 2001). These 
trea tm en ts  are used subject to  the  hormone receptor status, grade and stage
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of tumours. H erceptin/Trastuzum ab is a monoclonal antibody specific for the 
Her2 protein, approved as a trea tm en t for m etastatic  carcinoma in women with 
Her2 amplification (Lichtenstein, Berenson e t al. 1990). It is often used as a 
third like trea tm en t a fte r others have failed. Recent results of Herceptin in the  
adjuvant setting, following standard chem otherapy regimes in patients with 
non-m etastatic disease, show increased disease-free survival a fte r one year of 
trea tm en t (Piccart-Gebhart, Procter e t al. 2005). Over th e  relatively short 
period of follow up th e re  was, however, no significant difference in overall 
survival betw een those trea ted  with Herceptin and those in the  control group.
Nodal status remains the  single most im portant factor in breast cancer 
prognosis: it is predictive of outcom e and recurrence of the  disease. However, 
there  are patients with no detec tab le  lymph node involvement, who should be 
a t relatively low risk of recurrence and yet 20-33% of these  women will develop 
recurrent disease a fte r ten  year follow up (Camphausen, Jones e t al. 1986; 
Cole, Gelber e t al. 2001). Therefore, pathological predictors of outcom e in 
breast cancer remain im perfect.
In breast cancer, prognostic molecular profiles and predictive molecular 
signatures remain secondary to  pathological observations a t present. However, 
there  are subgroups of patien ts, such as those with node negative tumours, in 
whom molecular profiling may be helpful in predicting clinical behaviour (v an 't 
Veer, Dai e t al. 2002). The v an 't Veer study in 2002 used DNA microarrays in 
th e  analysis of 117 primary breast tumours, and applied supervised 
classification to  identify a gene expression signature strongly predictive of a 
short interval to  distant m étastasés, in lymph node negative tumours, in 
addition, they established a signature th a t identified tumours occurring in 
BRCA1 carriers. The poor prognosis signature includes genes regulating the  cell 
cycle, invasion, m etastasis and angiogenesis. However, this study has come 
under some criticism lately for including patients in the  study set th a t w ere
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also used to  build th e  algorithm (v a n 't  Veer, Dai e t  al. 2002). The ultim ate 
place therefore of these technologies remains undeterm ined.
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2.2.3 Familial Breast Cancer
Familial cases account for around 5-10% of breast cancer, a t most. BRCA1 and 
BRCA2 gene mutations are found in around 20-40% of these cases (Bishop 1999). 
Therefore, BRCA1 and BRCA2 germ line m utations are the  cause of less than 5% 
of all breast cancer. O ther familial syndromes th a t can m anifest as breast 
cancer include Li-Fraumeni syndrome, linked to  p53 mutations(Sidransky, 
Tokino e t al. 1992); Ataxia telangectasia, associated with m utations in the  ATM 
gene (Radford and Zehnbauer 1996) and Cowden's syndrome, in which 80% of 
cases have a m utation in th e  PTEN gene (Lynch, Ostermeyer e t  al. 1997). These 
together make up less than 5% of all familial b reast cancer (Blamey, Wilson e t 
al, 2000). From these  figures two facts can be deduced 1): a large proportion 
of familial breast cancers are caused by unidentified m utations, probably 
disparate  in character or of low penatrance (or else they would have been 
de tec ted  in th e  linkage studies th a t d e tec ted  the BRCA1 and 2 mutations); and 
2) most breast cancers are sporadic, and their aetiology must be explained in 
term s of the risk factors cited below.
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2.2.4 Sporadic Breast Cancer
2.2.4.1 Epidemiology and Risk Factors in Breast Cancer
Epidemiological data, combined with data  from animal and in v itro  models of 
breast cancer, highlight th ree  areas of im portance in the  pathogenesis of 
breast cancer: genetic factors, hormonal influences (such as increased levels or 
im balance of endogenous oestrogens) and possible environm ental influences. 
Many of the  risk factors for breast cancer (e.g. nulliparity) suggest th a t an 
increased num ber of m enstrual cycles confer a higher risk, but there  are 
others, especially geographical variation, th a t require further explanation.
2.2.4.1.1 Age
The average age a t diagnosis with breast cancer is sixty-five (MacMahon 2006). 
Breast cancer does not occur before th e  m enarche and is rare under the  age of 
tw enty-five (Armstrong, Eisen e t al. 2000). Incidence of breast cancer increases 
year on year (Armstrong, Eisen e t  al. 2000), but the ra te  a t which it increases 
slows a fte r th e  menopause and in some countries the incidence plateaus 
(MacMahon 2006). The change in the  slope of the  incidence curve a t m enarche 
and m enopause exposes th e  hormonal nature of the  condition. The incidence 
curve of colon cancer or gastric cancer when plotted against age does not have 
the  same sigmoid appearance (Garfinkel, Boring e t al. 1994; CRUK 2005).
2.2.4.1.2Sex
One in two hundred cases of b reast cancer occur in males in whom the  disease 
tends to  be diagnosed a t a la te r stage. Interestingly, the  prevalence of 
K linefelter’s syndrome in male breast cancers is 7.5%, implying a fifty-fold 
increased risk of breast cancer relative to  normal males (Hultborn, Hanson e t 
al. 1997; Weiss, Moysich e t al. 2005). Exactly why is unclear.
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2 .2 .4 .1 .3 Genetic Polvmorphisms
As with drug and chemical m etabolism , th e re  is considerable inter-individual 
variability in the  conjugation pathways for both oestrogens and catechol 
oestrogens. Polymorphismsin genes encoding relevant enzymes may define 
subpopulations of women with higher lifetim e exposure to  horm one-dependent 
growth promotion, or to  cellular damage from particular oestrogens and /o r 
oestrogen m etabolites (Kristensen and Borresen-Dale 2000; Thompson and 
Ambrosone 2000; Haimov-Kochman, Lavy e t al. 2002; Mitrunen and Hirvonen
2003) (Watts, Handel e t  al. 1992). Such variation could explain a proportion of 
the  cancer susceptibility associated with reproductive effects and hormone 
exposure. Preliminary studies investigating th e  role of polymorphic genes 
encoding enzymes involved in oestrogen biosynthesis (CYP17 (Feigelson, 
Coetzee e t al. 1997; W eston, Pan e t  al. 1998; Abrahamson, Tworoger e t  al. 
2006; Hu, Xie e t  al. 2006; Silva, Cabral e t al. 2006), CYP19 (Kristensen, 
Andersen e t  al. 1998; Olson, Ingle e t  al. 2006; Ribeiro, de Amorim e t  al. 2006), 
and 17-beta-HSD (Mannermaa, Peltoketo e t al. 1994)) and conversion of 
oestrogen m etabolites and the ir by-products (COMT (Bergman-Jungestrom and 
Wingren 2001), CYP1A1 (Huang, Chern e t al. 1999; Hu, Xie e t  al. 2006), CYP1B1 
(W atanabe, Shimada e t  al, 2000), GSTM1, GSTM3(Cheng, Chen e t al. 2005), 
GSTP1 (Lavigne, Helzlsouer e t  al. 1997), GSTT1 and MnSOD (Cheng, Chen e t  al. 
2005)) in modulating individual susceptibility to breast cancer have been 
carried out. Although some of these  low -penetrance genes are  good candidates 
for conferring an increased risk of breast cancer, b e tte r  designed and 
considerably larger studies than most studies conducted so far will be needed 
before firm conclusions can be drawn (Mitrunen and Hirvonen 2003).
2 .2 .4 .1 .4  Geography
There are m ajor differences in breast cancer incidence betw een geographically 
distinct populations; In North America the  incidence is 86.3 per 100,000; in 
China the  incidence is only 11.8 per 100,000 (McPherson, Steel e t al. 2000). 
Environmental factors must also be im portant in breast cancer, as genetically
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homogeneous populations living in different parts of the  globe have such 
different rates. However, th e re  is little  definitive evidence as to  w hat exactly 
these  environm ental factors are. Among immigrants from China to  North 
America th e  incidence rises to  m atch th a t of the  host country a fte r two 
generations. This appears to  be strong evidence for an environm ental effect, 
possibly due to  assimilation of th e  host country’s practices with regard to  risk 
factors for breast cancer, including diet. The reverse population migration 
analysis has not been carried out, and may not even be possible. The search for 
single m ajor environm ental agents th a t causes human breast cancer has been 
unsuccessful, and perhaps strangely, smoking is not an im portant risk factor 
(McPherson, Steel e t  at. 2000). Factors including nutrition and body size are 
im portant in w hat is probably a m ultifactorial causation.
2 .2 .4 .1 .5 Dietary Factors and Obesity
The relationship betw een obesity and breast cancer risk is d ifferent depending 
on th e  menopausal status of th e  fem ale. Premenopausal obesity reduces the  
chance of breast cancer, and postm enopausal obesity increases th e  risk of 
breast cancer (McTiernan, Raj an e t al. 2003). This dichotomy might be resolved 
by analysing th e  effects of excess adipose tissue in these two different phases 
of reproductive life.
Peripheral synthesis of oestrogen is dependent on arom atisation of the  A ring of 
Cl 9 androgens, a reaction catalysed by arom atase cytochrome P450 (coded for 
by th e  CYP19 gene). The product of this reaction is the  phenolic A ring of C l8 
oestrogens (Lorincz and Sukumar 2006). In obese post menopausal women 
peripheral adipose tissue deposits are the main sites of oestrogen biosynthesis 
Grodin (Grodin, Siiteri e t al. 1973). In premenopausal women peripheral 
oestrogen synthesis is not the  primary source of the hormone, however it is 
still synthesised peripherally and excessive oestrogen can inhibit ovulation in 
prem enopausal obese women (Barber, McCarthy e t al. 2006).
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Anovulatory cycles prevent the  formation of the  corpus luteum and hence may 
reduce subsequent proliferation and apoptosis of the breast epithelium  (Vogel, 
Georgiade e t al. 1981; Ramakrishnan, Khan e t al. 2002). In th e  case of the 
prem enopausal obese fem ale the  net e ffec t is to  reduce the  num ber of 
m enstrual cycles to  which the  breast is exposed. Hence, pre-m enopausal obese 
fem ale risk may be reduced in comparison to  a non-obese fem ale. 
Postmenopausally, peripheral synthesis of oestrogen may expose the  breast 
epithelium  to increased levels of this mitogen compared to  non-obese fem ales. 
This is to  large ex ten t a simplification of the  e ffect of obesity as a risk factor 
for developing breast cancer and only covers the  proposed effect of increased 
peripheral oestrogen synthesis in adipose tissue. O ther hypotheses linking 
obesity to  breast cancer place more emphasis on increased circulating insulin 
and insulin like growth factor in the  obese; acting as mitogens (Lorincz and 
Sukumar 2006), and a new er proposal champions the  autocrine, paracrine and 
endocrine functions of adipocytes as major influences on b reast epithelial 
malignancies (Dizdar and Alyamac 2004).
The role of preadipocytes in tum or growth is com plicated. A proposed 
definition of preadipocytes is an im m ature adipocyte positive for S-100 protein, 
a marker th a t is not found in fibroblasts or endothelial cells. Some studies 
suggest th a t pre-adipocytes support the  growth of breast tum or cells (Chamras, 
Bagga e t  al. 1998), while o ther studies show th a t preadipocytes are either 
inhibitory (Johnston, Rondinone e t  al. 1992) or have no e ffec t (Manabe, Toda 
e t al. 2003), on breast cancer cell growth.
2 .2 .4 .1 .6  Infective Agents
Despite the  existence of murine mammary transforming virus (MMTV), which 
causes mammary gland malignancies in mice (Zhou, Chen e t  al. 2001), no 
equivalent infective factor has been found in humans (McPherson, Steel e t  al. 
2000).
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2 .2 .4 .1 .7 Parity and the  Menstrual Cycle
Age, early m enarche, la te  menopause, nulliparity and a Longer tim e betw een 
m enarche and first child are all associated with increased risk of b reast cancer 
(Hartge 2003). During th e  m enstrual cycle there  are large fluctuations in the 
levels of progestogens and oestrogens, which have an effect on gene expression 
in breast epithelial cells. All of the  risk factors cited above, with th e  exception 
of age a fte r th e  m enopause, independently increase the  number of m enstrual 
cycles th a t a fem ale undergoes. Therefore, it may be proposed th a t the  
increased exposure to  this process, or to  the  hormones th a t are involved in the 
cycle, in some way drives carcinogenic processes in breast epithelium .
A com plete molecular explanation of the  link betw een the  m enstrual cycle and 
b reast cancer is not fully established (Hulka, Liu e t al. 1994; McTiernan, Raj an 
e t al, 2003). It is known th a t breast epithelium  and stroma express oestrogen 
and progesterone receptors and several growth factors are released in response 
to  these  hormones; some are stim ulatory e.g . p la te le t derived growth factor 
and endothelium  derived growth factor, and some are inhibitory e.g. 
transforming growth factor beta(H artge 2003). There are also effects on the 
intralobular stroma in response to  hormone synthesis and withdrawal. The 
e ffec t during th e  reproductive years of these hormones, as well as increased 
epithelial cell proliferation, may c rea te  an evolutionary pressure th a t selects 
cells on the  basis of ability to  avoid apoptosis on withdrawal of fem ale sex 
hormones. Each cycle then represents a round of evolutionary selection, 
explaining th e  link betw een the number of cycles and risk of breast cancer.
2 .2 .4 .1 .8 Benign Proliferative Breast Disease
Proliferative, but benign breast diseases are markers of increased risk of 
developing breast cancer. (Rosen 1993) . Hypotheses as to  why this relationship 
exist include abnormal oestrogen and progesterone metabolism promoting 
formation of benign en tities and cancers independently. In this model, benign
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proliferations are markers of abnormal hormone metabolism rather than 
precursor lesions to cancer (Mitrunen and Hirvonen 2003).
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2.2.5 The Pathology of Breast Cancer
The breast is composed of a variety of cell types and the relative proportions of 
the  constituents change depending on the  age and hormonal status of the 
person (Ross 1984; Rosai 2004). Therefore, the  breast can be th e  site of tumours 
th a t are derived from fibroblasts, endothelial cells, smooth muscle, adipocytes 
e tc . However, by far the  most common tumours in the  breast are 
carcinomas(Ross 1984; CRUK 2005).
Although there  is marked variation in the  histological phenotype of breast 
carcinomas from case to  case it is thought th a t these tumours derive from 
epithelial cells lining th e  term inal duct lobular unit (Wellings 1980). These cells 
proliferate and undergo intracellular secretory changes in response to 
oestrogen and progesterone stim ulation, then apoptosis in response to 
withdrawal of these  hormones during the  menstrual cycle. Increasingly it is 
being recognised th a t stem  cell com partm ents can be identified within normal 
and neoplastic cell populations and markers characterising such cells are 
beginning to  be identified (Liu, Dontu e t al. 2005).
Invasive breast cancer is thought to  arise in most cases from an intraepithélial 
proliferation of cells th a t have not yet acquired the  necessary phenotype to  
invade the  surrounding connective tissue(Buerger, Simon e t al. 2000). 
Depending on the  histological appearance of th e  process it may be labelled as 
ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), or unusually 
one of the  rarer subtypes. Less marked abnorm alities may be characterised as 
atypical hyperplasias of ductal or lobular type. Retrospective pathology studies 
have shown th a t low-grade forms of DCIS left w ithout trea tm en t ultim ately 
progress to  invasive disease in 75% of cases, while 25% do not(Aubele, W erner 
e t  al. 2002). This begs the  question w hat is the  difference in these two 
identical histological en tities a t the  molecular level? So far no unique 
m olecular signatures predictive of the  invasive phenotype have been identified.
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Perhaps in some cases it is th e  host immune phenotype th a t is im portant (DCIS 
often a ttrac ts  a brisk inflammatory response).
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2.2.6 DNA Méthylation and Breast Cancer
2.2.6.1 Introduction
Epigenetic cellular a lterations establish heritable features th a t do not involve 
change to  the  DNA sequence. DNA méthylation is the  commonest epigenetic 
alteration in the mammalian genome and has a role in cancer biology (Pellise, 
Castells e t  al. 2004), viral infections (Zsiros, Jebbink e t al. 1999), activity of 
mobile elem ents in the  genome, somatic gene therapy, cloning, transgenic 
(Chai, Locke e t  al. 2001) technology, genomic imprinting, developm ental 
abnorm alities, m ental health (Strunnikova, Schagdarsurengin e t al. 2005) and X 
chromosome inactivation.
Although there  are rare reports of CpA and CpT m éthylation in th e  mammalian 
genome, DNA m éthylation usually involves covalent a ttachm ent of a methyl 
group to  the  5’ position of a cytosine nucleotide, and alm ost always in the  
context of a 5'-CpG-3' palindrome. The observed frequency (1 in 160 to  1 in 
320) of CpG dinucleotides in the  human genome is only about 5-10% of the  
expected frequency of about 1 in 16 dinucleotides (Bird 1980). Uracil formed 
by deam ination of unm ethylated cytosine can be removed by uracil 
glycosylase(Lindahl 1974; Lindahl 1997. ), but thymine generated by
deam ination of 5-methylcytosine, cannot be so removed, and th e  m utation of 
5mC to T is up to  50-fold g rea ter than o ther transitions. This susceptibility to 
m utation may have depleted  CpG dinucleotides through tim e. Remaining CpGs 
are not randomly distributed in th e  genome, and nor is the ir m éthylation. 
Clusters of m ethylated CpGs e.g . in repetitive elem ents are found interspersed 
with CpG-rich regions known as CpG islands (Bird 1986). These GC rich (60-70%) 
islands are  200 bp-2,000 bp long, are usually found in association with the 
prom oter or first exon of a gene, and their CpG conten t approaches the 
frequency predicted for the  genome as a whole (observed:expected ratio >0.5). 
CpG islands are associated with both housekeeping genes and genes with
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tissue-spedfc patterns of expression, and of the  predicted 35,000 genes in the  
human genome, approximately half have associated CpG islands.
The transfer of a methyl group to  cytosine is catalysed by a DNA 
m ethyltransferase enzyme (DNMTs). To d a te  eight DNMTs have been detected : 
DNMT1, DNMTIb, DNMTI0, DNMTIp, DNMT2, DNMT3a, DNMT3b (plus isoforms) 
and DNMT31. DNMT3a and DNMT3b have de novo méthylation activity, acting on 
sites w here both CpGs in a palindrome are unm ethylated. DNMT1, which can 
also carry out de novo m éthylation, is more efficient a t m aintenance 
méthylation during DNA replication, transferring a methyl group to  th e  non- 
m ethylated cytosine in a hem i-m ethylated CpG. Mice deficient in e ither 
DNMT1, DNMT3a or DNMT3b fail to  develop, or die imm ediately a fte r birth. 
(Bird and Wolffe 1999). DNA m éthylation patterns are established early in 
developm ent. At th e  morula stage of Xenopus embryogenesis a wave of 
dém éthylation sweeps over th e  zygote reducing global CpG m éthylation by 
approximately 30%, with subsequent rem ethylation of the  genome prior to 
im plantation (Monk, Boubelik e t al. 1987). The control of this process remains 
unclear a t present. (Bird 2002)
In biological systems most reactions can be undone and DNA méthylation is no 
exception. The enzyme 5-methylcytosine glycosylase has dem ethylating 
activity; it removes m ethylated cytosines from DNA leaving deoxyribose, and 
subsequently local DNA repair enzymes reconstitu te  th e  nucleotide by adding 
an unm ethylated cytosine in place of the  m ethylated one. An alternative 
translational form of the  methyl binding domain protein MBD2, named MBD2b 
also possesses DNA dem ethylating activity. It is thought to ac t by hydrolysing 5- 
methylcytosine to  cytosine and m ethanol. However this result has only been 
published by one group and o ther laboratories have failed to  replicate these 
results in mammalian and Xenopus based studies(Ng, Zhang e t al. 1999; Wade, 
Gegonne e t al. 1999).
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The potential im portance of DNA méthylation in cancer biology was recognised 
when CpG island m éthylation was associated with down-regulation of 
transcription, and began to  be recognised as an alternative to  DNA mutation as 
a means of satisfying the  Knudson ‘two h it’ hypothesis (Jones and Laird 1999). 
However, the  role of m éthylation is more far reaching than as a pure repressor 
of transcription.
Tumour DNA is generally globally hypom ethylated (Bernardino, Roux e t al. 
1997; Johanning, Heimburger e t  al. 2002), and altering méthylation enzymes to  
c rea te  mice with hypom ethylated DNA can e ither prom ote or repress 
tum ourogenesis. For exam ple, multiple intestinal neoplasia (MIN) mice th a t 
carry a germline m utation in th e  mouse ARC orthologue are predisposed to  the 
developm ent of in testinal tumours. MIN mice heterozygous for DNMT1 
trea ted  with 2-deoxy-5-azacytidine show few er polyps (Laird, Jackson-Grusby 
e t  al. 1995). On an MLH1-deficient background DNMT1 mice again show a 
reduction in intestinal adenom as, however the  risk of lymphoma in these mice 
is increased (Trinh, Long e t  al. 2002). Homozygote mice with a crippled form of 
DNMT1, th a t reduces DNMT1 activity to  10% of wild type, have substantial, 
genome-wide hypomethylation in all tissues and develop aggressive T-cell 
lymphomas with a high frequency of chromosome 15 trisomy (Trinh, Long e t al. 
2002). Therefore, th e  role of méthylation in carcinogenesis may be more 
com plicated than was a t first supposed.
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2.2.6.2 DNA Méthylation and Gene Regulation
Eukaryotic gene expression is a complex process involving the  integration of 
c/s-acting elem ents within th e  DNA and trans-acting m odulators in th e  form of 
transcription factors. DNA m éthylation of a s  elem ents a t the  prom oter of a 
gene is associated with downregulation of th a t gene. In contrast méthylation of 
th e  coding region of the  gene has a variable e ffect on transcription (Wajed, 
Laird e t al. 2001).
Currently there  is much debate  over how prom oter m éthylation integrates with 
downregulation of transcription. Several explanations have been offered by 
those who believe méthylation is central to  gene silencing.
Stereochem ical in terference with protein-DNA interaction is the  simplest model 
to  em erge. The transcription factors AP-2, NF-kappa B, E2F, CREB and c- 
Myc/Myn all recognise sequences th a t contain CpG residues and méthylation of 
CpGs in these elem ents inhibits binding of these  transcription factors (Tate and 
Bird 1993; Jones and Wolffe 1999).
DNA m éthylation also recruits specific repressor complexes th a t recognise and 
bind m ethylated DNA (Bader, Walker e t al. 1999; Singal, Tu e t  al. 2000). MeCP1 
and MeCP2 w ere first of these  to be characterised. Using the  common methyl 
binding domain m otif to in terrogate the  genome database th ree  others were 
found: MBD1, MBD2 and MBD4 (Hendrich, Abbott e t  al. 1999), More recently 
Kaiso, a repressor th a t binds m ethylated DNA through a zinc finger motif, has 
been characterised (Prokhortchouk, Hendrich e t al. 2001). MBD4 is unusual 
amongst this group as it is associated with DNA repair. The others repress 
transcription in cell culture by interfacing with histone deacetylase complexes 
(Fuks, Hurd e t al, 2003).
DNA m éthylation and its relationship with histone modification is complex. 
Three of the  transcriptional repressors mentioned above, MeCP2, MBD2 and
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MBD3 are found complexed with MeCP-2, MeCP-1 and Mi-2 which have histone 
deacetylase activity. Methylated reporter gene constructs with binding sites for 
these complexes have shown partial reversal of transcriptional silencing 
following trea tm en t with th e  HD AC inhibitor Trichostatin A. This suggests th a t 
DNA m éthylation and histone deacetylation are both required to  maintain 
com plete silencing of a gene.
Méthylation of histone H3 a t lysine 9 (H3K9) appears to  be a molecular m arker 
of transcriptional silencing. Acétylation and méthylation a t this site  appear to 
be mutually exclusive: acetylated  H3 is commonly reported in the  context of 
unm ethylated, transcriptionally active euchrom atin and H3K9 méthylation in 
th e  setting of densely m ethylated, transcriptionally silent 
heterochrom atin(Herm an and Baylin 2003).
The tem poral relationship betw een DNA méthylation, histone H3 
acéty la tion / méthylation and transcriptional activity has been difficult to 
unravel experim entally. However, it has recently been shown, using a 
transfected  GSTP1 gene in a prosta te  cancer cell line, tha t: (a) histone 
acétylation is independent of gene expression; (b) histone deacetylation is 
triggered by low levels of DNA méthylation; (c) spread of DNA 
hyperm ethylation across th e  CpG island is associated with MBD2 but not MeCP2 
binding; and (d), H3K9 m éthylation occurs a fte r histone deacetylation and is 
associated with extensive DNA méthylation of the  CpG island (Stirzaker, Song 
e t  al. 2004).
With regard to which is more im portant in term s of gene silencing, DNA 
m éthylation or histone deacetylation and méthylation: it appears th a t reversal 
of DNA m éthylation leads to  gene re-expression and eventual reversal of the 
histone modifications, however reversal of th e  histone modifications does not 
lead to  DNA dém éthylation (Fahrner, Eguchi e t al. 2002).
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2.2.6.3 DNA Méthylation and Cancer
In the  last decade or so DNA m éthylation in cancer has received intense study. 
In general, tum our DNA shows global hypomethylation, but aberrant 
hyperm ethylation of specific tum our suppressor CpG islands.
2.2.6.3.1 Hypermethylation in Cancer
Hypermethylation in cancer is technically easier to  d e tec t and therefore  has 
been reported to  a far g rea ter degree than hypomethylation. Hypermethylation 
of a CpG island associated with a prom oter region is generally accepted to 
imply transcriptional silencing of th a t gene. CpG island m éthylation has been 
shown to  be an early event in cancer and may be related  to  aging (Jaenisch and 
Bird 2003). Méthylation profiles in disparate cancers have been studied 
extensively and DNA m éthylation is reported in many solid and haematological 
tumours(Costello, Fruhwald e t al. 2000). Some genes are m ethylated in many 
different tum our types, e.g . p16INK4a and RASSFIA, while o ther genes are 
specifically m ethylated in particular cancers e.g . GSTP1 méthylation occurs in 
more than 90% of prosta te  tumours, but it is reported as unm ethylated in AML 
(Melki, Vincent e t al. 1999; Millar, Paul e t al. 2000).
As m éthylation profiles w ere analysed, distinct patterns em erged in many 
malignancies, with known familial tum our suppressor genes m ethylated in 
sporadic forms of these tumours: e.g. VHL in clear cell carcinoma of the  kidney 
(Herman, Latif e t  al. 1994), BRCA1 in breast cancer (Catteau, Harris e t al.
1999), HMLH1 and APC in colon cancer (Kane, Loda e t  al. 1997). In familial 
cancers it was also shown th a t the  non-m utated allele was m ethylated in a high 
proportion of cases. (Esteller, Fraga e t al. 2001). As technology progresses the  
focus of hypermethylation is changing from analysis of a few loci a t a tim e to  
m ultiple CpG island analysis using DNA microarrays. In breast tumours, CpG
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island méthylation patterns established using DNA microarrays correla te  with 
ER status (Van, Yang e t al. 2001).
The role of DNA hyperm ethylation in carcinogenesis is proven in many tum our 
types (Table 2.1 page 67) th e re  is also evidence th a t it can be involved in the 
modulation of transcription a fte r an established breast cancer cell-line has 
been created . On disruption of estrogen receptor (ER) alpha signalling by small 
interfering RNA, polycomb repressors and histone deacetylases w ere recruited 
and in itiated stable repression of th e  progesterone receptor (PR) gene, a 
known ER alpha target, in breast cancer cells. This event was accompanied by 
DNA méthylation of the  PR prom oter. Re-establishing ER alpha signalling alone 
was not sufficient to  reactivate the  PR gene; DNA dém éthylation was also 
required. Méthylation microarray analysis has further shown th a t progressive 
DNA méthylation occurs in m ultiple ER alpha targets in breast cancer genomes. 
(Leu, Van e t al. 2004). Aberrations of DNA méthylation arising a fte r a 
m alignant cell line is established suggest th a t DNA méthylation control is 
abrogated during th e  carcinogenic process and remains so. There may also be a 
stochastic quality to DNA m éthylation, if th e  a ltered  méthylation pattern  of a 
cell confers an advantage it may be selected  as in a Darwinian model of 
evolution. However, o ther studies also suggest th a t DNA méthylation does not 
take place until a fte r transcriptional silencing has occurred and expression 
from a prom oter will block DNA méthylation (Song, Stirzaker e t al. 2002). 
Therefore, DNA méthylation and the  alteration of the  histone code may in 
some cases be secondary to the effects of transcription factor binding.
Hanahan and Weinberg form ulated six novel capabilities a cell has to  acquire to 
becom e a cancer cell: limitless replicative potential, self-sufficiency in growth 
signals, insensitivity to  growth-inhibitory signals, evasion of programmed cell 
death , sustained angiogenesis and tissue invasion and m etastasis (Hanahan and 
Weinberg 2000). This review not only highlighted the  hurdles a cell has to 
overcome, but also made the  observation th a t th e re  was possibly more than
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one pathway to  gain each capability. Jones and W idschwendter examined the 
scope of DNA méthylation as a means to  overcome these barriers and w ere able 
to  identify numerous targets in disparate cell types (Widschwendter and Jones
2002).
The observations of Jones and W idschwendter, in the  context of Hanahan and 
W einberg's formulation raises the  point th a t, although there  may be several 
d ifferent ways to  overcome, e.g . cell cycle checkpoints, m éthylation of certain 
tum our suppressor genes, e.g. P16INK4A, are extrem ely common in disparate 
tumours (Lamy, Sesboue e t  al. 2002; Shao and Nguyen 2002; Esteller 2003; 
Silva, Silva e t  al. 2003; Lind, Thorstensen e t  al. 2004; Lund, Andersson e t al.
2004). Genes th a t play such a central role are more likely to  be m ethylated 
ra ther than the numerous ancillary genes required for th e  same phenotype.
Méthylation of genes involved in DNA repair leads to  increased mutation rates 
as the  repair genes are transcriptionally silenced. This was first shown for the 
HMLH1 gene, m utated in patients with type II familial non-polyposis colon 
cancer (Herman, Umar e t  al. 1998). A precursor cell in this case develops a 
mismatch repair phenotype th a t results in instability of m icrosatellite 
sequences. Méthylation of this gene is probably an early event in the 
carcinogenic process, as it has been observed in colonic epithelium  th a t is 
normal histologically but has m icrosatellite instability (Nakagawa, Chadwick e t 
al. 2001; Nakagawa, Nuovo e t al. 2001).
MGMT removes DNA adducts and this gene is m ethylated in a number of 
tumours - lung, colon, lymphoid (Esteller, Catasus e t al. 1999; Fleisher, Esteller 
e t al. 1999; Sanchez-Cespedes, Esteller e t  al. 1999; Gallardo, Esteller e t  al. 
2004; Lind, Thorstensen e t  al. 2004) and therefore  is not expressed. Lack of 
MGMT expression leads to  increased accumulation of 0-6 methylguanine 
adducts, leading in turn to increased G to A transition m utations. Tumours with
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MGMT silencing are more likely to  have TP53 and K-RAS m utations (Esteller, 
Gonzalez e t al. 2001) (Esteller, Hamilton e t al. 1999).
2 .2 .6 .3 .2 Méthylation and Increased Mutation Rates in the  genome 
CpG m éthylation increases m utation ra tes by hydrolytic deam ination of 
cytosine to  thymine (Schmutte and Jones 1998). Fifty percen t of the  m utations 
in TP53 in somatic cells occur a t m ethylated sites (Fahrner, Eguchi e t  al. 2002). 
This increased m utagenic ra te  is observed in th e  germ line of all organisms th a t 
m ethylate their DNA.
Methylated CpGs are are also more likely to  undergo UV induced deam ination - 
this is due to the  methyl group shifting the  UV absorption spectrum  for cytosine 
to  a spectrum  closer to  th a t which is prevalent in sunlight. Not only does 
m éthylation affect the cytosine directly, but it also has an indirect e ffect on 
the  ad jacen t guanidine residue, making it more susceptible to  G to  T
transversions m utations, induced by th e  tobacco carcinogen m etabolite
benzo(a)pyrene diol epoxide (Pfeifer 2000; Pfeifer, Tang e t al. 2000)
2.2.6.3.3 Hypomethylation in Cancer
Hypomethylation of the  genome is a global phenomenon and tends to be 
associated with higher grades and by inference more poorly d ifferentiated 
tumours (Ehrlich 2002; Ehrlich, Jiang e t  al. 2002). It is found in solid 
malignancies, such as breast and cervical (Kang, Kim e t al. 2001), prostate  
(Prasad, Thraves e t  al. 1999) and hepatocellular carcinomas (Yoshikawa,
Matsubara e t al. 2001), and also in haematological malignancies such as chronic 
B-cell lymphocytic leukaemia (Feinberg and Vogelstein 1983).
Hypomethylation has a role in th e  genetic disease immunodeficiency,
centrom eric instability, and facial abnorm alities (ICF). This condition is 
characterised by facial dysmorphism, m ental retardation, and recurrent 
infections. The disease is linked to m utations in the  DNMT3B gene (Hansen,
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W ijmenga e t  al, 1999) th a t leads to  chromatin instability as a result of 
abnorm alities in the  m éthylation of DNA. Hypomethylation of the 
pericentrom eric regions of chromosomes 1,9 and 16 is found in both this 
condition and in breast cancers.(Narayan, Ji e t  al. 1998). All Children born with 
this condition die before adulthood due infections th a t cannot be com bated by 
a crippled immune system. It is therefo re  not known w hether abnorm alities in 
DNMT3B lead to increased incidence of cancers.
The role of hypomethylation in carcinogenesis may be threefold. Initially there  
w ere suspicions th a t hypomethylation of CpG regions would lead to  activation 
of oncogenes, previously repressed by m éthylation. It was initially reported 
th a t H-RAS hypomethylation was found in genes of cancer cells compared with 
the ir normal counterparts (Feinberg and Vogelstein 1983). This study was 
carried out on only 5 cases and larger studies have not yielded further 
evidence, so dém éthylation as a means of directly activating oncogenes 
remains only a theoretical possibility. The reactivation of transposable 
e lem ents through dém éthylation, and their role in oncogene expression has, 
however, been established: LI m utational inserts disrupt the  ARC gene and the 
CMYC gene in colon and breast cancer, respectively (Costello, Fruhwald e t  al.
2000). Hypomethylation has also been shown to prom ote chromosomal 
instability (Eden, Gaudet e t  al. 2003) and therefore cancer.
2 .2 .6 .3 .4 Folic Acid, Gene Polymorphisms, DNA Méthylation and Cancer
There are two main branches to  the  metabolism of methyl groups in a cell. One 
is concerned with purine and thymidine synthesis and th e  o ther involves 
m ethionine and s-adenosylmethionine for protein and polyamine synthesis and 
méthylation reactions. M ethylenetetrahydrofolate reductase (MTHFR) transfers 
methyl groups from the  first of these  branches to the second. Specifically, it 
converts 5 ,10-m ethylenetetrahydrofolate to  5-m ethyl-tetrahydrofolate which 
then transfers a methyl group to homocysteine to produce methionine.
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Deficiency in this enzyme leads to  increased homocysteine in the  serum and 
urine and causes thrombo-occlusive vascular disease and m ental retardation. 
Two less severe polymorphisms also exist, MTHFR C677T and MTHFR A1298C. 
The C677T variant is associated with higher serum homocysteine levels and 
increased risk of vascular disease and neural tube defects. It is also associated 
with an increased risk of some cancers: a 677TT genotype confers 6-fold 
increased risk of developing oesophageal squamous carcinoma [adjusted odds 
ratio (OR), 6.18; 95% confidence interval (Cl), 3.32-11.51] com pared with those 
who had the  677CC genotype (Baiqiu, Songbin e t al. 2000; Hong, Song e t  al. 
2001; Song, Xing e t al. 2001 ; Song, Song e t  al. 2001). Breast cancer has also 
been investigated for an association betw een polymorphisms in MTHFR. A 
significant excess of th e  A677T polymorphisms was observed among th e  breast 
cancer cases (odds ratio 1.43, 95% confidence interval 1.02-2.00). The 
association was more pronounced in those with breast cancer diagnosis under 
th e  age of 40 years (odds ratio 1.66, 95% confidence in tervall. 12-2.41) 
(Campbell, Baxter e t  al. 2002) . The MTHFR 677TT variant genotype conferred 
a 2-fold increased risk of cancer of the  gastric cardia (odds ratio, 2.04; 95% 
confidence interval, 1.28-3.26), and a significantly elevated risk was also seen 
in MTHFR 677CT heterozygotes (odds ratio, 1.56; 95% confidence interval, 1.03- 
2.36). The MTHFR A1298C polymorphism had no e ffect on risk, which is in 
keeping with other studies (Miao, Xing e t al. 2002).
The mechanism by which a 677TT genotype confers increased risk of cancer is 
still open to  speculation. It has been suggested by some authors th a t 
inadequate thymidine pools, caused by the  altered  MTHFR enzyme, lead to 
increased incorporation of uracil into DNA. This results in increased strand 
breaks and creates precursors for chromosome translocations and deletions. 
Confusingly the  677TT genotype seems to  be associated with a decreased risk 
of leukaemia (Wiemels, Smith e t  al. 2001).
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Hypomethylation and hyperm ethylation of genes is associated with folate 
deficiency. In animals, fo late deficiency initially results in exon-specific 
hypomethylation of TP53 and increased DNA m ethyltransferase activity (Kim, 
Pogribny e t  al. 1996); as the  deficiency continues th e re  is an increase in both 
TP53 and genome wide méthylation (Pogribny, Miller e t al. 1997).
Interpretation of these results is difficult as there  are confounding factors. The 
deficiency in the  MTHFR gene would cause decreased folate, increased uracil 
incorporation and in turn lead to  DNA strand breaks. p53 would be upregulated 
in response to  this DNA damage. The méthylation changes noted in the  p53 
gene might be secondary to  expression, not a direct consequence of folate 
metabolism .
However, population studies do indicate th a t low serum folate and 
homozygosity for C677T confer an increased risk of colorectal adenomas when 
com pared to  wild type and heterozygotes, but only in individuals with low 
folate levels. Further work in this field is necessary to  provide more detailed 
understanding of the  mechanisms a t work, and the e ffec t of intervention to 
increase folate levels.
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2.2.6.4 DNA Méthylation as a Marker for Tumour Diagnosis and Prognosis
With exception of the  lymphomas and some o ther haematological malignancies, 
most molecular markers of cancer still have less prognostic significance than 
th e  histological and clinical staging of th e  disease. Méthylation aberrations of 
th e  genome occur a t an early stage in tumours and there  are tumour-specific 
forms of m éthylation. Relatively recently breast tumours have been sub­
classified by their molecular profiles, and it has been claimed th a t th e re  are 
gene expression signatures predictive of a short interval to  d istan t m étastasés 
in node-negative patients (without tum our cells in local lymph nodes a t 
diagnosis). The estim ated hazard ratio for d istant m étastasés in the  group with 
a poor-prognosis signature, in comparison to  th e  group with the  good-prognosis 
signature, was 5.1 (95 percen t confidence interval, 2.9 to  9.0; p<0.001). These 
m olecular categories cannot be d ifferentiated  by microscopy alone (v an 't Veer, 
Dai e t al. 2002; van de Vijver, He e t al. 2002).
Earlier diagnosis of b reast cancer is an im portant goal. Detection of sub-clinical 
tum ours through mammographie b reast screening may not have exhausted the 
possibilities for increased survival, and smaller yet may need to  be the  goal. 
Early detection of tumours by picking up m ethylated DNA in the  serum is a 
possibility. As tumours grow and invade they shed DNA into the circulation and 
m éthylation changes in this DNA can be d e tec ted  through MSPCR of the  serum. 
There have been no reports of DCIS DNA detection in serum and a t present 
th e re  is no clear evidence to  indicate a t w hat stage in a tum our's evolution 
tum our DNA appears in the serum. There is also the  question as to  which 
m éthylation changes should be looked a t in relation to  which tumours, and the 
issue of m éthylation changes with increased age is also an im portant 
consideration. Large population-based studies are required to  assess these 
issues and a t present the  m éthylation profiles of cancers and the  ageing 
genome have not been characterised  to  the  degree required to  move into such 
a large study. The production of CpG island DNA m éthylation chips th a t cover
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th e  en tire  genome may lead to profiling of m éthylation in the  aging genome 
and a profile of breast tum our m éthylation. As yet molecular cancer screening 
is in its infancy.
2.2.6.5 DNA Méthylation and Novel Therapeutic Strategies
That epigenetic modifications to the  genome are potentially reversible has 
been shov/n many tim es in cell culture (Plumb, S trathdee e t  al. 2000). 
Therapeutic reversal of DNA m éthylation with re-expression of critically 
affected  genes is a plausible aim and presents an a ttractive  option for the  
trea tm en t of some malignancies. Many clinical trials are being carried out a t 
p resent using azacytidine, phenylbutyrates and histone deacetylase inhibitors 
to  reactivate  genes in haematological(Ruter, Wijermans e t  al. 2004) and solid 
tum ours(Strathdee, Mac Kean e t al. 1999).
The most well trialled dem ethylating drugs in use a t present are azacytidine (5- 
azacytidine), decitabine (5-2-deoxyazacytidine), fazarabine (1-B-D- 
arabinofurasonyl-5-azacytosine), and dihydro-5-azacytidine. They all share a 
common structural m otif in the  form deoxycytidine, but they differ in the 
functional group located a t th e  fifth position in the  pyrimidine ring. Reversal of 
epigenetic changes using histone deacetylase inhibitors (HDACIs) is also in trial 
(Thiagalingam, Cheng e t al. 2003).
The mechanism of action of th e  d ifferent deoxycytidine analogues varies, with 
the  functional group they possess. Decitabine itself is phosphorylated by the  
cell (Lubbert 2000) and is subsequently incorporated into DNA causing 
disruption of DNA synthesis, structural instability and DNA damage(D'lncalci, 
Covey e t  al. 1985; Ju tterm ann, Li e t al. 1994). It also binds to  DNMT, which is 
clearly the  pharmacological aim. Azacytidine is preferentially incorporated into 
RNA (Santini, Kantarjian e t al. 2001). The direct DNA dam age caused by these 
agents may account for the ir myelotoxicity. Pre-clinical trials with decitabine
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confirm th a t they can reverse m éthylation changes in cell lines and cells from 
human leukaemia patients(M omparler, Bouchard e t al. 1984; Steuber, Krischer 
e t al. 1996). The evidence of effectiveness in clinical trials differs betw een 
solid tumours, where the  response ra te  is reported as less than 10% {Goffin and 
Eisenhauer 2002), and haem atological malignancies, w here the  results are 
more encouraging. In childhood induction-resistant AML the  combination of 
etoposide, am sacrine and azacytidine had a higher com plete response ra te  
than etoposide and am sacrine by them selves (Kantarjian, O’Brien e t al. 2003). 
CML and myelodysplastic syndrome have shown a significant response to 
decytibine (Daskalakis, Nguyen e t al. 2002; Kantarjian, O'Brien e t  al. 2003). In 
the  responding myelodysplastic syndromes th e  p15-cyclin dependent kinase 
inhibitor is dem ethylated and re-establishm ent of normal gene expression is 
reported (Galm, Wilop e t al. 2004). This is supportive evidence for 
dém éthylation as a therapeutic  mechanism, ra ther than DNA damaging 
pathways. Si-RNA techniques directed against DNMT 1, DNMT3A and DNMT3B 
have also been used to  dem ethylate genes, but only in cell culture (Espada, 
Ballestar e t  al. 2004). One of the  most significant conclusions from this study 
was th a t DNMT1 in terference was required for dém éthylation, but not DNMT3A 
or DNMT3B.
DNA m éthylation and histone acétylation co-ordinate to  control gene 
expression and HDACIs activate gene expression from m ethylated genes. 
HDACIs alone, however, are  not adequate  to  activate gene expression from 
densely m ethylated genes, but when HDACIs are used in combination with a 
DNA dem ethylating agent they have a synergistic effect (Cameron, Bachman e t 
al. 1999). Three patients with cutaneous T-cell lymphoma involved in a phase I 
clinical trial showed a partial response to  trea tm en t with depsipeptide, an 
HDACI, and one patien t with peripheral T-cell lymphoma had a com plete 
response (Piekarz, Robey e t al. 2001). HDACIs also induce remission in 
transgenic models of promyelocytic leukaemia(He, Tolentino e t  al. 2001).
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Combination therapies using an HDACI and DNA dem ethylating drug are in 
clinical trials a t present.
Surprisingly, sodium valproate, a drug traditionally used for trea tm en t of 
epilepsy and bipolar disorder, has an e ffect on m ethylation-m ediated gene 
expression, as do the  anti-arrhythm ic drugs hydralazine and procainamide. 
(Segura-Pacheco, Trejo-Becerril e t  al. 2003). The sodium valproate cell culture 
studies show direct inhibition of HDACs, with an associated increase in 5- 
lipoxygenase mRNA in both proliferating and differentiated  cells. 
Déméthylation of ER, RARB and p16 in cell culture experim ents using 
procainam ide and hydralazine have been dem onstrated in breast cancer 
derived cell lines (Segura-Pacheco, Trejo-Becerril e t al. 2003). It would be 
interesting to  analyse b reast cancer patients who have been tre a ted  for 
cardiovascular disease with these  drugs in co-ordination with normal 
chem otherapy for breast cancer. The model of drug resistance in ovarian 
tumours suggests th a t th e  HMLH1 gene is down-regulated through méthylation 
(Plumb, S trathdee e t al. 2000). The end-result of this is to  increase th e  chance 
of m utations in th e  cell, favouring th e  em ergence of drug resistance. This 
exact model may not hold in breast cancer, however there  is evidence th a t 
tum our méthylation is a ltered  as cancers progress and therefore  reversal of 
méthylation may revert a tum our to  a drug susceptible phenotype. Women with 
breast cancer who have taken procainamide or hydralazine during 
chem otherapy might have longer disease free survival if méthylation 
aberrations are prevented from developing both during the  chem otherapy and 
a fte r trea tm en t. Clinical evaluation of these drugs in a case of cervical 
carcinom a and a head and neck cancer case resulted in re-expression of p16 
and RARB (Segura-Pacheco, Trejo-Becerril e t al. 2003). This is evidence th a t 
they are viable dem ethylating agents and further work is needed to  establish 
the ir role, if any.
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Side effects of dém éthylation include, not only myelotoxicity (a dose limiting 
side effect), but also activation of dorm ant oncogenes. This was reported in 
th e  case of a pancreatic cancer which was thought to m etastasize more rapidly 
as a consequence of invasion promoting genes being released from méthylation 
(Sato, Maehara e t al. 2003). There are also issues with regard to dosage. 
Monitoring m éthylation of genes in the  peripheral circulation is used in some 
clinical trials as a means of assaying th e  e ffec t of the dem ethylating agent. 
Unfortunately, this surrogate may not give an accurate picture of w hat is going 
on in solid tumours.
Combinations of drugs may be the  way forward, as synergy betw een HDACIs and 
dem ethylating drugs has been shown. Scheduling is also im portant - if 
chem oresistance is encountered due to  m éthylation then chem otherapy should 
be planned for the  ‘window’ produced by dem ethylating drugs. Monitoring of 
dém éthylation trea tm en t may become more advanced as CpG island chips 
becom e available, allowing profiling of a large number of CpG islands in one 
sample. Individualised trea tm en t may then allow more effective trea tm en t 
than standardised regimes.
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2.3 Project Aims
It is thought th a t specific DNA m éthylation events occur early in the  evolution 
of b reast cancer. This p ro jec t aspired to  screen a sample of b reast cancers for 
novel, aberrantly m ethylated CpG Islands (CpG islands). Following this initial 
gathering of ‘ta rg e ts’ it was proposed to  characterise ta rget méthylation 
changes in a larger cohort of new breast tumours. In addition, m éthylation 
profiles of the  larger cohort w ere to  be related  to  available clinico-pathological 
data.
Screening for méthylation changes in cancer has evolved as technology has 
becom e more advanced. At the  inception of this p ro ject there  w ere few 
screening techniques available: restriction landmark genomic scanning (RLGS) 
(Costello, Fruhwald e t al. 2000) was difficult to  in terp re t and had only been 
used successfully in one laboratory. Differential méthylation hybridization 
(DMH) (Huang, Perry e t al. 1999) is limited to  a candidate gene approach and 
does not screen th e  whole genome. RLGS and DMH are also dependent on 
m ethylation-sensitive restriction enzyme digests as a means of differentiating a 
m ethylated locus from an unm ethylated one. Restriction digests have been 
shown to  leave up to  10% of restriction sites undigested despite extended 
digestion with more than one se t of isoschizomers, and incom plete digests may 
lead to  false positive signals.
A technique was selected which had been used successfully in this laboratory 
(Brock, Huang e t  al. 2001), th a t relied on the  methyl binding domain of the  rat 
MeCP2 protein. It is a technique first developed by Professor Adrian Bird and 
Dr. Sally Cross of Edinburgh University to  isolate CpG islands in the  human 
genome. It was la ter adapted  by Dr Graham Brock, with th e  addition of a 
subtractive hybridisation step , to  isolate differentially m ethylated sequences 
from tum our DNA. This approach has yielded novel CpG islands in the  past 
(Van, Chen e t al. 2001), and th e  m éthylation status of one of these, HS3ST3B,
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in combination with th e  m éthylation status of a few o ther genes, can segregate 
b reast tumours into ER positive or negative tumours. (Van, Chen e t  al. 2001). 
The méthylation status of HS3ST3B also has a similar role in ovarian tumours 
(Professor Tim Huang, Ohio University, personal communication). It was 
therefore  regarded it as a tested  method th a t was functioning robustly.
Following screening for CpG islands the  targets w ere to  be sequenced to  assess 
the ir CpG and GC conten t and provide DNA code th a t could be used to 
in terrogate the  human genome database. If th e  genes m et the criteria for CpG 
islands they w ere to  be included in a DNA array th a t was being developed in 
th e  laboratory a t this tim e.
It is generally accepted  th a t dense m éthylation of a CpG island is associated 
with transcriptional silencing of th a t gene (Esteller 2005). Despite the 
robustness of this association correlation of the  relationship betw een 
transcription and méthylation was also sought.
These w ere the  aims a t th e  s ta rt of this p ro ject - some w ere realised and some 
w ere not.
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Gene Role in Tumor Development Site of Tumour
ARC
Deranged regulation of cell proliferation, 
cell migration, cell adhesion, cytoskeletal 
reorganization, and chromosomal stability
Breast
Lung
Esophageal
BRCA1 Implicated in DNA repair and transcription activation
Breast
Ovarian
CDKN2A/p16 Cyclin-dependent kinase inhibitor
GIT
Head and neck
NHL
Lung
DAPK1
Calcium/calmodulin-dependent enzyme that 
phosphorylates serine/threonine residues on 
proteins; Suppression of apoptosis
Lung
E-cadherin Increasing proliferation, invasion, and/or metastasis
Breast
Thyroid
Gastric
ER Hormone resistance BreastProstate
GSTP1 Loss of detoxification of active metabolites of several carcinogens
Prostate
Breast
Renal
hMLHI Defective DNA mismatch repair and gene mutations
Colon
Gastric
Endometrium
Ovarian
MGMT p53-related gene involved in DNA repair and drug resistance
Lung
Brain
pi 5 Unrestrained entry of cells into activation and proliferation
Leukemia
Lymphoma
Squamous cell 
carcinoma, lung
RASSFIA
Loss of negative regulator control of cell 
proliferation through inhibition of Gi/S- 
phase progression
Lung, Breast, Ovarian, 
Nasopharyngeal, Kidney
Rb
Failure to repress the transcription of 
cellular genes required for DNA replication 
and cell division
Oligodendroglioma
Retinoblastoma
VHL Altered RNA stability through and erroneous degradation of RNA-bound proteins Renal cell cancer
Table 2.1 Table of genes that are methylated In cancer.
Abbreviations: ARC, adenom atous polyposis coli; BRCA1, breast cancer 1; CDKN2A/p16, cyclin- 
dependent kinase 2A; DAPK1, death-associated  protein kinase 1; ER, estrogen receptor; GSTP1, 
glutathione S-transferase Pi 1; hMLH1, Mut L hom ologue 1; MGMT, 0 -6  methylguanine-DNA  
m ethyltransferase; RASSFIA, Ras association domain fam ily m em ber 1; Rb, retinoblastoma; 
VHL, von Hippel-Lindau; GIT, gastrointestinal tract; NHL, non-Hodgkin’s lymphoma.
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3.2.1 Protein Purification
Figure 3-3 shows a 15% polyacrylamide gel protein gel which was run a t 200V 
for 1hour. The lanes contain progressive steps in the  extraction process 
starting from th e  crude bacterial ex tract, ending with th e  purified form of the 
protein which was e lu ted  from th e  nickel agarose matrix. The specific 
contents of each lane are given in th e  figure legend. The gel proves th a t a 
band weighing betw een 10 and 15kDa was purified from th e  nickel agarose 
slurry. The cloned Rat MBD domain and associated polyhistidine tail weighs 
11.2KDa. This protein purification process was carried out for every new 
column th a t was m anufactured; this am ounted to eight columns in to tal, 
although only six of these  w ere used to  construct libraries.
3.2.2 Column Testing
Figure 3-4 is a 2% agarose gel, which was run at 100V for 2hours and the  
associated radiograph of the  gel. The sites of the  restriction enzymes Hpall and 
Hhal are given in Table 3-2 and m ethyltransferase recognition sites and density 
of m éthylation are given in Table 3-3. This se t of experim ent is designed to 
te s t for efficacy of an HMBD column to bind densely m ethylated plasmid DNA a t 
0.4M NaCl and 0.6M NaCl and also to  te s t th a t densely m ethylated plasmid DNA 
is elu ted  a t 0.85M NaCl. An HMBD column was loaded with a linearised, end- 
labelled radioactive pTEST plasmid and then washed with 0.4M, 0.6M and 
0.85M NaCl. Following the  collection of each fraction the  DNA was precipitated 
resuspended, split into th ree  digests and lug of unm ethylated unlabelled pTEST 
plasmid was added to  each digest. The 3 samples from each fraction w ere 
digested with Hpall or Hhal or w ere undigested (as a negative control). Hpall 
and Hhal cut the  unm ethylated plasmid, Hpall cuts partially m ethylated 
plasmid, and neither cut the densely m ethylated plasmid. Only the 
unm ethylated, unlabelled pTEST plasmid can be seen on th e  agarose gel; the
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end-labeled pTEST plasmid, which was fractionated on the HMBD column, falls 
below the  mass required to  be visible on an agarose gel. It can be seen from 
the  agarose gel th a t th e  restriction digests proceeded to completion and none 
w ere inhibited by the  process of fractionation. The lower picture is an 
autoradiograph of the  agarose gel a fte r it was dried and incubated a t -80oC 
with the  radiographic film for 48hours. This autoradiograph dem onstrates th a t 
there  is unm ethylated plasmid (digested by both Hpall and Hhal) in the  low salt 
fraction, partially m ethylated plasmid (digested by Hpall, but not Hhal) in the  
medium salt fraction and densely m ethylated plasmid (resistant to  digestion by 
e ither enzyme) in the high salt fraction. It can be concluded th a t this HMBD 
column binds and separates pTEST plasmid DNA on the  basis of méthylation 
density. This assay of a colum n's ability to  separate  pTEST plasmid DNA on the  
basis of méthylation density was carried out for each new column th a t was 
constructed prior to fractionation of tum our and normal DNA. All columns 
tested  w ere able to fractionate plasmid DNA on the basis of m éthylation.
3.2.3 Subtractive Hybridisation Library Generation
Figure 3-6 A), B) and C) shows th e  successive steps in the  construction of CPD 3 
and CPD 4 subtractive hybridization libraries. These are representative results. 
The first gel A) is an agarose gel of CPD3 and CPD4 following PGR with the  
catch linker 2 .4 /2 .44. This PGR step  is carried out to enrich th e  library for 
tum our specific m ethylated DNA. In the  case of these two particular libraries 
the  portion of gel indicated by th e  w hite box was cut out and gel purified, and 
the  DNA was then cloned into pGem Teasy. This step  was carried out as 
previous libraries had given only fragm ents of DNA less than 200bp in size. This 
was thought to have been a result of th e  cloning process favouring smaller 
fragm ent sizes and perhaps the  bacteria favouring smaller inserts. In order to 
bias the  cloning process in favour of larger inserts the  gel purification approach
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outlined above was carried out. This gel also proves th a t th e  2 .4 /2 .44  ligation 
step  was working.
Figure 3-6B) shows an agarose gel with PCR products obtained from cloned 
products of library CPD3. These clones w ere selected  for PCR on the  basis of 
th e  COT-1 DIG labeled screen. Colonies th a t did not label with the  COT-1 
probe w ere included for PCR. PCR was carried out using T4 and SP6 primers 
which are  located in the  pGem Teasy vector. Again the  decision to  use a clone 
following PCR analysis was based on the  size of the product. If the  product was 
g rea ter than 350bp in size it was included for further analysis (i.e. subsequent 
digestion with Hpall and Hhal). 350bp was chosen as a cut off point because 
th e  vector th a t th e  insert was cloned into added 120bp to  th e  insert size. So in 
th e  case of this se t of clones only 2 (numbers 4 and 7) w ere included for Hpall 
and Hhal digestion. This gel does, however prove, th a t the  cloning process was 
to  some ex ten t working, although there  was still a bias towards small inserts 
being cloned despite the  gel purification step.
Figure 3-6C) 92 shows the  result of digesting the  two clones from the  CPD3 
library with the  restriction enzyme Hpall. The restriction site  for this enzyme 
is frequently found in CpG islands m ultiple tim es and is an indirect assay of the  
CG conten t of a sequence of DNA. Restricting the  cloned inserts with Hpall 
resulted in four fragm ents. There is one restriction site in the  vector 
sequence, this means th a t there  are only 2 sites within the  cloned insert. 
Figure 3-7 95, shows th e  HMLHI CpG island and it can be seen th a t there  is a 
discrepancy in th e  number of Hpall sites in th e  HMLHI CpG island and these 
cloned inserts. It was therefore  in terpreted  th a t these inserts did not contain 
many CG dinucleotides, w ere not CpG islands and subsequently they w ere not 
subm itted for sequencing.
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3.2A Summary of Results of Libraries Constructed
Subtractive
Hybridisation
Library
Clones
examined
Clones 
excluded by 
DIG-COT-I 
screening
Clones 
excluded 
after PCR 
analysis
Clones
excluded
after
Hpall.
Candidate
CpG
Islands
CPD1 490 480 8 2 0
CPD2 1200 1079 96 25 0
CPD3 490 490 0 0 0
CPD4 490 478 5 7 0
CPD5 490 474 8 8 0
CPD6 490 470 8 12 0
Table 3-1 Results of screening the subtractive hybridisation libraries generated from six 
different HWIBD columns.
This is a summary of results from six subtractive hybridisation libraries that w ere constructed  
using th e six d ifferent HMBD columns and tumour DNA donated by Professor Tim Huang. Each 
library was constructed using a new HMBD colum n. The table shows th e original number of 
clones picked and exam ined in th e first column and then goes on to  give the number of 
colonies excluded in th e  subsequent screening steps.
Table 3-1 above shows th e  num ber of clones examined in the  cases of the 
hybridisation libraries CPD1-CPD6. Each library was constructed using a new 
HMBD column and subsequent fractionation, subtraction and screening steps. 
In to ta l 3,650 clones w ere picked from these  libraries (six libraries in to tal), 
3,471 (95.9%) w ere excluded on th e  basis of COT-1 DIG labelled screening of 
libraries, 125 (3.4%) w ere ruled out on the basis of size and 54 (1.7%) w ere 
re jec ted  by the  Hpall screening step.
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3.2.5 PCR for the HS3ST2 CpG Island in Subtractive 
Hybridisation Libraries
Figure 3-5 shows a PCR for the HS3ST2 CpG island which was found in a 
subtractive hybridization library constructed by Dr. Brock. PCR was carried out 
on th e  subtractive hybridization libraries CPD1-CPD5 for the  HS3ST2 CpG island 
and also on a library constructed by Dr. Brock th a t was known to contain the  
HS3ST2 CpG island. This result shows th a t HS3ST2 is not present in the  CPD 
libraries and it infers th a t the  libraries are not enriched for densely m ethylated 
CpG islands in the  same way as those th a t were constructed in th e  lab 
previously. It cannot be sta ted  th a t th e  CPD libraries contained no CpG islands 
from this gel, however, it may be sta ted  th a t they do not contain enrichm ent 
for a CpG island th a t has been shown to be m ethylated in 75/88 breast tumours 
in a previous study (Miyamoto, Asada e t al. 2003). This is quite compelling 
evidence th a t there  may be a problem with e ither th e  tum our samples being 
used for the  fractionation process or the  subtractive hybridization process. 
The column appears to  work correctly in th a t it can fractionate densely 
m ethylated pTEST plasmid. However, th e re  may be a difference in the  
functionality of the  column to fractionate  densely m ethylated genomic DNA.
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Figure 3-3 HMBD Protein 15% polyacrylamide gel. This is a 15% polyacrylam ide gel run 
in MOPS buffer for 1hour at 200V. The HMBD protein  is 11.2KDa in s iz e . The ladder used has 
markers a t 15kDa and lOKDa which are marked with arrows. Lanes 1-12 are progressive stages  
in th e  purification o f th e  protein . Lane 1 is a sam ple o f th e  preinduction  broth, lane 2 is th e  
postinduction broth a t 2hours, lane 3 is th e flow  through from loading th e  protein extract onto  
a seph arose anion exch an ge colum n, subsequent w ashes of this colum n w ith 0.4M, 0.85M and 
1M NaCl are shown in lanes 4-6 . Lane 7 is th e rem aining protein  ex tra ct th a t did not bind to  
the nickel agarose matrix Lanes 8-12 are w ashes of a 200ul sam ple of th e nickel agarose matrix- 
HMBD protein colum n: 200ul o f m atrix slurry w as ex tracted  and w ashed  six tim es w ith 200ul 
of 250uM im id azole , an an alogue of th e histid ine side chain . Im idazole com p etitively  inhibits 
chelation  of th e nickel ion of th e  agarose m atrix by the polyhistid ine tail o f th e HMBD protein. 
At a concentration of 250uM all the protein bound to the nickel agarose matrix is e lu ted . These 
w ashes w ere  p ooled  and th e  protein  con cen tration  ca lcu la ted  as d escrib ed  in M aterials and 
M eth od s, th e  p r o te in  c o n c e n tr a t io n  ran ged  b e tw e e n  1 4 -1 6 m g /m l o f m atrix  slurry.
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Figure 3-4 Separation of Unmethylated, Partially methylated and Densely Methylated pTEST Plasmid on the HMBD Column Plasmids w ere m odified  as described  in th e main 
tex t, en d labelled  with dCTP m ixed, loaded on to the HMBD column and fractions w ere co llected  
over a NaCl gradient. The salt fractions are indicated above each  lane. Following the collection  
of each  fraction th e  DNA w as p recip itated , resuspended and lu g  of unm ethylated  unlabelled  
pG em -test plasm id w as added to  each  fraction. The fractions w ere then  d igested  with Hpall 
and Hhal: both en zym es w ill cut th e unm ethylated  plasm id, Hpall w ill cu t partially m ethylated  
plasm id, and neither w ill cu t th e  d en sely  m ethylated  plasm id. The upper gel is the agarose  
gel d igest o f th e  fractions. Only th e unm ethylated  plasmid spike can be seen ; th e labelled  
plasm ids fall b elow  th e  m ass required to  be v isib le on an agarose gel. It can be seen  from this 
gel that th e  restriction d igests proceed ed  to com pletion  and none w ere  inhibited . The lower 
picture is an autoradiograph of th e  th e agarose gel a fter it w as dried and incubated at -SOoC 
with th e radiographic film for 48hours. This autoraiograph d em onstratres that th ere is 
unm ethylated  plasm id (d igested  by both Hpall and Hhal) in th e low  salt fraction , partially  
m ethylated  plasm id (d igested  by Hpall, but not Hhal) in th e m edium  sa lt fraction and densely  
m ethylated  plasm id (resistant to  d igestion  by e ith er enzym e) in th e  high salt fraction. It can 
be concluded that this HMBD colum n binds and separates DNA on th e  basis of m éthylation  
density.
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PRODUCT SIZE(IN BASE PAIRS)
Recognition
Site
Méthylation
Sensitive
Pgem-Test
Unmmethylated
Pgem-Test
Partially
Methylated
Pgem-Test
Densely
Methylated
Hpall C/CGG
GGC/C
Yes 762, 489, 404, 
351, 347, 309
762, 489, 404, 
351, 347, 309
3543
Hhal GCG/C
C/GCG
Yes 452, 393, 337, 
332, 270, 263
3543 3543
MspI C/CGG
GGC/C
No 762, 489, 404, 
351, 347, 309
762, 489, 404, 
351, 347, 309
762, 489, 
404, 
351,347, 309
Table 3-2 pGem-test product sizes following digestion with the restriction enzymes Hpall, 
MspI and Hhal.
Product sizes are given for the six largest products produced by cleavage of each  enzym e. 
Product sizes are also given following m éthylation of the plasmid with Hhal m ethyltransferase, 
and Sss m ethyltransferase
Recognition Site No of sites in 
pGem - Test
Density of 
méthylation (No of 
sites/ size of 
plasmid)
Hhal GCGC 28 0.0079
Methyltransferase CGCG
Sss CG 490 0.014
Methyltransferase GC
Table 3-3 Methyltransferase recognition sites and density of méthylation in pGem-test. 
The site of modification is marked in bold.
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3 Isolation of Methylated CpG Islands Using a 
Methyl Binding Domain Column
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3.1 introduction
Aberrant méthylation of CpG islands in breast cancer is thought to be a 
significant, early event in breast carcinogenesis (Costello, Fruhwald et al.
2000). One of the principal aims of this project was to isolate, through a 
screening process called ICEAMP, novel CpG islands methylated in breast 
tumours. ICEAMP is an acronym derived from the title of an article, “Isolation 
of CpG islands Exhibiting Abnormal Méthylation Patterns” (Brock, Huang et al. 
2001 ) and it is a technique developed by Dr. Graeme Brock. The steps of this 
process are outlined below.
3.1.1 Overview of Methodology
Tumour DNA digested 
with Msel leaving TA 
overhangs.
Low Salt (0.4M)- -High Salt (0.85M)T
High Salt Tumour Fraction 
DNA precipitated
i
Tumour fraction left 
un ligated, retaining 
TA overhangs.
Stepi ) DNA is 
digested 
separately with 
Msel to leave a 5’ 
TA overhang.
Methyl Binding 
Domain Column
StepZ) DNA from tumour and 
normal breast tissue is 
fractionated separately on the 
MBD column, which binds 
densely methylated DNA more 
stringently than unmethylated 
DNA. The high (0.85M) salt 
fraction collected from the 
column contains densely 
methylated sequences.
Step3) The high salt fraction 
from both normal and tumour 
are precipitated separately. 
These fractions should contain 
sequences that are densely 
methylated.
Step4) The normal densely 
methylated sequences are 
then ligated to a catchlinker 
(2.1/2.11 ), which requires a 
5’TA overhang.
DNA digested 
with Mse I leaving TA 
overhangs.
Subtractive
Hybrisation
Step
QQQQQ5I
Low Salt (0.4M)- -High Salt (0.85M)T
High Salt Normal Fraction 
DNA precipitated
i
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Catchlinkers 2.1/2.11 
ligated to Normal High 
gg Salt Fraction ^
T^2T/2006'
Msel digested densely methylated tumour DNA 
fractionated on the HMBD column with the 
overhangs intact. yel digested densely methylated normal DNA with 2.1/2.11 catchlinkers ligated.
MIX,
DENATURE (lOOoC) 
a  REANNEAL (48hrs)
steps ) The normal ligated fraction is mixed with 
the tumour fraction at a ratio of 3:1 
normaUtumour or greater. The mixture is heated 
to lOOoC and allowed to cool and re-anneal over 
48hrs at room temperature.
Add 2.4/2.44 catchlinker 
and ligate (this only 
l i ^ e s  to TA o v e rh ^ s )
Step6) as the mixture re-anneals only the 
tumour homoduplexes have TA overhangs. 
These are used as a means of ligating a 
second catchlinker 2.4/2.44. Again this 
catchlinker is specific for TA overhangs.
PCR amplify using 
2.4/2.44 as a 
primer.
Clone into TA* vector
Step 7) Following ligation the catchlinkers 
2.4/2.44 are again used for PCR primer 
sites and the mixture is PCR for 40 cycles.
This greatly increases the proportion of 
the DNA in the mixture that is composed of 
tumour homoduplexes.
StepS) The PCR enriched 
annealing mixture is then cloned 
in the pGem Teasy vector and 
transformed into E.coli XL1 -Blue. 
The bacteria are then plated on 
selectable media and colonies 
with inserts are picked and 
grown in 90 well plates.
Figure 3-1 Flow diagram of DNA fractionation and subtractive hybridisation technique.
This is an outline of the DNA fractionation and subtractive hybridisation process. Normal 
genomic breast DNA is coloured yellow and breast tumour genomic DNA is coloured red. The 
catchlinker 2.4/2.44 is coloured black and the catchlinker 2.1/2.11 is coloured blue.
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Figure 3-1 above is an outline of the  DNA fractionation and subtractive 
hybridisation steps of the  ICEAMP technique. The diagram shoves separate  
samples of tum our DNA and normal DNA, which have been digested with Msel to 
leave 5' TA overhangs, being fractionated on a methyl binding domain column. 
This column is constructed as described in m aterials and methods and contains 
th e  m ethyl binding domain of the  ra t MeCP2 protein. The MBD domain is 
a ttached  to  a nickel-agarose matrix via a polyhistidine tail th a t was cloned into 
th e  protein. The column binds DNA, but has a g rea ter affinity for densely 
m ethylated DNA com pared to  unm ethylated DNA and partially m ethylated DNA, 
One protein molecule binds one m ethylated CpG and hence the  g rea ter the 
density of m ethylated CpG's the  greater th e  affinity the  DNA has to  the  column 
(Nan, Meehan e t al. 1993; Cross, Charlton e t al. 1994) (Brock, Huang e t al.
2001). When functioning correctly th e  column will bind densely m ethylated 
DNA up to a salt concentration of 0.85M (Cross, Charlton e t  al. 1994) a t which 
point the  column no longer retains densely m ethylated DNA and it is released. 
This capability is utilised to  fractionate the  tum our and normal DNA separately 
and retrieve the  densely m ethylated sequences from each. The 0.85M salt 
fraction which is shown in th e  diagram for both tum our and normal is then 
ethanol precipitated  and the  normal densely m ethylated sequences, which 
have TA overhangs, are ligated with the  catchlinker 2 .1 /2 .11, which will only 
ligate to  DNA with a 5’ TA overhang. Densely m ethylated tum our DNA is left 
with the  TA overhangs in tac t a t this point. It is worth stressing th a t up until 
this step tum our and normal DNA have not been mixed and the  previous 
fractionation steps have all been carried out separately.
The next step is th e  subtractive hybridisation step . The normal m ethylated 
and now blunt ended DNA is mixed with th e  m ethylated tum our DNA, which has 
TA overhangs. This is then heated  to  lOOoC and allowed to  re-anneal a t room 
tem peratu re  over a period of 48hours. As the  mixture re-anneals there  are 
th ree  possibilities as seen in Figure 3-1 steps 5-6 above, the  tum our will re ­
anneal to  tum our (hopefully this will only occur in the  case of densely
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m ethylated CpG islands), the tum our will re-anneal to  normal or normal will re ­
anneal to  normal. The purpose of this step  is to  remove sequences, such as 
Alus Sines and Lines and o ther repetitive elem ents or non-CpG islands th a t are 
densely m ethylated and common to both tum our and normal. It is expected 
th a t densely m ethylated CpG islands in the  tum our DNA will re-anneal to 
tum our. Assuming this is the  case th e  penultim ate step  in th e  fractionation 
process is the  ligation of a fu rther catchlinker (2.4/2.44) to  th e  reannealed 
mixture. Again this catchlinker will only anneal to  strands of DNA with a 5’ TA 
overhang and therefore  should only anneal to  tum our homoduplexes. If the  
fractionation process has worked correctly these should be densely m ethylated 
sequences th a t are found in tum our DNA but not normal DNA.
The last step in the  subtractive hybridisation step  is a PCR step , which uses the 
2 .4 /2 .44  catchlinkers as a prim er site. 40 cycles of PCR are carried out. The 
purpose of this step is to  greatly increase the  number of tum our homoduplexes 
in the  re-annealed mixture. The PCR mixture is then ligated into a selectable 
vector, in this case pGem Teasy, and transform ed into E. coli XL-1 blue strain 
and plated on a selectable media. Clones with inserts are picked and seeded 
into th e  well of a 96 well p late . The subsequent screening process is outlined 
below:
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Step9) Colonies 
with inserts 
(white dots) are 
picked from the 
agarose plate and 
seeded into a well 
in the 96 well 
plate.
Step 11 ) The membrane is 
hybridised with COT-1 DNA 
which is rich in repeat 
sequences. Clones containing 
repetitive elements should 
hybridise to COT-1 DNA and 
CpG islands should not.
Step 12) clones that do not 
hybridise with COT-1 DNA are 
PCR’d with primers that 
anneal to sequences in the 
cloning vector. This adds an 
extra 120bp to the PCR 
product. The products are run 
on agarose gels and assessed 
for size.
Step 10) Following 
overnight incubation (12- 
16hours at 36oC) lOul of 
each well is pippetted 
onto a nitrocellulose 
membrane and incubated 
for 2hours at 36oC then 
UV cross-linked to the 
membrane.
Step 13) Clones that are 
>350bp (marked with arrows) 
are gel purified and digested 
with Hpall as a means of 
assessing the CpG content. 
The restriction digests are 
then run on a 2% agarose gel.
Figure 3-2 Schematic of the screening process for DNA libraries created using MBD 
colum ns and subtractive hybridisation.
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3.1.1.1 Outline of Screening Process
The schem atic above shows the  screening process for th e  sequences th a t are 
cloned following subtractive hybridisation. In brief colonies with inserts are 
picked and grown in 100ul of L-broth containing ampicillin in a 96 well form at. 
The colonies are then p ipetted  onto a nitrocellulose m em brane, grown for a 
fu rther 2 hours and then cross-linked to  th e  mem brane using UV radiation. The 
m em brane is then hybridised with a COT-1 DIG labelled probe, which fluoresces 
and activates photographic paper. COT-1 DNA is rich in DNA from repetitive 
elem ents. These elem ents are usually densely m ethylated and constitu te  a 
high proportion of sequences in most of the  libraries produced in th e  past 
(Brock, Charlton e t  al. 1999), it is therefo re  necessary or helpful to screen 
them  out. Following hybridisation the  m em brane is dried and exposed to 
radiographic paper for 72hours a t -SOoC. In addition to  th e  colonies th a t are 
p ipetted  onto the m em brane controls are also cross linked to  the m embrane; 
CpG islands for BRCA1 and HMLH1 (which should not hybridise COT-1 DNA) and 
Alu rep ea t sequences which should.
Clones th a t did not hybridise the  COT-1 probe w ere PCR amplified using 
primers located in the  plasmid vector; this added 120bp to  an insert's  size. A 
slightly arbitrary figure of 350bp was used as a cu t off point to  select clones 
th a t w ere likely to  be CpG islands. This figure was based on the  literatu re  a t 
th a t tim e and also on previous experience of screening libraries. Clones larger 
than 350bp w ere gel purified and digested with Hpall, a restriction enzyme 
with the  recognition sequence *CCGG' whose site is generally dense in CpG 
islands (Bird, Taggart e t  al. 1985; Antequera, Macleod e t al. 1989; Antequera 
and Bird 1993). Hpall digestion was used as a pseudo marker for CpG density. 
No specific density of Hpall sites was decided on as definitive of a CpG island 
and as discussed la te r on in this chap ter this may have been an erroneous step 
in screening for CpG islands.
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3.1.2 ICEAMP
There are two central features of th e  ICEAMP technique: 1) Isolation of 
m ethylated DNA from malignant and normal breast tissue using a poly histidine 
methyl binding domain (HMBD) column. 2) Subtraction of m ethylated normal 
DNA from m ethylated tum our DNA to  generate  sequences exclusively 
m ethylated in breast tumours.
3.1.2.1 HMBD Protein Expression and Purification
An HMBD column is constructed from a 79-amino acid m ethyl binding domain, 
cloned from th e  Rattus norvegicus MeCP2 protein, modified to  include six 
histidine residues a t th e  N-terminus. The HMBD protein is linked to  a nickel- 
agarose matrix, which forms th e  solid support of the column, via chelation of 
th e  nickel ion by the poly-histidine sequence. Expression, purification and 
construction of the HMBD column are described below.
3.1.2.1.1 HMBD Expression
The plasmid pET6-HMBD, coding for the MBD-polyhistidine protein, was kindly 
donated by Dr Graeme Brock. This was transform ed, expressed and purified, as 
described in Materials and Methods. Protein purification is dem onstrated in 
Figure 3-3 below.
3.1.2.2 Column Function and Ability to Bind Methylated DNA
Following construction of an HMBD column it was tested  for its ability to 
separa te  DNA on th e  basis of m éthylation density. A pGEM®-T Easy plasmid 
vector containing the  HMLH1 CpG island (referred to as pTEST) was used to  te s t 
each column. Three separa te  pTEST preparations w ere m ade, and linearised 
using Ncol. One was left unm ethylated, the  second was m ethylated using Hpall
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m ethyltransferase and the  third was m ethylated using Sss m ethyltransferase. 
This gave th ree  different densities of pTEST méthylation; unm ethylated, 
partially m ethylated and densely m ethylated (table 2).
500ng of each pTEST plasmid was digested with the  enzymes Hpall, Hhal (which 
are m éthylation sensitive) and MspI (which is not sensitive to  méthylation) to 
ensure the  m éthylation reactions had modified pTEST appropriately. All th ree  
plasmids w ere end-labelled with gamma CTP, as described in Materials and 
Methods. All fractionations w ere carried out in the  cold room a t 4°C. 50ng of 
each pTEST was mixed in buffer A and loaded onto the  HMBD column. The 
column was washed with th ree  increasing NaCl concentrations of buffer A: Low 
Salt 0.4M (LS), Medium Salt 0.6M (MS) and High Salt 0.85M (HS). The th ree  
fractions w ere collected for further purification. To remove any remaining DNA 
th e  column was washed with 50mls of 1M NaCl buffer A and equilibrated with 
0.4M NaCl buffer A. The HS fraction was diluted to  0.4M NaCl and loaded onto 
th e  HMBD column again. The fractionation process was repeated  and the 
second HS fraction was collected (HS2). Repeating the  fractionation step 
increased th e  purity of densely m ethylated DNA. The LS, MS and HS2 fractions 
w ere pooled and precipitated  using isopropanol/ethanol, as described in 
Materials and Methods.
Each fraction was ‘spiked’ with 1ug of unm ethylated, non-radioactive pTEST 
plasmid prior to  digestion with Hpall and Hhal restriction enzymes. Addition of 
th e  unm ethylated, non-radioactive plasmid is an internal control for the 
restriction digests. If the  unm ethylated plasmids are digested then the  DNA 
th a t is in the  th ree  fractions must also have been subject to  digestion and any 
inhibition of restriction is therefo re  due to  m éthylation a t their recognition 
sites. The th ree  fractions: LS, MS and HS2 w ere digested and run on a 2% 
agarose gel. This was photographed to d e tec t the non-radioactive pTEST 
digests. The gel was dried and radiographic film was used to  d e tec t
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 ^ radioactive digest products. Exposure was carried out for 48hrs a t -80°C. The
results for column testing are shown in Figure 3-4 page 90,
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3.1.2.3 Fractionation of Tumour and Normal Genomic DNA
The HMBD column binds double stranded methylated CpG dinucleotides, with 
one MBD molecule binding one methylated CpG dinucleotide; this characteristic 
was used to fractionate genomic DNA into unmethylated DNA (which elutes 
between 0.1-0.4M NaCl), partially methylated DNA (which elutes between 0.4- 
0.6M NaCl) and densely methylated DNA (which elutes between 0.6-0.85M 
NaCl).
lOOug of normal breast carcinoma genomic DNA was digested with the 
restriction enzyme Msel (recognition site TTAA) to leave TA overhangs. This 
digest cleaves genomic DNA into smaller fragments whilst maintaining the  
integrity of the  majority of CpG islands. Msel was heat Inactivated, an aliquot 
of the  digest was run on a 0.8% agarose gel, the  remainder was diluted into 
15mls of 0.1 M NaCl buffer A and loaded onto an HMBD column. The normal HS2 
(NHS2) e luate  was collected, precipitated and ligated to catchlinker 2.1/2.11 
(referred to as 2.1/2.11-NHS2 from now on). T4 DNA polymerase and dNTPs 
were then added to the  ligation reaction to convert any remaining TA 
overhangs tha t had not ligated to 2.1/2.11, to blunt ended DNA.
lOOug of breast carcinoma DNA was also digested with Msel, fractionated on 
the  HMBD column and the  tumour HS2 (THS2) fraction was collected. The 
source of breast carcinoma DNA in this case was pooled from of 36 ductal 
carcinomas (provided by Professor Tim Huang, Ohio University).
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3.1.2.4 Subtractive Hybridisation
2.1/2.11-NHS2 was mixed, a t  a ratio of 3:1, with the  THS2 fraction of the 
tumour DNA. The mixture was heated to 95°C for 5mins. and held a t 68°C for 
48hrs in hybridisation buffer.
As the  mixture anneals over 48hours there  are three  possibilities:
Tumour DNA will reanneal to tumour DNA- theoretically this should only happen 
in the  case of a sequence th a t  is exclusive to THS2. This homoduplex will have 
TA overhangs, as a result of the  Msel digest.
Tumour DNA will anneal to normal DNA - ideally this will occur when a 
sequence is common to THS2 and NHS2. The likelihood of common sequences 
forming heteroduplexes was increased by altering the  ratio of NHS2:THS2 
(range 3:1-10:1) in the  subtractive hybridisation mixture. Heteroduplexes will 
not have TA overhangs, the  NHS2 strand has a 2.1/2.11 catchlinker ligated to 
it.
Normal DNA will anneal to normal DNA. This homoduplex will not have TA 
overhangs.
Following hybridisation the  mixture was cooled rapidly on ice and the 
catchlinker 2.4/2.44 was ligated to the  subtractive hybridisation mixture. 
2.4 /2 .44 catchlinker requires TA overhangs for ligation, therefore it will only 
ligate to THS2:THS2 homoduplexes. Again, any overhangs remaining were 
removed by T4 DNA polymerase and the  addition of dNTPs.
The hybridisation mixture was amplified using 2.4 and 2.44 as primers, thus 
only amplifying THS2:THS2 homoduplexes, and products were cloned into
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PGEM®-T Easy. All clones were transformed into XLI-Blue E.Coli and plated on 
selective media. Prior to cloning the  PCR products were run on a gel, to check 
th a t  the  PCR step had worked. If the  PCR step was successful a smear would 
be created  on the  gel. Cloning was not yielding sufficiently sized products, 
therefore  the  region of the  gel th a t  contained products greater than 500 base 
pairs was gel purified and used for cloning purposes. (See Figure 3A)
3.1.2.5 Subtractive Hybridisation Screening
Previous experience by Dr. Graeme Brock with the  ICEAMP technique showed 
th a t  26% of 173 sequences isolated following library generation met the  criteria 
of CpG islands (Brock, Huang e t  al. 2001).
To increase the  efficiency of screening for CpG islands three  additional steps 
were added to the original protocol:
Screening for repetitive elements using DIG labelled COT-1 DNA; repetitive 
elements made up 19% of the  173 clones isolated.
Screening for sizes >350bp; the  average size of a clone in the  original ICEAMP 
libraries was 350bp and the smaller clones were low in CpG islands, they 
tended to be bulk genomic DNA. (See Figure 3B)
Screening for Hpall restriction enzyme sites; these are frequent in CpG islands, 
but not in genomic DNA (see Figure 3C).
3.1.2.5.1 Screening Using a DIG Labelled COT-1 DNA Probe
A subtractive hybridisation library was plated on selective media. Each colony 
was used to seed a single well of a 96 well plate containing lOOul of specified 
medium. Colonies were grown overnight a t 36°C then lOul of each well was 
spotted onto a nitrocellulose membrane, which was placed on a selective agar 
medium, and again grown overnight a t 36°C. The colonies were lysed, as
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described in Materials and Methods, and DNA was cross-linked to the  membrane 
using UV radiation.
Colonies were then screened with COT-1 DNA to identify repetitive elements: 
COT-1 DNA was labelled using the  DIG-labelling system, as described in 
Materials and Methods, and hybridised to the  nitrocellulose membrane. The 
membrane was dried and incubated with radiographic paper for 24 hours a t  - 
80°C. The autoradiograph was developed and assessed for COT-1 positive 
clones.
The COT-1 probe is rich in the  repetitive e lem ent sequences th a t  constituted 
19% of previous subtractive hybridisation libraries. If a clone hybridised with 
the  DIG labelled probe it was presumed to be due to the  presence of a 
repetitive elem ent in tha t clone and hence it was discarded as a potential CpG 
island.
3.1.2 .5 .2Screening Using PCR and Restriction Digest.
Clones th a t  made it through the COT-1 DIG labelled screen were seeded into 
lOOul volume of ddH20, heated  to 100°C, to lyse bacteria, and lu l of the  lysate 
was used as a PCR tem plate. PCR using vector specific primers tha t  spanned 
the  cloned insert was carried out as described in Materials and Methods. 
Products were run on an agarose gel and assessed for size. If a clone was 
greater than 350bp it was thought to have potential as a CpG island and was 
selected for restriction enzyme digest with Hpall. The restriction enzyme 
digest gives an idea of the  CpG and GC density of a clone. After this third and 
final level of selection any clones tha t  met the  criteria of a CpG island, and 
were specifically methylated in tumour but not normal DNA were sequenced.
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3.2 Results
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702bp
Figure 3-5 PCR for the HS3ST2 CpG Islands using an HMBD Subtractive Hybridisation Libraries
B) L 1 2 3 4 5 6 7 8 9  1011 L
Area cut out and 
gel purified for 
cloning into  
pGem Teasy 
vector
C) 0>■OT310
(U oc cOu u
Figure 3-6 Preparation and Screening of Subtractive Hybridisation Libraries. A) PCR
of th e  su btractive hybridisation libraries CPD3 and CPD4 with th e catchlinker 2 .4 /2 .4 4 . In this 
case  th e area within th e  w h ite  box w as cut out and gel purified to  s e le c t  larger fragm ents for 
cloning. Following screening o f 490 clones for repetitive e lem en ts w ith DIG labelled  COT-1 DNA 
only 10 c lon es w ere  se le c te d  for PCR analysis. B) PCR analysis o f 10 c lon es from th e CPD3 and 
CPD4 libraries. Of th e  10 c lon es se le c te d  only tw o, clon es 4 and 7 in this ca se , w ere large 
enough to  m erit further screen ing. It should be noted  w hen interpreting th e  s ize  of th e PCR 
products in gel B that th e  primers used to amplify clones integrated 120 base pairs of the plasmid 
vector in to  th e  product, th is w as taken into account w hen assessing th e s ize  of cloned inserts. 
C) Restriction en zym e d igests of clon es 4 and 7 with Hpall. Each c lon e  has three Hpall sites . 
There is on e Hpall s ite  in th e 120bp vector seq u en ce am plified  by th e PCR reaction , thus there  
are only 2 Hpall s ites  in both seq u en ces. T herefore, th e clon es w ere  not rich enough in Hpall 
s ites  to  consider them  as CGIs.
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3.3 Discussion
Interpretation of what went wrong is difficult. In Dr. Brock’s original ICEAMP 
paper, 173 sequences were selected and sequenced to identify their nature. 
The same approach was not used in this case. Rather than seeking to 
characterise all sequences generated by ICEAMP the purpose of the  exercise 
was to screen for CpG islands. No samples made it through the  screening 
process and therefore the  identity of clones in the  libraries was never 
revealed. It may be asked why the  clones isolated were never sequenced and 
the  answer to this is simply tha t  none of them at tha t  time appeared to merit 
sequencing - none passed the  criteria set down a t the inception of the  project: 
they were e ither screened out a t  the C0T1-DNA hybridisation stage, or they 
were of insufficient size to be a CpG island. In retrospect, for the  sake of this 
thesis, it might have been useful to have sequence data for a few of these 
clones to prove the  assumption tha t  they were repetitive elem ents or indeed 
non-CpG island elements.
Review of this screening process is important. Firstly, could the  COT-1-DIG 
screen have been overly sensitive, resulting in false positives? This could 
explain the  lack of CpG islands in the  libraries. To control for such an event 
each clone was grown in a single well of a 96 well plate. In each plate there 
were four clones known to have a repetitive elem ent, an Alu, as positive 
controls. There were also four clones th a t  had the  HMLH1 CpG island, as 
negative controls. On two occasions only the  screening process did result in 
either the  CpG island clone hybridising with C0T1 DNA, or the  Alu clone failing 
to hybridise. In this situation selection of the  clones based on tha t 
nitrocellulose (NC) membrane was not made, a new NC membrane was spotted 
with the  colonies and a further hybridisation carried out. Without sequencing 
all clones from the  libraries it would be hard to say th a t  the COT-1-DIG 
screening process was producing false positives, but they were being controlled 
for.
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More than 90% of clones from each library were excluded on the  basis of the 
COT-1-DIG signal. This suggests th a t  the  libraries were extremely rich in 
repetitive elements. Why this was so is difficult to say, e ither the  methylated 
DNA from the  normal was not removing the  repetitive elements from the 
tumour DNA in the subtractive hybridisation stage or the  tumour DNA had an 
abundance of repetitive methylated elements in comparison to the  normal 
DNA.
Efficacy and reproducibility of the  fractionation process were issues tha t  may 
have affected the  content of the  HS2 fraction when genomic DNA was 
fractionated. Using plasmid DNA as an assay of the  column's functionality may 
not have been sensitive enough to trouble shoot a column's efficacy to 
fractionate genomic DNA. Fractionation of DNA on the  column could have been 
assayed using female genomic DNA, assessing the  ability to separate  an 
imprinted genomic sequence such as the  monoamine oxidase gene from the 
rest of the  genome, rather than a plasmid DNA sequence from other plasmids. 
This would have been a more specific te s t  of a column's ability to fractionate 
genomic DNA based on méthylation a t a CpG island.
The mechanism used to produce a salt gradient may have affected the 
reproducibility of the  fractionation process. The columns produced were not 
used on an HPLC system, they were in an open system a t atmospheric pressure 
and the  salt gradient was stepped rather than linear. An open system and a 
stepped salt gradient had been used previously in the  laboratory to produce 
subtractive hybridisation libraries, however when problems arise the  more 
standardised a technique is the easier it is to track down the source of a 
problem. The deviations from the  original technique may have made a 
difference to the  ratio of methylated DNA:bulk genomic DNA in HS2 fractions.
Several HMBD columns were manufactured successfully and all fractionated 
pTEST plasmid on the  basis of méthylation density Figure 3-4 page 90.
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However, this set of experiments aimed to isolate CpG islands tha t were 
exclusively methylated in breast tumours.
Enzyme Cut Position Fragment Size
Hpall 205 236
207 205
261 54
497 32
520 23
2
Hhal 330 330
370 182
40
Table 3-4 HMLH1 CpG Island Hpall and Hhal Restriction Sites and Product Sizes.
The table above shows th e position of th e Hhal and Hpall restriction sites within the HMLH1 
CpG island which is a 552bp sequ en ce spanning the start of transcription (-60bp from the TATA 
box) and extends into th e first exon of the gen e. The figure below  shows th e restriction sites in 
a diagrammatic form.
TATA-BOX
ZOObp 400bp
Figure 3-7 HMLH1 CpG Island Hpall and Hhal Restriction Sites
The figure above shows a line diagram of the CpG island of the HMLH1 gene. The TATA box is 
shown at position 60 and the sites o f the restriction sites o f the enzym es Hpall are marked by 
th e red arrows and the position is given in Table 3-4.
In retrospect it cannot be stated w hether or not the process failed due to the 
lack of sequencing data. Not sequencing some of the clones, especially the 
ones tha t were above 350bp in size was incorrect. Hpall digestion of these 
clones was only an indirect measure of the CG content, it did not give any 
indication of the  nature, or the genomic location of the DNA and was an 
incomplete assessment of the identity of these clones. Another criticism of the 
last step in the assessment of the clones by Hpall digestion is apparent if the
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size of the  HMLH1 fragments following restriction are assessed, Table 3-4. Four 
are smaller than 100bp in size, one is only 2bp in size, one is 23bp, one 32bp 
and one 53bp. The 2bp fragment would definitely not be seen on an agarose 
gel and it is doubtful if the  23bp and 32bp fragments would be identified. This 
would leave three  fragments visible, this is only one more than the  number 
seen in clones 4 and 7 from the  CPD3 library and these were only 
representative results from one library. The decision to exclude clones as non- 
CpG island sequences on the  basis of an Hpall restriction digest may have been 
correct; however it is not proven on the basis of the  analysis carried out.
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3.4 Conclusions
The HMBD columns were capable of binding and fractionating pGem-test 
plasmids dependent on méthylation status.
The subtractive hybridisation libraries were thought to be composed of 
repetitive elements, and non-CpG island sequences. This judgem ent was based 
on the restriction of clones with an Hpall digest. It has been shown tha t for the 
HMLH1 CpG island, a t  least, Hpall digestion may not be a good assay of CG 
content of a DNA sequence. Lack of sequence data makes it impossible to say 
w hether there  were any CpG islands in the  clones isolated and failure to 
sequence the  clones was an error.
Further work was required to assess the  efficacy of the  subtractive 
hybridisation process and screening steps.
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4 Méthylation Status of the HS3ST Family of 
Genes in a Cohort of 80 Breast Carcinomas
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4.1 Introduction
The subtractive hybridisation libraries CPD1-CPD6 produced using the  HMBD 
columns did not reveal any CpG island méthylation in the  group of breast 
tumours analysed. Whilst examining these  libraries for CpG islands o ther 
subtractive hybridisation libraries previously produced in the  laboratory by Dr 
Graham Brock were also being screened. CpG islands from two genes of the  
same family w ere found in one of these  subtractive hybridisation libraries: 
Heparan sulphate D-glycosaminyl-3-O-sulphotransferase 3B (HS3ST3B) and 
Heparan sulphate D-glycosaminyl-3-O-sulphotransferase 1 (HS3ST1). This result 
prompted in terest in the  méthylation status of this gene family.
A search of the  lite ra ture  and genome databases found one publication on 
Heparan sulphate D-glycosaminyl-3-O-sulphotransferase 2 (HS3ST2) méthylation 
and breast cancer (Miyamoto, Asada e t  al. 2003). Using MSPCR, the  authors of 
this study reported  méthylation of the  HS3ST2 CpG island in seven breast cancer 
cell lines, 77/85 breast tumours, 8 /10 colon tumours, 7 /10  lung tumours and 
10/10 pancreatic  tumours. They also reported decreased transcription of 
HS3ST2 in 37 breast tumours th a t  w ere  methylated a t  the  CpG island. This 
association was also found in the  7 breast cancer cell lines, and re-expression of 
HS3ST2 in cell lines was achieved by déméthylation of the  CpG island.
HS3ST3B CpG island méthylation, following isolation using ICEAMP(Brock, Huang 
e t  al. 2001), was also previously reported  in 30/93 breast tumours (Chen, 
Duncan e t  al. 2003). Furthermore, hypermethylation of this locus, in 
combination with 5 to  7 o ther CpG islands, was significantly correla ted  with 
hormone receptor status, clinical stages, and age a t  diagnosis of th e  patients 
analysed (Chen, Chen e t  al. 2003; Chen, Duncan e t  al. 2003).
The human genome database  and Ensembl databases contain six entries  to  da te  
for the  heparan sulphate D-glycosaminyl-3-O-suLphotransferase gene family: 
HS3ST1, HS3ST2, HS3ST3A, HS3ST3B, HS3ST4, and HS3ST5 (Shworak, Liu e t  al. 
1999; Xia, Chen e t  al. 2002). All have a CpG island apar t  from HS3ST5.
These six enzymes differ in substrate  specificity but all catalyse the  same 
reaction (Yabe, Shukla e t  al. 2001), namely the  transfer of a suLphuryl group to
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the  3’ position of glucosamine within the  polysaccharide heparan sulphate(Liu, 
Shworak e t  al. 1999). This modification is the  last in a series of alterations th a t  
take  place in the  Golgi apparatus during heparan sulphate synthesis (David 
1991). Biologically, heparan sulphates are  im portant for various functions 
(Sasisekharan, Shriver e t  al. 2002) Table 4-1102and HS3ST1 activity is 
specifically required to  produce the  active site in antithrombin iila(Zhang, 
Lawrence e t  al. 2001).
Heparan sulphates are  large polysaccharides constructed from a disaccharide 
unit: the re  are up to 200 of these  disaccharide units in a heparan sulphate 
molecule. The monomer is constitu ted  from th ree  sugars: iduronic acid or 
glucuronic acid which is bound to glucosamine. The backbone of the  heparan 
sulphate chain is constructed by heparan sulphate polymerase, the  sugar is then 
modified by heparan sulphate N-deacetylase and N-sulphotransferase, then 
uronosyl C5-epimerase. At the  end of this sequence of reactions the  sugar is 
sulphated, firstly a t  the  2 ' position, then the  6 ’ position and finally HS3ST 
enzymes transfer a sulphuryl group to the  3’ position. These la tte r  modifications 
split the  heparan sulphate into d ifferent zones; sulphated, non-sulphated and 
transition zones. The sulphated zones are  thought to harbour im portant domains 
for biological functions such as growth fac tor binding and enhancem ent of 
enzymes e.g. antithrombin Ilia (Liu, Shriver e t  al. 2002; Sasisekharan, Shriver e t  
al. 2002; Shriver, Liu e t  al. 2002).
Previous modifications to heparan sulphate molecules determ ine w here 3-0- 
sulphation by HS3ST enzymes occurs (Yabe, Shukla e t  al. 2001). 3-0-sulphation 
was first described in 1969 (Danishefsky, Steiner e t  al. 1969) and accounts for 
<5% of the  sulphuryl groups found on a heparan sulphate molecule. This rare 
sulphation reaction is performed by six d ifferent enzymes, all of which have 
different substrate  specificities. This suggests 3-0-sulphation c rea tes  an 
im portant functional group th a t  has specific biological activities.
The importance of heparan sulphates in cancer has been well docum ented (Liu, 
Shriver e t  al. 2002; Liu, Shriver e t  al. 2002; Sasisekharan, Shriver e t  al. 2002; 
Shriver, Liu e t  al. 2002) but the  relationship of specific heparan sulphate 
modifications to cancer biology is not as clear or well researched. There is 
evidence th a t heparan sulphate sulphation pa tte rns  are  important, even
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necessary for certain  biological functions: the  two paradigms are  HS3ST1 and 
antithrombin Ilia function (HajMohammadi, Enjyoji e t  al. 2003): in short heparin 
sulphate dramatically enhances the  neutralization of coagulation proteases by 
antithrombin Ilia, provided it has been sulphated a t  appropria te  sites by HS3ST1. 
Another paradigm is the  well studied relationship betw een heparan sulphate, 
FGF receptor dimérisation and FGF (Ishihara, Guo e t  al. 1993) (Kinnunen, Huang 
e t  al. 2005). The sulphation pa tte rn  of a heparan sulphate covalently linked to 
the  FGF monomer is im portant for dimérisation of the  bFGF receptor, lack of 
sulphation inhibits dimérisation and prevents signal transduction. In addition it 
has been shown th a t  Hs3st-B is involved in Notch signalling in Drosophila  
m elanogaster by affecting stability or Intracellular trafficking of Notch protein. 
Reduction of Hs3st-B function by transgenic RNA interference  compromised 
Notch signaling, producing neurogenic phenotypes (Kamimura, Rhodes e t  al. 
2004).
From this evidence it appears th a t  sulphation patterns  of heparan sulphates are 
im portant and in some cases necessary for their function. The FGF family is 
large and if heparan sulphate sulphation patterns  are  im portant in bFGF 
signalling then they may also be im portant in signaling of receptors in this 
family.
The biological significance of heparan sulphates, the  importance of heparan 
sulphation patterns, the  rarity of heparan sulphate 3-0-sulphation and the  
relatively high number of enzymes required for this modification indicate th a t  
this is an im portant family of enzymes which may have a role to play in 
carcinogenesis. We there fo re  sought to  define the  méthylation status a t  each 
HS3ST CpG island in a cohort of 80 breast tumours.
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Table 4-1 Proteins of the cellular microenvironment bound by heparin/heparan sulphate 
(partial list)
Morphogenesis and Tissue 
Repair
Host Defence
Morphogens Coagulation Anti-angiogenic factors
Activin Antithrombin III Angiostatin
BMP-2, -4 Factor Xa Endostatin
Chordin Leuserpin Cell adhesion molecules
Frizzled-related peptides Tissue factor pathway 
inhibitor
L-select! n
Sonic hedgehog MAC-1
Sprouty peptides Thrombin N-CAM
Wnts (1-13) Growth factors PECAM-1
ECM components EGF family Chemokines
Fibrin AmphireguLin C-C
Fibronectin BetacelluUn CXC
Interstitial collagens Heparin-binding EGF Cytokines
Laminins Neuregulin IL-2, -3, -4, -5, -7, -12
Pleiotropin (HB-GAM) FGFs (1-15) GM-CSF
Tenascin IGF-II Interferon
Thrombospondin PDGF-AA TNF-
Vitronectin TGF-1,2 EC superoxide dismutase
Tissue remodelling factors VEGF-165, 189 pro-arg-rich antimicrobial 
peptides
Tissue plasminogen 
activator
Growth factor binding 
proteins (BP)
Bac-5, -7
PR-39
Plasminogen activator 
inhibitor
Follistatin Energy metabolism
IGF BP-3, -5 Agouti-related protein
Protease nexin 1 TGF- BP ApoB, ApoE
Proteinases Lipoprotein lipase
Neutrophil elastase Triglyceride lipases
Cathepsin G
Abbreviations: BMP, bone m orphogenetic protein; FGF, fibroblast growth; EGF, epiderm al growth  
factor; IGF, insulin-like growth factor; PDGF, p la te let-d erived  growth factor; TGF, transforming  
growth factor; IL, interleukin; GM-CSF, granulocyte-m onocyte colony stim ulating factor; TNF, 
tum or necrosis factor; N-CAM, neural ce ll adhesion m olecule; PECAM, p la te le t-en d o th e lia l ce ll  
adhesion m olecule; Bac, bactinecin .bC ell adhesion m olecu les are also involved in m orphogenesis.
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4.1.1 PCR for HS3ST2 and HS3ST4 CpG Islands in Subtractive 
Hybridisation Libraries
Prior to embarking on a full investigation of méthylation status of the  HS3ST 
genes in a Large cohort of breast tumours a screen of a successful hybridization 
library (constructed by Dr Graeme Brock) for the  presence of the  HS3ST2 and 
HS3ST4 CpG islands was made. A successful library was determ ined by assessing 
the  number of m ethylated CpG islands th a t  had been isolated from it. A PCR 
product was identified in this library for both the  HS3ST2 and HS3ST4 products.
Figure 4.3 contains a 1% agarose gel and shows a PCR for the  HS3ST4 CpG island 
using a subtractive hybridization library, constructed using a protein column 
manufactured by Dr. Graham Brock. This figure dem onstrates  th a t  the  CpG 
island for the  HS3ST4 gene is present in this particular library. This infers, 
assuming th a t  the  fractionation process was 100% successful, th a t  this particular 
CpG island was densely m ethylated  in a t  least one of the  tumours in the  128 
which were pooled and used to construct this library. This result is of more 
significance as it is used as evidence for pursuing the  HS3ST family as a ta rge t 
for méthylation in breast carcinogenesis. This result is also consistent with the  
hypothesis th a t  expression of these  genes could be modulated through 
méthylation a t  the  CpG islands in b reast cancer.
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4.1.2 Tumour Collection and Harvesting of DNA
Tumour samples w ere collected in line with the  ethics approval given for this 
pro jec t (Appendix 1). In to ta l ninety tumour samples w ere  collected e ither  by 
signed consent prior to surgery (39 cases), or from tissue bank archives in the  
Royal Infirmary, Glasgow (51 cases). The tissue in both cases was removed from 
the  specimen, frozen in liquid nitrogen and stored a t  -70°C. Naked eye 
assessment of the  tissue was made to determ ine if tum our was present or not 
and this was confirmed by frozen section histology in all cases. Of the  ninety 
samples collected 80 were analysable. Clinico-pathological data  was derived 
from the  original pathology report w here  possible, or from the  entry in the  
tum our da ta  bank if this was not possible. Prior to MSPCR analysis histology 
reports w ere  collected w here possible for all samples and relevant da ta  was 
added to a database. The samples w ere then linked to the  clinical information 
and anonymised to prevent identification, in line with the  ethical consent. The 
identifiers used for the  tumours throughout this thesis re la te  to the  database  
c rea ted  for this analysis alone and cannot be linked to  pa tien t identities.
Table 4-6 gives a summary of the  tumour details including the  number with 
unknown clinicopathological variables. The tumours w ere  categorised; by age 
into pre-menopausal (<50), peri-menopausal or early menopausal (51-65) and 
la te  menopausal (>65); by tum our size, as shown in the  table; into grades 1 ,2 ,or 
3; by nodal status, which in this sense is the  same as stage; by NPI into low risk 
(<3.4), medium risk (3.4-5.4) and high risk (>5.4); by ER/PR status and by the  
presence or absence of lymphovascular space invasion.
ER/PR status was determ ined positive if e ither ER or PR was g rea ter  than 40%. 
The reason for grouping ER and PR together was somewhat practical and also 
biological. The practicality was older tumours from the  tumour bank in Glasgow 
Royal infirmary only had ER status and not PR status and the  newer tumours, 
which w ere prospectively collected had both ER and PR status. In e ither  case 
the  presence of a positive result indicated th a t  the  tumour would be t rea ted  
with e ither tamoxifen or latterly  with an arom atase  inhibitor. The biological 
argum ent is ER or PR positivity indicates a tumour th a t  may be responsive to 
steroid antagonists. The problem with this approach is th e re  is a group of ER 
negative tumours in samples gleaned from the tumour bank th a t  are  PR positive,
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but have been called negative, and this must be rem em bered  when interpreting 
results.
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4.1.2.1 DNA Extraction
DNA was ex trac ted  as described in Materials and Methods and Figure 4-4 2% TBE 
agarose gel of DNA ex trac ted  from tumour samples, shows representative  
extractions from a number of tumours. In the  case of any tum our which 
produced a band th a t  was largely limited to the  well and had not progressed or 
smeared down the  gel it was deem ed to  be of good quality, non - degraded DNA. 
In comparison tumour CDTD123 was borderline, but accep tab le , tum our CDTD100 
was of poor quality and was not used for MSPCR and tum our CDTDXX1 was non­
existent. The tumours which did not produce good quality DNA w ere r e ­
ex trac ted  a second tim e and w here  necessary a third time. In the  case of 
CDTDXX1 the  tumour was ex trac ted  a second tim e, unsuccessfully and then 
eventually yielded DNA on the  third a ttem p t. This is why CDTD 100 and CDTDXX1 
appear in subsequent figures for MSPCR. The com plete  history of the  extractions 
for all tumours is given in the  tab le  in the  appendix. However, the  tab le  below 
shows the  ten  tumours th a t  did not produce any DNA in the  course of th ree  
ex traction a ttem pts .  The corresponding year of collection can be found in the  
appendix (range 1982-1988), they  were all from GRI tumour bank and 
significantly they were from a freezer reported to have had the  power supply 
inadvertently turned off, for an unspecified period of tim e, on more than one 
occasion, in the  last ten  years. With such storage conditions it is likely th a t  
samples will degrade.
Tumour ID Result 01r DMA ExtT a c tio n s
CDTDBXX (-) (-) (-)CDTD4Y4 (-) (-) (-)CDTD2X2 (-) (-) (-)CDTD7A6 (-) (-) (-)CDTD6JQ. (-) (-) (-)
CDTD0J6 (-) (-) (-)CDTDCID (-) (-) (-)CDTD1DC (-) (-) (-)CDTDD2C (-) (-) {-)CDTD333 (-) (-) (-)
Table 4-2 Summary of tumours that failed to produce DNA.
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4.1.3 Méthylation Specific PCR for the HS3ST CpG islands
Méthylation specific PCR (MSPCR) was carried out on each tumour sample, 
according to protocols (Materials and Methods.)
4.1.3.1 MSPCR Controls
In order to control for the  reaction itself, each CpG island was cloned using 
primers given in Materials and Methods. This was then transformed into XLI-Blue 
E.Coli, grown on selective media and harvested using the  Quiagen plasmid 
extraction kit. Plasmids containing each CpG island were then m ethylated with 
SssI Methyltransferase, creating a stock of m ethylated CpG islands for each 
gene. These m ethylated plasmids w ere  modified with sodium bisulphite and 
used as positive controls for the  m ethylated form of the  CpG island.
4.1.3.2 Primer Design
Primers w ere  designed for each region examined with the  aim of creating a 
product th a t  lay within the  CpG island of each gene. CpG island status was 
determ ined  using the  web-based program GRAIL, found in the  human genome 
da tabase  search engine when performing BLAST searches. The sequence derived 
from this was then analysed fu r ther using the  program gene-jockey to  determ ine 
the  GC content, CpG con ten t and presence of Hpall and Hhal sites. The criteria 
used to determ ine a CpG island have been s ta ted  earlier and we verified th a t  
each proposed set of primers spanned a region th a t  m et these  criteria.
Target sequences were then manipulated to determ ine the  base sequence th a t  
would result from tre a tm en t with sodium bisulphite for a m ethylated ta rge t 
sequence and also for an unm ethylated ta rge t sequence. The web-based 
program ‘Primer 3’ was then used to design primers for each sequence (details 
of primer sequences are  given in Materials and Methods.) We aimed to  produce 
primers th a t  had CpG sequences a t  the  3’ end, to reduce the  possibility of mis- 
priming, and in addition we aimed for a high annealing tem pera tu re , also to 
avoid this problem.
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4.1.3.3 Determination of MSPCR Results
The determ ination of w hat constitu tes  a positive result and a negative one is a 
somewhat contentious issue when using MSPCR. Faint bands appearing in some 
MSPCR reactions, were  ruled to  be ‘negatives’ in this study. The term  ‘fa in t’ in 
this laboratory was defined as the  PCR product being less intense than the  200 
base pair band of the  DNA ladder when 10ul of the  ladder was loaded per well. 
The 200bp band in the  DNA ladder corresponds to approximately 100ng of DNA. 
The visual limit on an agarose gel is thought to be betw een 20-50ng. Admittedly 
this is a somewhat arbitrary method, however it was practical, easily applicable 
and the  use of an internal standard is likely to  improve specificity.
Consistency in declaring a sample to  be ‘negative’ or ‘positive’ overall by MSPCR 
requires a decision t re e  of some sort. To tackle this two sets of primers for each 
CpG island were designed, one se t was specific for the  methylated form of the  
CpG island, the  o ther for the  unm ethylated form. When conducting each MSPCR 
th e re  was a positive control for the  methylated form of each CpG island and two 
negative controls: unmodified genomic DNA and a PCR mixture without any DNA 
tem pla te .  The unm ethylated reactions also used the  same negative controls.
MSPCR for a tumour sample therefore  has the  following possible outcomes:
Table 4-3 Possible outcomes in MSPR analysis of a locus
Methylated Unmethylated Outcome Determination
+ + 1 Methylated
+ - 2 Methylated
- + 3 Unmethylated
- - 4 Void
Methylated and unm ethylated PCRs w ere set up for each CpG island and the  
results in terpre ted  as follows: Outcome 4 was determ ined  as void and the  
reactions were repea ted . If the  result was the  same the  DNA was remodified and 
MSPCR was repeated . Outcomes 1-3 is were considered valid results providing 
the  positive and negative MSPCR controls were  appropriate . Using these  rules 
false negatives, resulting from DNA degradation or from failure of reactions were 
controlled for. False positives w ere  also controlled for through the  two negative 
controls used in m ethylated MSPCRs.
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A tum our sample was te s ted  a t  least th ree  times for méthylation until two 
identical, concordant valid outcomes w ere obtained. In all cases, apar t  from 5 
tumours, concordant results w ere  obtained for all th ree  reactions. The tumours 
and the  associated results th a t  did not produce concordant results are  given in 
the  Table 4-4 below.
Tumour
D atabase
ID.
DNA
Extractions
Successive  
MSPCR’s for 
HS3ST2M
HS3ST2M
Final
Result
Year Source
CDTD100 (-) (-) (+) (+) (-) (+) (+) (+) 2002 F
CDTDBMX (+) (+) (+) (■) (+) (+) 2002 F
CDTDPLY (+) ( 4 (+) {-) (+) (+) 1989 TB
CDTDC9H (+) (+) (■) (+) (+) (+) 2002 F
CDTDXX1 (-) (-) (+) (+) (+) (-) (+) (-*-) 2000 TB
Table 4-4 Tumours which did not give concordant results for MSPCR for the HS3ST2 CpG 
Island.
Source (TB=Tumour Bank, F=Fresh)
As can be seen from the  tab le  all the  non-concordant results cam e from the  
HS3ST2 gene, and all of the  non-concordant results are  false negatives. Two of 
the  samples showed difficulty in extraction of DNA, bu t significantly they are not 
the  oldest tumour samples to be analysed.
Reasons for false negatives for méthylation in this context are most probably 
technical and re la te  to  the  possible degradation of samples by repeated  freeze 
thawing, this is a well recognised draw-back of the  sodium bisulphite t rea tm e n t  
of DNA(Clark, Harrison e t  al. 1994). Other specific reasons for false negative 
results for méthylation status include degradation of DNA during sodium 
bisulphite modification causing breakage of the  sugar phosphate backbone of the  
molecule - this may result in degradation of the  m ethylated form of the  gene in 
a sample th a t  has a low proportion of methylated DNA; failure of specific PCR 
reactions; failure of a well in a PCR block; and also poor technique when setting 
up numerous reactions a t  one time. In the  context of the  number of PCR 
reactions carried out and the  results generated  this re la tes  5 false negative 
reactions out of 240 (2%).
The experience gained from doing such a large number of PCRs lead to the  
realisation th a t  the  number of times a sample was freeze  thaw ed was re la ted  to 
the  likelihood of failed PCRs with th a t  sample. This likelihood could be reduced
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by the  use of a buffered solution, ra ther than ddH20 alone for storage, however, 
this was not 100% effective.
Representative results for all genes, including 2 loci of the  HS3ST3BE1 gene are  
given in the  results section. MSPCR for m ethylated and unm ethylated forms of 
the  gene are  shown in each figure and tumours are identified by their da tabase  
identification code. This code is also used for the  gels showing DNA extractions. 
The code can be used to identify the  tumour in the  appendix.
The figures are  accompanied by a tab le  th a t  describes the  result for each 
sam ple’s MSPCR, m ethylated and unmethylated, for the  given gene, and where 
possible the  overall result of this specific round of MSPCR. Again the  tumour 
da tabase  identification code is used in the  tab le  and can be re la ted  to  the  
information in the  appendix. It should be noted th a t  some results cannot be 
in te rpre ted  from these  gels alone as e ithe r a m ethylated or unm ethylated result 
is absent. These results are  indicated as such in the  table
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4.1.4 Méthylation Status of HS3ST2 and HS3ST4 in Normal Breast 
Tissue
Méthylation of the  HS3ST gene family in normal breast tissue was assessed using 
Méthylation Specific PCR (MSPCR). This was to determ ine if CpG island 
méthylation was tum our specific or if it also occurs in histologically normal 
breast. Méthylation of the  HS3ST2 and HS3ST4 CpG islands in normal breast 
tissue was not d e tec ted  in any of the  20 normal b reast samples analysed. 
Normal breast in this case included normal ad jacen t breast tissue from 
mastectom y specimens for breast cancer (15 cases) and normal breast tissue 
from reduction mammoplasty specimens (5 cases). All samples w ere assessed 
histologically to  ensure they contained normal breast epithelial tissue only and 
did not contain carcinoma or benign proliferative disease. Representative 
results are  shown in Figure 4-5 MSPCR for HS3ST2 in normal breast tissue taken 
from mastectom y specimens, and Figure 4-6 MSPCR for HS3ST4 in normal breast 
tissue taken from m astectom y specimens
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4.1.5 Structure of the HS3ST3B Locus
Table 4-5 below shows the  HS3ST gene loci. HS3ST3B and HS3ST3A are  
homologues, located on chromosome 17. They are more than 90% identical a t  
the  nucleotide transcrip t level and overlap in the ir  substrate  specificities 
(Shworak, Liu e t  al. 1999). However, HS3ST3B is d ifferen t from HS3ST3A in 
having two possible CpG islands. One is located in exon 1 (HS3ST3BE1) and the 
o ther is 3kb upstream of this, proximal to  the  HS3ST3B promoter. It is this 
proximal CpG island th a t  has been analysed in previous reports (Chen, Chen e t  
al. 2003). Interestingly the  human genome da tabase  software predicts a 
transcript from the  anti-sense strand a t  this upstream CpG island, suggesting the  
CpG island a t  this locus may be re la ted  to HS3ST3B and possibly the  putative 
gene coded on the  antisense strand. It is unusual for a CpG island to be 
separa ted  into two parts and therefo re  both GC rich regions w ere analysed 
separately. For the  purposes of identification they were named as HS3ST3B (the 
upstream  CpG island) and HS3ST3BE1 (exon 1 CpG island).
Table 4-5 Chromosome location of the HS3ST Genes
G e n e L o c a t io n
HS3ST1 4p: 11.08m
HS3ST2 16q:22.73m
HS3ST3A 17p:13.3
H53ST3B 17p:14.15m
HS3ST4 16q:25.61m
HS3ST5 6q;114.49m
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4.1.6 MSPCR Sequencing of the HS3ST2 and HS3ST4 Loci
MSPCR sequencing was carried out on both the  HS3ST2 and HS3ST4 loci to 
determ ine  if the  CpG dinucleotides betw een the  primer annealing sites were 
also m ethylated, it is expected  th a t  gene silencing will be associated with dense 
méthylation of the  relevant CpG island [Laird, 2005 #2190.
Ten tumours positive by MSPCR for HS3ST2 méthylation and ten tumours positive 
by MSPCR for HS3ST4 méthylation were again subjected  to  MSPCR and the 
products were  cloned into pGEM Teasy as described in Materials and Methods. 
These clones w ere transformed into E.Coli pLys and grown on selective media. 
Clones were then sequenced as described in Materials and Methods and 
compared to the  non-modified sequence.
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4.2 Results
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Table 4-6. Summary of clinicopathological variables.
No. of patients 
(n=80)
Age
<50
51-65
>65
Unknown
17 (21%) 
25 (31%) 
30 (38%) 
8 (10%)
Tumour size (mm) 
0-20 
21-50 
>50
Unknown
16 (20%) 
41 (51%) 
7 (9%)
16 (20%)
Grade
1
2
3
Unknown
9 (11%) 
24 (30%) 
32 (40%) 
15 (19%)
Nodal status
Negative 
1 -3 Positive 
>3 Positive 
Unknown*
18 (23%) 
21 (26%)
19 (24%) 
22 (28%)
NPI
<3.4 
3.4-5.4 
>5.4
Unknown
7 (9%)
28 (35%) 
23 (29%) 
22 (28%)
ER status
Negative
Positive
Unknown
20 (25%) 
39 (49%)
21 (26%)
LV invasion
Negative
Positive
Unknown
33 (41%) 
26 (33%) 
21 (26%)
In clu d es one p atien t w ith  Inadequate n egative  sam ple (only on e node sam pled).
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Table 4-6 above summarises the  clinicopathological da ta  associated with the  
tum our bank th a t  was used for this analysis. Samples th a t  do not have 
clinicopathological d a ta  available for a param eter are  labelled as unknown for 
th a t  variable. The reason for lack of information for th a t  param eter  varied with 
each case and a specific cause is given for each sample in the  appendix. 
However, th e re  w ere a few primary reasons: 1) The sample did not have a case 
number a ttached  to  it and no clinical da ta  could be re trieved o ther than what 
was available in the  tum our bank d a ta  book 2) The pa tien t had limited surgery, 
e ither  a very small biopsy for diagnostic purposes or a ‘to i le t ’ procedure without 
axillary sampling for lymph node status.
Some of the  variables can be compared to local and national statistics to  give an 
idea if the  tumour bank is representa tive  of breast cancers in the  UK and locally. 
The ratio of age groups <50, 51-64 and >64 in the  tum our bank is 1:1.5:1.8. 
Using the  online resource from the  Scottish Health Statistics the  ratio of these  
age groups for the  w est of Scotland in 2003 was 1:2:2.4. This discrepancy in 
proportions may be explained by the  tumour bank's probable skew towards non­
screen d e tec ted  younger patients. Sampling screen d e tec ted  lesions w ithout a 
definitive diagnosis of invasive malignancy compromises pa tien t safety, this 
category of lumpectomy specimen was therefore  not sampled and probably lead 
to  the  change in ratios described above.
The ratio of grades in the  tum our bank was 2:5.4:7.2 for grades 1,2 and 3, this is 
slightly out of s tep with the  grading ratios suggested by the  Royal College of 
Pathologists (Elston and Ellis 1991) which are  2:3:5 for symptomatic breast 
cancers. The increased ratio of higher-grade cancers may be explained by the  
sampling of larger tumours and non-sampling of smaller tumours. Larger 
tumours tend to have higher grades and therefore  the  tum our bank has a 
g rea ter  proportion of these  tumours(Elston and Ellis 1991).
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4.2.1 Méthylation at CpG islands and Correlation with 
Ciinicopathoiogicai Data.
Table 4-7 Number of Tumours Positive for Méthylation at each Locus
G e n e N u m b e r  M e th y la te d
HS3ST1 0/80
HS3ST2 45/80
H53ST3A 0/80
HS3ST3B 30/80
HS3ST3BE1 15/80
HS3ST4 34/80
M éthylation a t each single locus was correla ted  w ith the  clinicopathological 
param eters listed in Table 4-6. Fisher’s exact te s t was used to  calcu late  
significance of m éthylation a t a locus with respect to  ER/PR positivity and 
lymphovascular invasion. The chi-squared te s t for trend  was used to  calcu la te  
significance for NPI, nodal s ta tu s, grade, tum our and age. W here th e  continuous 
variables; age, tum our size and NPI w ere concerned a Mann W hitney te s t was 
also perform ed to  te s t  for significance. The association betw een m éthylation a t 
d ifferen t loci was assessed using Fisher’s exact te s t. M éthylation of more than 
one locus and relationship to  clinicopathological variables was assessed using th e  
chi-squared te s t for trend .
The full results of all the  sta tistica l analyses carried  out a re  p resen ted  in Table 
4-14, Table 4-15, Table 4-16, Table 4-17, Table 4-18, Table 4-19, Table 4-20, 
Table 4-21, Table 4-22 and Table 4-23 a t th e  end of th e  results section. 
Correlations with a p value of 0.05 or less are term ed significant and those th a t 
have a p value betw een 0.05 and 1 a re  term ed  as showing a trend .
The correlations th a t w ere significant a re  as follows:
There is a positive correlation betw een m éthylation a t th e  HS3ST3BE1 CpG island 
and m éthylation a t HS3ST2 (p=0.009) and HS3ST4 (p=0.009).
There is a negative correlation betw een m éthylation a t the  HS3ST3BE1 CpG 
island and m éthylation HS3ST3B (p=0.04).
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There is a correlation betw een HS3ST2 m éthylation and grade (p=0.015) and 
strangely th e re  is a very strong correlation betw een lack of HS3ST2 m éthylation 
and nodal sta tus unknown (p=0.009) and NPI sta tus unknown (p=0.002).
HS3ST3B m éthylation is co rre la ted  with lymphovascular invasion (p=0.028).
HS3ST3BE1 m éthylation is co rre la ted  w ith age (p=0.04), NPI (p=0.047) and size 
(p=0.04).
The num ber of loci m ethylated  co rre la tes  with grade (p=0.04)
The correlations th a t show a trend  are as follows:
There is a trend  for num ber of loci m ethylated  to  be co rre la ted  with ER/PR 
negativity (p=0.054), NPI (p=0.06) and lymphovascular invasion (p=0.096).
4.2.2 MSPCR Sequencing
R epresentative results of MSPCR sequencing for HS3ST2 and HS3ST4 are  given in 
Figure 4-1 and Figure 4-2 respectively. In all cases th e  CpG dinucleotides 
betw een prim er annealing sites w ere  m ethylated , confirming th a t m éthylation 
a t th e  HS3ST2 and HS3ST4 CpG islands is not restric ted  to  th e  prim er annealing 
sites. In addition all of th e  intervening cytosines, not found in the  con tex t of a 
CpG dinucleotide, w ere converted  to  uracils, proving th a t this finding is not an 
a rte fa c t of incom plete sodium bisulphate conversion.
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Figure 4-1 HS3ST2 MSPCR Sequencing Data 
CLONE
HS2ST CPCDl 
HS2ST CPCD2 
HS2ST CPCD3 
HS2ST CPCD4 
HS2ST CPCD5ITAAGAGTTTGGGAGj TAAGAGTTTGGGAG TAAGAGTTTGGGAG TAAGAGTTTGGGAG TAAGAGTTTGGGAG TAAGAGTTTGGGAG
HS3ST2 MF
GTTGTT
GTTGTT
GTTGTT
GTTGTT
GTTGTT
GAGTTTTAT
GAGTTTTAT
GAGTTTTAT
GAGTTTTAT
GAGTTTTAT
TTAGGA
TTAGGAT
TTAGGAT
TTAGGAT
TTAGGAT
GGAGATGTTGGAAATGTAATgTTTGTTTTTj
g g a g a t g t t g g a a a t g t a a t H t t t g t t t t t I
GGAGATGTT ATGTAAt H t TTGTTTTt I
g g a g a t g t t g g a a a t g t a a t H t t t g t t t t t I
g g n n n t g t t g g a a a t g t a a t H t t t g t t t t t I
iG G A G T gT T G T T T T gG G A T T T T T T
æ g a g t H t t g t t t t H g g a t t t t t t
æ g a g t H t t g t t t t H g g a t t t t t t
g^ g a g t H t t g t t t t H g g a t t t t t t
g^ g a g tB t t g t t t t H g g a t t t t t t
GGTATTGTGgTATTTTGGTTAGTAGTTTTgGAGAAG^
g g t a t t g t g H t a t t t t g g t t a g t a g t t t t H g a g a a g /
GGTATT H t ATTTTGGTTAGTAGTTTt H gAGAAG/
g g t a t t g t g H t a t t t t g g t t a g t a g t t t t H g a g a a g ^
g g t a t t g t g B t a t t t t g g t t a g t a g t t t t H g a g a a g ^
TG G TA G gTT  
T  gH t T
t g g t a g B t t
t g g n a g H t t
t - g t a g H t t
GTTTTTTAGG
g t t t t t t a g g I
g t t t t t t a g g I
g t t t t t t a g g I
g t t t t t t a g g I
IG g T T T T T
IgH t t t t t  
IgH t t t t t a  
IgH t t t t t  
JgH t t t t t a
^TfcTAGGGTTATAGTAGTT
t^ H t a g g g t t a t a g t n g t t
t^ H t a g g g t t a t a g t a g t t
t^ H t a g g g t t a t a g t a g t t
t^ H t a g g g t t a t a g t a g t t
TAGT
TAGT
TAGT
TANT
TAGT
G T G T T T T T T g G A A A T T A T -A T T T T gG l
g n g t t t t t t H g a a a t t a t g a t t t t H g
g t g t t t t t t H g a a a t t a t g a t t t t H g
g t g t t t t t t H g n n a t t a t g a t t t t H g
g t g t t t t t t H g a a a t t a t g a t t t t H g
GGTTTAT
GGTTTAT
IGGTTTAT
GGTTTAT
GGTTTAT
GATTTTCGGCGCGGGTTTAT 
HS3ST2 MR (inverted)
PGem Teasy Vector Sequence is highlighted in m agenta. CpGs are  highlighted 
red. Cytosines converted to  thym idines are  highlighted yellow. Primer 
sequences are  also given and ann o ta ted . Clones HS3ST2 CPD1- HS3ST2 CPD5 are 
exam ples of sequencing results obtained  from MSPCR of tum ours followed by 
cloning into PGem Teasy and sequencing as described in M aterials and Methods. 
Sequences w ere aligned using th e  Gene Jockey program . N delineates a 
nucleotide th a t was unreadable and a dash indicates an artificial gap c rea ted  by 
th e  program to  allow best fit alignm ent
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Figure 4-2 HS3ST4 MSPCR Sequencing Data
CLONE 
HS3ST4CD1 
HS3ST4CD2 
HS3ST4CD3 
HS3ST4CD4 
H S3ST4CD5
g^I ^ R ttgti iGAGNGGGAAGi
Ig a g a g g g a a g I
jGAGAGGGAAGj 
Ig AG AG G G AAGI
Ig a g a g g g a a g I 
Ig ag ag g
lA G G A G T ffA N f ^  TTA" 
JAGGAGTTTAGTATTA^
:a g g a g t t t a g t a t t a | |
?A— AGTNNAGTATTAfj 
?AGGAGTTTAGTATTAT|
.GGATTTHr a g
g g a t t t B R a g
— a t t t B R AG
g g a t t t B R a g
g g a t t t B R a g
HS3ST4M.F
GGAGTAGi
g g a g t a g I
GGAGTAGi
Ig g a g t a g I
g g a g t a g I
ÆNGGGG
^GAGGGG
vG-------G G
iGAGGGGl
iGAGGGG
TTAGTATTTT
It t a g t a t t t t i
TTAGTATTTT
TTAGTATTTT
TTAGTATTTT
TTAT
TTAT
TTAT
TTAT
TTA T
GGGGAGAAGAAGTTGTTATAGGgTTTATTAT
g g g g a g a a g a a g t t g t t a t a g g H t t t a t t a t I 
GN— g a a g a a g t t g t t a t a g g H t t t a t t a t I 
g g g g a g a a g a a g t t g t t a t a g g H t t t a t t a t I 
g g g g a g a a g a a g t t g t t a t a g g B t t t a t t a t I IGGGTTAAGAAAGGAGGGATTg g g t t a a g a a a g g a g g g a t t
GGGTTAAGAAAGGAGGGATT
g g g t t a a g a a a g g a g g g a t t !
GGGTTAAGAAAGGAGGGAT 
TTCTTTCCTCCCTAA^^m 
HS3ST4M.R (Inverted)
PGem Teasy Vector Sequence is highlighted in m agenta. CpGs are  highlighted 
red. Cytosines converted to  thym idines are  highlighted yellow. Primer 
sequences are  also given and anno ta ted . Clones CD1-CD5 are  exam ples of 
sequencing results obtained from MSPCR of tum ours followed by cloning into 
PGem Teasy and sequencing as described in M aterials and Methods. Sequences 
w ere aligned using th e  Gene Jockey program. N delineates a nucleotide th a t was 
unreadable and a dash indicates an artificial gap c rea ted  by the  program to  
allow best fit alignm ent.
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lOObpFigure4 -5 MSPCR for HS3ST2 in normal breast tissue taken from mastectomy specimens L=ladder. Marker sizes are given in base-pairs. All tissu e w as taken from either  
normal m eastec tom y  sp ecim en s for reduction m am oplasty or from normal breast tissu e in 
a m astectom y sp ecim en  for tumour.
10 11 12 13 14 15 16 -
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200bp
Figure 4 -6 MSPCR for HS3ST4 in normal breast tissue taken from mastectomy specimens L=ladder. Marker sizes are given in base-pairs. All tissu e w as taken from either  
normal m ea stec to m y  sp ecim en s for reduction m am oplasty or from normal breast tissu e in 
a m astectom y sp ecim en  for tumour.
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Table 4-8 Méthylation Status of HS3ST1 in Relation to the Tumours Described In the gels on
the previous page.
HS3ST1M HS3ST1UM Tum our
Database
ID
O utcom e
- + CDTDNX1 Unmethylated
- + CDTDER5 Unmethylated
- + CDTDC9H Unmethylated
- + CDTD24T Unmethylated
■ + CDTDGD1 Unmethylated
- + CDTDQ11 Unmethylated
- + CDTDHG5 Unmethylated
- + CDTDBDO Unmethylated
- + CDTDNL2 Unmethylated
- + CDTDSH3 Unmethylated
- + CDTD100 Unmethylated
" + CDTDNN5 Unmethylated
- + CDTDA3B Unmethylated
- Absent CDTDB4I Requires UM
- + CDTDTT2 Unmethylated
“ Absent CDTD2BS Requires UM
- Absent CDTDBBC Requires UM
- + CDTD123 Unmethylated
- + CDTDLFT Unmethylated
- + CDTDW90 Unmethylated
- + CDTDRS40 Unmethylated
- + CDTDHG7 Unmethylated
- + CDTDQWE Unmethylated
- + CDTDLD9 Unmethylated
Absent + CDTDGMH Requires M
(-) in d icates a n egative result for that form of th e  gen e, (+) in d icates a p ositive result for that 
form of th e  gen e and th e  ou tcom e is given in th e  right hand colum n.
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Table 4-9 Méthylation status of HS3ST2 in relation to the tumours described in the gels in
the previous page
HS3ST2M HS3ST2UM Tum our
Database
ID
O utcom e
+ + CDTDA45 Methylated
+ + CDTDD13 Methylated
- + CDTDB03 Unmethylated
+ + CDTDW90 Methylated
- + CDTDB66 Unmethylated
+ + CDTDRS40 Methylated
- + CDTDP07 Unmethylated
+ + CDTDL09 Methylated
- + CDTDV11 Unmethylated
+ + CDTDNQ2 Methylated
+ + CDTDF22 Methylated
- + CDTDE10 Unmethylated
- + CDTDRF3 Unmethylated
- + CDTDQ11 Unmethylated
+ + CDTDA37 Methylated
- + CDTDP30 Unmethylated
- - CDTDSS2 Unmethylated
+ + CDTDX10 Methylated
- - CDTDHD1 Repeat/Void
- - CDTDRP4 Unmethylated
(-) in d icates a n egative  result for th a t form o f th e gen e, (+) in d icates a p ositive result for that  
form of th e g en e, and th e  ou tcom e is given in th e  right hand colum n.
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Table 4-10 Méthylation status of HS3ST3A in relation to the tumours described in the gels in
the previous page
H S 3S T 3A U M H S 3S T 3A M T u m o u r
D a ta b a s e
ID
O u tc o m e
+ - CDTDP30 Unmethylated
+ - CDTDRS40 Unmethylated
- - CDTDV11 Unmethylated
+ - CDTD13 Unmethylated
+ - CDTDA45 Unmethylated
+ - CDTDA37 Unmethylated
+ - CDTDW90 Unmethylated
+ - CDTDFET Unmethylated
+ - CDTD101 Unmethylated
+ - CDTDWB6 Unmethylated
+ - CDTDQ11 Unmethylated
+ - CDTDFR2 Unmethylated
+ - CDTD123 Unmethylated
+ - CDTDOOY Unmethylated
+ - CDTDGD1 Unmethylated
+ - CDTDB4I Unmethylated
+ - CDTD1XY Unmethylated
+ - CDTDXX1 Unmethylated
+ - CDTDC9H Unmethylated
+ - CDTDNN5 Unmethylated
(-) in dicates a negative result for that form of th e  g en e, (+) in d icates a p ositive result for that  
form of th e  g en e, and th e  ou tcom e is given in th e  right hand colum n.
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Table 4-11 Méthylation status of HS3ST3B in relation to the tumours described in the gels in
the previous page
HS3ST3B
M
HS3ST3B
U M
Tum our
D atabase
ID
O utcom e
+ + CDTDW90 Methylated
+ + CDTDP07 Methylated
- + CDTDQ11 Unmethylated
+ + CDTDRS40 Methylated
+ + CDTDL09 Methylated
+ + CDTDJD1 Methylated
+ + CDTDNQ2 Methylated
+ + CDTDNL2 Methylated
+ + CDTDAA1 Methylated
+ + CDTDFR3 Methylated
+ + CDTDBB8 Methylated
+ + CDTDB04 Methylated
+ + CDTDL99 Methylated
+ + CDTDWB6 Methylated
+ 4- CDTDXP6 Methylated
+ + CDTDTT2 Methylated
E E CDTDF07 Void
+ + CDTDNX1 Methylated
+ + CDTDER5 Methylated
- - CDTDBDO Void
(-) in d icates a n egative result for th a t form of th e  g en e, (+) in d icates a p ositive result for that 
form of th e  g en e, and th e  ou tcom e is given in th e  right hand colum n.
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Table 4-12 Méthylation status of HS3ST3BE1 in relation to the tumours described in the gels
in the previous page
HS3ST3BE1
M
HS3ST3BE1
U M
Tum our
D atabase
ID
O utcom e
- + CDTDSS2 Unmethylated
- + CDTDB03 Unmethylated
- + CDTDA64 Unmethylated
- - CDTDV11 Void
- - CDTDBS1 Void
- - CDTDE10 Void
- + CDTDB66 Unmethylated
+ - CDTDF22 Methylated
- + CDTDRP4 Unmethylated
+ + CDTDP30 Methylated
- + CDTDWB6 Unmethylated
" - CDTDBB7 Void
- - CDTDG41 Void
+ + CDTDFR2 Methylated
+ + CDTDLH8 Methylated
- + CDTDNX1 Unmethylated
+ CDTDHG5 Methylated
- CDTDER5 Requires UM
- CDTDGD1 Requires UM
- CDTDG11 Requires UM
+ CDTDNQ2 Methylated
{-) in d icates a n egative  result for that form o f th e  gen e, (+) in d icates a p ositive result for that  
form of th e  g en e, and th e  ou tcom e is given in th e  right hand colum n
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Table 13 Méthylation status of HS3ST4 in relation to the tumours described in the gels in the
previous page
HS3ST4M HS3ST4UM Tum our
Database
ID
O utcom e
- Absent CDTDA45 Requires UM
- Absent CDTDD13 Requires UM
+ Absent CDTDX10 Methylated
+ Absent CDTDP30 Methylated
“ - CDTDBIG Void
- + CDTDQ11 Unmethylated
+ - CDTDP07 Methylated
+ + CDTDL09 Methylated
+ + CDTDW90 Methylated
+ + CDTDJD1 Methylated
+ + CDTDB66 Methylated
- - CDTDSS2 Void
+ + CDTDBS1 Methylated
- - CDTDE10 Void
+ + CDTDHG5 Methylated
+ + CDTDAA1 Methylated
+ + CDTDFR2 Methylated
- + CDTDNQ2 Unmethylated
+ - CDTDG41 Methylated
- + CDTDBB7 Unmethylated
+ + CDTDB03 Methylated
+ + CDTDFS2 Methylated
+ + CDTDHG7 Methylated
+ - CDTDHD1 Methylated
- - CDTDRF3 Void
- - CDTDRP4 Void
- - CDTDH19 Void
- + CDTDGG1 Unmethylated
- - CDTDNP1 Void
- + CDTDFF5 Unmethylated
- + CDTDBDO Unmethylated
+ + CDTDRZ3 Methylated
E + CDTDNN5 Repeat
Absent + CDTDXP6 Requires M
(“) in d icates a n egative result for th a t form of th e  gen e, {+) in d icates a p ositive result for that 
form of th e  g en e , and th e  ou tcom e is given in th e  right hand colum n, in th e  ca se  of th e  tum our 
CDTDNN5 th e  band w as eva lu ated  as equ ivocal as th e sam ple had flo a ted  out o f th e w ell w hilst it  
w as being loaded and th e  PCR w as rep eated  in this case.
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Table 4-14 Association between méthylation status at different loci.
HS3ST2 
Negative Positive
HS3ST3B 
Negative Positive
HS3ST3BE1 
Negative Positive
HS3ST3B
Negative
Positive 21 (60%) 29 (64%) 14 (40%) 16 (36%)
P=0.82
HS3ST3BE1
Negative
Positive 33 (94%) 32 (71%) 2 (6%) 13 (29%)
P=0.009
37 (74%) 28 (93%) 
13 (26%) 2 (7%)
P=0.040
HS3ST4
Negative
Positive 20 (57%) 26 (58%) 15 (43%) 19 (42%)
P=1.00
32 (64%) 14 (47%) 
18 (36%) 16 (53%)
P=0.16
40 (62%) 6 (40%) 
25 (38%) 9 (60%)
P-0.009
Significance a ssessed  by Fisher’s ex a c t te s t
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Table 4-15 Association between HS3ST2 méthylation and clinicopathological variables.
HS3ST2 M éthylation 
N egative Positive 
n=35 n=45 Significance*
Age
<50
51-65
>65
Unknown
8 (23%)
9 (26%) 
13 (37%) 
5 (14%)
9 (20%)
16 (36%)
17 (38%) 
3 (7%)
X^=0.02, df=1, P=0.90
including unknown: 
f= 1 .8 3 , df=3, P=0.61
T um our s ize  (mm) 
0-20 
21-50 
>50
Unknown
7 (20%) 
15 (43%)
2 (6%) 
11 (31%)
9 (20%) 
26 (58%) 
5 (11%) 
5 (11%)
f= 0 .5 1 , df=1, P=0.48
Including unknown: 
X^=5.57, df=3, P=0.13
G rade
1
2
3
Unknown
5 (14%) 
13 (37%) 
7 (20%) 
10 (29%)
4 (9%) 
11 (24%) 
25 (56%)
5 (11%)
X^=5.93, df=1, P=0.015
Including unknown: 
X^=10.99, df=3, P=0.012
Stage
1
2
3
Unknown
4 (11%) 
8 (23%) 
7 (20%) 
16 (46%)
14 (31%) 
13 (29%) 
12 (27%) 
6 (13%)
X^=0.86, df=1, P=0.35
Including unknown: 
X^=11.54, df=3, P=0.009
NPI
<3.4
3 .4 -5 .4
>5.4
Unknown
2 (6%) 
13 (37%) 
4 (11%) 
16 (46%)
5 (11%) 
15 (33%) 
19 (42%)
6 (13%)
xM . 83, df=1, P=0.18
Including unknown: 
X^=14.74, df=3, P=0.002
ER s ta tu s
N egative
Positive
Unknown
5 (14%) 
18 (51%) 
12 (34%)
15 (33%) 
21 (47%) 
9 (20%)
P=0.16 
Including unknown: 
xM . 48, df=2, P=0.11
LV invasion 
N egative 
Positive 
Unknown
12 (34%)
11 (31%)
12 (34%)
21 (47%) 
15 (33%) 
9 (20%)
P=0.79 
Including unknown: 
x"=2.28, df=2, P=0.32
* The first sign ifican ce te s t  for each  variable is th e  chi squared te s t  for trend or Fisher’s exact  
te s t  {for ER statu s and LV invasion) excluding th e  “unknown” category. The second te s t  is th e  chi 
squared te s t  for association  including th e  “unknown” category
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Table 4-16 Association between HS3ST3B méthylation and clinicopathological variables.
HS3ST3B M éthylation 
N egative Positive 
n=50 n=30 Significance*
Age
<50
51-65
>65
Unknown
9 (18%) 
16 (32%) 
20 (40%) 
5 (10%)
8 (27%)
9 (30%)
10 (33%) 
3 (10%)
X^=0.78, df=1, P=0.64
Including unknown: 
x"=0.91, df=3, P=82
T um our size  (mm) 
0-20 
21-50 
>50
Unknown
7 (14%) 
29 (58%) 
5 (10%) 
9 (18%)
9 (30%) 
12 (40%) 
2 (7%)
7 (23%)
X^=2.79, df=1, P=0.10
Including unknown: 
xM . 09, df=3, P=0.25
G rade
1
2
3
Unknown
6 (12%)
17 (34%)
18 (36%) 
9 (18%)
3 10%) 
7 (23%) 
14 (47%) 
6 (20%)
X^=0.81, df=1, P=0.37
Including unknown: 
X^=1.35, df=3, P=0.72
Stage
1
2
3
Unknown
12 (24%) 
14 (28%) 
11 (22%)
13 (26%)
6 (20%)
7 (23%)
8 (27%)
9 (30%)
X^=0.43, df=1, P=0.58
Including unknown: 
X^=0.57, df=3, P=0.90
NPI
<3.4
3 .4 -5 .4
>5.4
Unknown
4 (8%) 
19 (38%) 
14 (28%) 
13 (26%)
3 (10%) 
9 (30%) 
9 (30%) 
9 (30%)
X^=0.01, df=1, P=0.93
Including unknown: 
X^=0.56, df=3, P=0.91
ER s ta tu s
Negative
Positive
Unknown
10 (20%) 
28 (56%) 
12 (24%)
10 (33%)
11 (37%) 
9 (30%)
P=0.09 
Including unknown: 
X^=3.03, df=2, P=0.22
LV invasion 
Negative 
Positive 
Unknown
26 (52%) 
13 (26%) 
11 (22%)
7 (23%) 
13 (43%) 
10 (33%)
P=0.03 
Including unknown: 
X^=6.39, df=2, P=0.04
T h e  f i r s t  s ig n if ic a n c e  t e s t  fo r  e a c h  v a r ia b le  is th e  ch i s q u a r e d  t e s t  fo r  t r e n d  o r  F is h e r’s e x a c t  t e s t  {for ER s ta tu s  a n d  LV 
in v asio n ) e x c lu d in g  t h e  “ u n k n o w n ” c a te g o ry . T h e  s e c o n d  t e s t  is t h e  ch i s q u a r e d  t e s t  fo r  a s s o c ia t io n  in c lu d in g  th e  
“ u n k n o w n ” c a te g o ry .
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Table 4-18Association between HS3ST4 méthylation and clinicopathological variables.
HS3ST34 M éthylation 
N egative Positive 
n=50 n=30 Significance*
Age
<50
51-65
>65
Unknown
8 (17%) 
7 (37%) 
16 (35%) 
5 (11%)
9 (27%) 
8 (24%) 
14 (41%) 
3 (9%)
X^=0.03, df=1, P=0.89
Including unknown: 
X^=2.18, df=3, P=0.54
T um our size (mm) 
0-20 
21-50 
>50
Unknown
9 (20%) 
23 (50%)
4 (9%)
10 (22%)
7 (21%) 
18 (53%) 
3 (9%)
6 (18%)
X^=0.001, df=1, P=0.98
Including unknown: 
X^=0.21, df=3, P=0.98
G rade
1
2
3
Unknown
4 (9%) 
15 (33%) 
17 (37%) 
10 (22%)
5(15%) 
9(27%) 
15(44%) 
5 (15%)
X^=0.01, df=1, P=0.93
Including unknown: 
X^=1.64, df=3, P=0.65
Stage
1
2
3
Unknown
10 (22%) 
13 (28%) 
10 (23%) 
13 (28%)
8 (27%) 
8 (20%)
9 (27%) 
9 (27%)
X^=0.04, df=1, P=0,85
Including unknown: 
X^=0.40 df=3, P=0.94
NPI
<3.4
3 .4 -5 .4
>5.4
Unknown
4 (9%) 
18 (39%) 
11 (24%) 
13 (28%)
3 (9%) 
10 (29%) 
12 (35%) 
9 (27%)
xM . 40, df=1, P=0.50
Including unknown: 
X^=1.43, df=3, P=0.70
ER s ta tu s
N egative
Positive
Unknown
9 (20%) 
24 (52%) 
13 (28%)
3 (32%) 
8 (44%)
4 (24%)
P=0.27 
Including unknown: 
xM . 71, df=2, P=0.43
LV invasion 
N egative 
Positive 
Unknown
21 (42%)
12 (31%)
13 (28%)
12 (40%) 
14 (40%) 
8 (20%)
P=0.20 
Including unknown: 
X^=2.05, df=2, P=0.36
* The first sign ifican ce te s t  for each  variable is th e  chi squared te s t  for trend or Fisher’s exact  
te s t  (for ER status and LV invasion) excluding th e  "unknown” category . The second te s t  is th e  chi 
squared te s t  for association  including th e  "unknown” category.
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Table 4-17 Association between HS3ST3BE1 méthylation and clinicopathological variables.
HS3ST3BE1 Méthylation 
Negative Positive 
n=50 n=30 Significance*
Age
<50
51-65
>65
Unknown
16 (18%) 
21 (32%) 
21 (32%) 
7 (11%)
1 (7%) 
4 (27%) 
9 (60%) 
1 (7%)
xM . 32, df=1, P=0.04
Including unknown: 
xM . 67, df=3, P=0.20
Tumour size (mm) 
0-20 
21-50 
>50
Unknown
16 (25%) 
31 (48%) 
5 (8%) 
13 (20%)
0 (0%) 
10 (67%)
2 (13%)
3 (20%)
X^ =4.99, df=1, P=0.04
Including unknown: 
xM . 99, df=3, P=0.17
Grade
1
2
3
Unknown
9 (14%) 
19 (29%) 
25 (39%) 
12 (19%)
0 (0%) 
5 (33%) 
7(47%) 
3 (20%)
X^=2.38, df=1, P=0.31
including unknown: 
X^=2.37, df=3, P=0.50
Stage
1
2
3
Unknown
14 (22%) 
18 (28%)
15 (23%) 
18 (28%)
4(27%) 
3 (20%) 
4(27%) 
4(27%)
X^=0.01, df=1, P=0.94
including unknown: 
X^=0.49 df=3, P=0.92
NPI
<3.4
3.4-5.4
>5.4
Unknown
7 (11%) 
24 (37%) 
16 (25%) 
18 (28%)
0 (10%) 
4 (27%) 
7 (47%) 
4 (27%)
X^=3.93, df=1, P=0.047
Including unknown: 
X^=4.05, df=3, P=0.26
ER status
Negative
Positive
Unknown
17 (26%) 
31 (48%) 
17 (26%)
3 (20%)
8 (53%)
4 (27%)
P=0,73 
Including unknown: 
X^=0.27, df=2, P=0.088
LV invasion 
Negative 
Positive 
Unknown
27 (42%) 
20 (31%) 
18 (28%)
6 (40%) 
6 (40%) 
3 (20%)
P=0.75 
including unknown: 
X^=0.60, df=2, P=0.74
* T h e  f i r s t  s ig n if ic a n c e  t e s t  fo r  e a c h  v a r ia b le  is t h e  ch i s q u a r e d  t e s t  fo r  t r e n d  o r  F is h e r’s e x a c t  t e s t  (fo r ER s ta tu s  a n d  LV 
in v asio n ) e x c lu d in g  t h e  “ u n k n o w n ” c a te g o ry . T h e  s e c o n d  t e s t  is t h e  chi s q u a r e d  t e s t  fo r  a ss o c ia t io n  in c lu d in g  th e  
“ u n k n o w n ” c a te g o r y .
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Table 4-19 Association between HS3ST2 méthylation and continuous clinicopathological
variables.
HS3ST2 M éthylation
N egative Positive Significance
Age 61 (47 - 75) 62 (52 - 70) P=0.66
T um our size (mm) 25 (17-34) 30 (22-40) P=0.16
NPI 4.6 (4.2-5.4) 5.4 (4.4-6.4) P=0.09
Results shown as m edian (interquartile range). Significance assessed  by Mann-Whitney test.
Table 4-20 Association between HS3ST3B méthylation and continuous clinicopathological 
variables.
HS3ST3B M éthylation 
N egative Positive Significance
Age 62 (53 - 74) 60 (46 - 67) P=0.15
T um our size  (mm) 30 (25-40) 24 (18-36) P=0.18
NPI 4,7 (4.2-5.7) 5.4 (4 .4-6.6) P=0.46
Results shown as m edian (interquartile range). S ignificance a ssessed  by Mam
Table 4-21 Association between HS3ST3BE1 
clinicopathological variables.
méthylation
HS3ST3BE1 M éthylation 
N egative Positive Significance
Age 60 (48 - 72) 68 (60 - 72) P=0.13
T um our size  (mm) 28 (18-38) 32 (26-47) P=0.11
NPI 4.7 (4.2-5.9) 5.6 (4.5-5.9) P=0.15
Results shown as m edian (interquartile range). Significance a ssessed  by Mann-Whitney test.
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Table 4-22 Association between HS3ST4 méthylation and continuous clinicopathological
variables
HS3ST4 M éthylation
N egative Positive Significance
Age 61 (53 -72) 62 (46 - 72) P=1.00
T um our size  (mm) 30 (21-40) 29 (21-36) P=0.88
NPI 4.9 (4.2-5.6) 5.4 (4.3-6.5) P=0.62
Results shown as m edian (interquartile range). S ignificance assessed  by Mann-Whitney te st .
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Table 4-23 Association between number of methylated loci and clinicopathological
variables.
0
n= 13
N um ber of m e th y la ted  loci 
1 2 3 
n=27 n=24 n=15
4
n =1
Significanc
e*
Age
<50
51-65
>65
Unknown
1 (8%)
4 (31%)
5 (39%) 
3 (23%)
7 (26%) 
9 (33%) 
9 (33%) 
2 (7%)
7 (29%)
8 (33%) 
8 (33%) 
1 (4%)
2 (13%) 
4 (27%) 
7 (47%) 
2 (13%)
0 (0%) 
0 (0%) 
1(100%) 
0 (0%)
f= 0 .1 3 ,
df=1,
P=0.72
T um our size  
(mm)
0-20
21-50
>50
Unknown
3 (23%) 
5 (39%) 
1 (8%)
4 (31%)
6 (22%) 
14 (52%) 
2 (7%) 
5 (19%)
2 (8%) 
15 (63%) 
2 (8%) 
5 (21%)
5 (33%)
6 (40%) 
2 (13%) 
2 (13%)
0 (0%) 
1(100%) 
0 (0%) 
0 (0%)
%^=o.io,
df=1,
P=0.75
G rade
1
2
3
Unknown
1 (8%) 
6 (46%) 
2 (15%) 
4(30%)
5 (19%)
8 (27%)
9 (33%) 
5 (19%)
2 (8%) 
6 (25%) 
12(50%) 
4 (17%)
1 (7%) 
4 (27%) 
8 (53%)
2 (13%)
0 (0%) 
0 (0%) 
1(100%) 
0 (0%)
%"=4.18,
df=1,
P=0.04
Nodal s ta tu s  
N egative 
1-3 Positive 
>3 Positive 
Unknown
1 (8%) 
4 (31%) 
2 (39%) 
6 (23%)
7 (26%)
6 (33%)
7 (33%) 
7 (7%)
5 (29%) 
8 (33%)
5 (33%)
6 (4%)
5 (13%)
3 (27%)
4 (47%) 
3 (13%)
0 (0%) 
0 (0%) 
1(100%) 
0 (0%)
f = 0. 12,
df=1,
P=0.94
NPI
<3.4
3 .4 -5 .4
>5.4
Unknown
1 (8%)
5 (39%) 
1 (8%)
6 (46%)
3 (11%) 
12 (44%) 
5 (19%) 
7 (26%)
1 (4%) 
7 (30%) 10 (42%) 
6 (25%)
2 (13%) 
4 (27%) 
6 (40%)
3 (20%)
0 (0%) 
0 (0%) 
1(100%) 
0 (0%)
%'=3.53,
df=1,
P=0.06
ER s ta tu s
N egative
Positive
Unknown
1 (8%) 
8 (62%) 
4 (31%)
6 (22%) 
13 (48%) 
8 (30%)
7 (29%) 
12 (50%) 
5 (21%)
5 (33%)
6 (40%) 
4 (27%)
1(100%) 
0 (0%) 
0 (0%)
%'=3.71,
df=1,
P=0.05
LV invasion 
N egative 
Positive 
Unknown
6 (46%)
3 (23%)
4 (31%)
13 (48%) 
7 (26%) 
7 (26%)
9 (38%) 
8 (33%) 
7 (30%)
5 (33%) 
7 (47%) 
3 (20%)
0 (0%) 
1(100%) 
0 (0%)
%'=2.77,
df=1,
P=0.01
Chi squared te s t  for trend excluding th e “unknown” category.
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Discussion
M éthylation within th e  HS3ST gene family is variable in b reast tum ours, HS3ST3A 
and HS3ST1 are  never m ethy lated , w hereas th e  o thers HS3ST2, HS3ST3B and 
HS3ST4 are  all found to  be m ethylated . The high num ber of tum ours m ethylated 
a t th e  HS3ST2, HS3ST3B and HS3ST4 loci suggests th a t m éthylation of these  
genes may be significant in the  carcinogenic process. However, it must be borne 
in mind th a t this argum ent is based on the  prem ise th a t m éthylation has a 
functional consequence th a t is se lec ted  for during tum ourogenesis. The 
a lte rnative  hypotheses are th a t HS3ST1 and 3A loss of function are non-viable for 
a cell and loss of th ese  enzym es through m éthylation is never selec ted  for: Loss 
of HS3ST1 expression, may be selec ted  against as it is required for enhanced 
activity  of anti-throm bin III. Silencing of such an enzym e may lead to  g rea te r 
activation of th e  clotting system during invasive growth and m etastasis, a 
disadvantage for a cancer cell. The role of HS3ST3A is not as well defined, but 
th e  substra te  specificity of th e  enzym e is similar to  and overlaps th a t of 
HS3ST3B. Again, it may be speculated  th a t HS3ST3A and HS3ST3B function is of 
g rea t significance as th e re  has been gene duplication in this case and 
preservation of this arrangem ent during the  evolution of humans. M éthylation of 
th e  o ther loci may be a purely stochastic even t and have no functional 
significance for a cell. However, it has been shown th a t  tum our DNA is globally 
hypom ethylated (Bernardino, Roux e t  al. 1997) and th e re  is specific 
hyperm ethylation of areas in the  genom e. Hypomethylation is th e  defau lt 
position of a tum our cell DNA as a whole and therefo re  any hyperm ethylation, it 
could be argued, is significant.
M éthylation of HS3ST2 has been shown before to  be a high frequency even t in 
b reast cancers [Miyamoto, 2003 #43] and o ther tum ours, so this result is in 
keeping w ith previous analysis. In th e  study by Dr. Miyamoto (Miyamoto, Asada 
e t  al. 2003) 77 out of 85 b reast tum ours w ere m ethy lated  a t th e  HS3ST2 CpG 
island, this am ounts to  88% of th e ir sam ple num ber. In con trast, w e found 45/80  
tum ours to  be m ethylated  a t this locus, 56% of th e  sam ple num ber. This 
d ifference in findings may be due to  disparity in b reast tum ours or it could be 
due to  sensitivity, or specificity of MSPCR.
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In o rder to  validate th e  results of MSPCR a t th e  HS3ST2 and HS3ST4 loci and also 
to  assess th e  density of m éthylation a t these  loci m éthylation specific 
sequencing was carried  out on a to ta l of 20 clones. The intervening CpG 
dinucleotides, located betw een each set of prim ers, w ere all found to  be 
m ethy lated . This suggests th a t  m éthylation d e tec ted  using th e  MSPCR prim ers 
was also a surrogate m arker for dense m éthylation and therefo re  should 
correspond to  transcrip tional silencing of th a t gene. In th e  previously reported  
study of Dr. Miyamoto m éthylation a t  th e  HS3ST2 locus was also corre la ted  with 
dow n-regulation of transcrip tion.
4.2.3 Statistical Correlation of Méthylation and 
Clinicopathological Variables
Prior to  discussing any of th ese  findings it must be s ta ted  th a t the  likelihood of 
finding significant correlations in any form of sta tistica l analysis becom es more 
probable th e  g rea te r th e  num ber of te s ts  perform ed. It is with this caveat in 
mind th a t th e  results for th ese  analyses are in te rp re ted .
The negative correlation betw een m éthylation a t HS3ST3BE1 and HS3ST3B, and 
th e  positive correlation betw een m éthylation a t HS3ST3BE1 and HS3ST2 and 
HS3ST4 is in teresting . These observations are open to  some speculation. With 
respect to  3B and 3BE1 m éthylation it could be argued th a t m éthylation a t 
e ith e r of th ese  two loci causes th e  sam e e ffec t and th e re fo re  m éthylation may 
be m utually exclusive. There is however, evidence to  support th e  idea th a t 
m éthylation a t one site Leads to  infiltration of m éthylation a t ad jacen t sites 
(Millar, Ow e t  al. 1999) and this does n o t appear to  h appen in this case. 
T herefore it may be argued th a t m éthylation a t only one of these  sites confers a 
closed chrom atin struc tu re  th a t prevents fu rther m éthylation a t the  ad jacen t 
site , certainly it would be in teresting  to  know th e  functional e ffec t of 
m éthylation a t  wach of th e  loci - it is not known if they  both have th e  same 
e ffec t.
In th e  case of HS3ST2 and HS3ST4 th e  seeding hypothesis does not hold as these 
genes are  located on d ifferen t chromosomes and th e re fo re  it may be (assuming 
m éthylation has a functional significance in the  case of th ese  genes) th e re  is an 
advantage conferred  from having lack of HS3ST3B and HS3ST2 or HS3ST3B and
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HS3ST4. This dual loss of expression would have th e  functional e ffec t of 
reducing th e  com plem ent of HS3ST genes in th e  endoplasm ic reticulum  and 
th e re fo re  some substra tes would escape sulphation. If this confers an advantage 
to  a cell in th e  form of increased growth facto r binding, or poten tia tion  then  it 
may be selec ted  for. A lternatively it may be th a t th e  prom oter regions of these  
genes have similar fea tu res  and a re  likely to  be m ethy lated  concordantly. There 
is evidence to  suggest th a t m éthylation of CpG islands occurs following down- 
regulation of transcription and this is d ependen t on lack of expression from th e  
gene(Song, Stirzaker e t  al. 2002; Stirzaker, Song e t al. 2004). If th ese  genes are 
silenced due to  lack of a common upstream  factor then  m éthylation a t th ese  loci 
may occur concordantly and this may explain th e  positive association.
Increasing tum our grade is co rre la ted  with m éthylation a t th e  HS3ST2, and 
num ber of loci m ethylated  co rre la tes with grade. Tumour grade is calcu lated  by 
counting m itotic activity, assessing nuclear pleomorphism and lastly by 
evaluation of tum our d ifferen tia tion  by form ation of acinar struc tu res. It is 
thought to  indicate tum our aggressiveness, larger, m ore advanced tum ours tend  
to  have a higher grade and sm aller, earlie r d e tec ted  lesions tend  to  be of lower 
grade. It is of in te rest th a t HS3ST2 is more likely to  be m ethylated  th e  higher 
th e  grade of th e  tum our, and suggests th a t silencing of this gene is required  in 
la te r stages of tum ourogenesis, not in th e  transform ation of benign to  DCiS, or 
DCIS into an invasive phenotype. The finding th a t num ber of loci m ethylated  
co rre la tes  w ith grade is in keeping w ith o th er studies th a t have shown increased 
CpG island m éthylation w ith increasing grades of tum our. (Herman, Civin e t  al. 
1997; Soares, Pinto e t  al. 1999; Salem, Liang e t  al. 2000; Dong, Pang e t  al. 2001; 
Uhlmann, Rohde e t al. 2003). The significance of this la tte r  finding is not 
readily in te rp re tab le  as th e  study does not have th e  power to  say which with 
confidence which specific genes are m ethylated  as tum our grade increases. It 
would be of g rea te r in te re s t to  know if two specific genes tended  to  increase in 
frequency of m éthylation in association with increasing tum our grade as this may 
allow m ore specific questions to  be asked over substra te  overlaps in the 
associated transferases, or perhaps prom oter sim ilarities betw een genes.
There is a very strong correlation  betw een lack of m éthylation a t HS3ST2 and 
NPI unknown and nodal s ta tu s unknown. In fac t this is th e  strongest correlation 
of all he sta tistica l analyses. The tum ours th a t are  negative for HS35T2
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m éthylation and have missing NPI or nodal sta tus a re  all from th e  GRI tum our 
bank with th e  exception of 2 tum ours which w ere co llected  fresh. The reason 
for this correlation may be due to  a common fac to r in th e  storage of these  
specim ens causing degradation of the  methyl group, they  may have been in a 
batch th a t was analysed to g e th er and th e re  was a technical problem w ith th a t 
particular batch of PCRs or m odifications. However, all reactions w ere  carried 
out in trip lica te , th e re fo re  it would have had to  be a recurring problem . The 
age a t operation da tes  from 1989 to  2003 for this group, which is not d isparate  
from th e  rem ainder of th e  tum ours in th e  bank. To some ex ten t this finding 
rem ains an anomaly, however it suggests th a t th e re  is a common non- 
pathological fac to r linking th e  tum ours and the  sta tus of th e  HS3ST2 locus.
HS3ST3B m éthylation is co rre la ted  with lymphovascular invasion. This finding 
can be re la ted  in a positive way to  previous work by Tim Huang and G raem e 
Brock (Brock, Huang e t  al. 2001; Huang, Cheng e t  al. 2003) th a t showed HS3ST3B 
was co rre la ted  with stage and grade of b reast tum ours. The previous studies did 
not provide a functional explanation of why this correlation existed . The d a ta  in 
this study would suggest th a t LVI may be increased in tum ours th a t lack HS35T3B 
expression thereby  leading to  increased nodal m étastasés and increased grade.
HS3ST3BE1 m éthylation is co rre la ted  with age, NPI and size. It is difficult to 
specu late  on th e  significance of th ese  particular findings in relation to  the  
HS3ST3B gene product, as it is not known w hat th e  functional significance of 
m éthylation a t this locus is. It may be re la ted  to  th e  product, but equally it may 
not and previous studies (Brock, Huang e t  al. 2001) have concen tra ted  on the  
dow nstream  locus ra th e r than  this one.
The trend  for num ber of loci m ethylated  to  be co rre la ted  with ER/PR negativity, 
NPI and lymphovascular invasion may be consistent with th e  finding in previous 
studies th a t m éthylation of CpG islands as a whole is increased with grade, stage 
and degree of d ifferentia tion  of a tum our (Costello, Fruhwald e t  al. 2000). NPI 
is calcu lated  from grade and stage, and LVI is associated with lymph node 
m etastasis and thereby  with increased stage.
There a re  a few  thorny issues th a t have to  be addressed in th e  discussion section 
th a t this analysis has thrown up. The first is the  lack of any HS3ST1 m éthylation, 
desp ite  this gene being found in a subtractive hybridisation library and being
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pivotal in the  decision to investigate the  méthylation s tatus of these  genes as a 
whole family. MSPCR only analysis the  méthylation status of the  few CpGs which 
are  located in the  primer sites and as such it is a limited examination of a CpG 
island. There have been studies th a t  dem onstrate  downregulation of a gene by 
méthylation a t  only a few CpG dinucleotides (Clark, Harrison e t  al. 1997; Graff, 
Herman e t  al. 1997; Millar, Ow e t  al. 1999; Stirzaker, Song e t  al. 2004) and it 
may be th a t  this is the  case in HS3ST1, however, the  method used to isolated 
this CpG island would suggest it is densely m ethylated. Therefore it is e i the r  the  
case th a t  the  CpG island was not m ethylated in the  initial tumours used to 
c rea te  the  library and represents  an error a t  th a t  stage, or the  number of 
tumours in this study was not significant enough to  pick up méthylation a t  tha t 
locus, or the  HS3ST1 primers w ere  ta rge ted  a t  the  wrong section of the  CpG 
island. Further work is required to resolve this issue.
With regard to the  s tatistical tests  performed on the  da ta  for HS3ST3BE1 
méthylation a slight aberration, or discontinuity is found between the  Mann- 
Whitney te s t  for the  continuous variables and Fisher's exact te s t  for these  
variables when th e re  are  examined as categorical statistics. The p values for 
Age, Tumour and NPi in the  Mann-Whitney te s t  a re  0.13, 0.11 and 0.15 
respectively and the  p values in Fisher’s exact te s t  a re  0.04. 0.04 and 0.047. 
The discrepancy is more apparen t than real when the  p values are  looked a t 
individually, however, th e  Mann-Whitney te s t  should be more sensitive than 
Fisher’s exact te s t  a t detecting  a significant association.. The reason for this is 
unclear however the  groups for age and tumour size and NPI have a number of 
samples th a t  fall into the  middle category in each case, but are a t  th e  ex trem e 
ends of the  categories. These tumours do not have as much e ffec t on the  
correlation when they a re  viewed as continuous variables. This issue may be 
more fully resolved with increased numbers of specimens.
An im portant question th a t  arise out these  findings is functional and re la tes  to 
the  relationship th a t  méthylation a t  these  loci has with transcription of the  
associated gene. In most of the  studies published to d a te  it has been shown th a t  
dense CpG island méthylation correla tes  with silencing of the  associated 
gene(Esteller 2005). Indeed, this relationship has been dem onstra ted  already 
for HS3ST2 by Dr Miyamoto in Tokyo. However, the  proportion of tumours, in 
this study, m ethylated a t  HS3ST2 is d ifferen t to  Miyamoto’s study. Therefore, it
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was necessary to  establish the  relationship in this particular setting, as 
transcription may be dependen t on which region of a CpG island is m ethylated. 
It was also sought to establish this relationship with regard to HS3ST4, and 
HS3ST3B, as these  genes had never been investigated with regard to  méthylation 
and transcription. This was possible in the  case of HS3ST4, but technical 
difficulties w ere  encountered  in the  case of HS3ST3B as the  gene is 96% 
homologous to HS3ST3A, making analysis of transcription a t  an RNA level 
impossible.
The biological e ffec t  of turning the  genes off is not fully understood, specifically 
w hat this means in terms of substrates in heparan sulphate molecules th a t  would 
still have sulphation a t  the  3’OH and substrates th a t  would no longer be 
sulphated. From a critics point of view this is im portant, it may be tha t  
silencing a t these  loci has no biological e ffec t and th e re  is sufficient substrate  
overlap betw een HS3ST3A and HS3ST1 to  catalyse the  necessary modifications to 
all the  heparan sulphates a tum our cell requires and turning the  others off is 
efficient, but not advantageous.
The issue of density of méthylation a t  the  HS3ST2 and HS3ST4 loci is addressed 
above and it appears th a t  for these  two genes a t  least MSPCR of the  CpG island 
shows an association with dense méthylation a t  th a t  sight. The issue of the  
biological e ffec t  of turning these  genes off has not been broached 
experimentally in this particular piece of work, however, an examination of the 
l ite ra ture  suggests th a t  each FIS3ST gene is required for specific substrates. 
There is some substra te  overlap betw een enzymes, but this is not broad and 
certain  substrates can only be sulphated by one specific HS3ST enzyme (Liu, 
Shworak e t  al. 1999). The relationship between méthylation a t  the  HS3ST2 and 
HS3ST4 genes and transcription is covered in the  next chapter.
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5 The Relationship of CpG isiand Méthylation to 
RNA Expression at the HS3ST2 and HS3ST4 
Loci
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5.1 Expression of HS3ST2 and HS3ST4 in Normal Breast 
Tissue
As dem onstrated  by MSPCR HS3ST2 and HS3ST4 genes are  frequently methylated 
in breast cancers. The significance of this observation is dependen t on the  
normal expression pattern  of these  genes, specifically if they are expressed in 
normal breast tissue. Therefore, analysis of expression in normal breast tissue 
was undertaken.
During the  collection of breast tumours from m astectomy specimens normal 
breast tissue was collected from sites more than 4cm away from the  tumour. 
The tissue was snap-frozen in liquid nitrogen, sectioned and RNA was ex tracted  
using Tri-reagent (Sigma) as described in Materials and Methods. Histological 
normality was confirmed on frozen section in every case.
DNA contamination was assessed using GAPDH trans-intronic primers and RNA 
concentrations were determ ined  by UV spectroscopy, as described in Materials 
and Methods.
RTPCR for HS3ST2 and HS3ST4 was carried out on the  ex tracted  RNA using the  
invitrogen superscript II system. In brief: first strand synthesis used a poly T 
primer, the  cDNA derived from this step  was used as a tem pla te  for PCR. In 
order to control for DNA contamination of PCRs two first strand synthesis 
reactions w ere set up for every sample, identical apart from the  omission of 
Superscript II (SSII) reverse transcriptase from one of the  reactions. Two PCRs 
w ere then set up for each sample: one used the  reaction th a t  contained SSII 
reverse transcriptase as a tem pla te , the  o ther used the  reaction th a t  did not 
contain SSII as a negative control. If a PCR product appeared in the  negative 
control there  was DNA contamination of th a t  sample and in terpreta tion was null 
and void.
GAPDH RTPCR was also carried out on all RNA samples using primers which span 
intron 2 within the  GAPDH gene. The forward primer anneals to a exon 1 and 
the  reverse primer anneals to  exon 2. The size of the  product is therefore  an 
indicator of the  tem pla te  th a t  the  primers anneal to. If a sample is pure 
processed mRNA the  primers produce a band 320bp in size and if a sample is
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contam inated by DNA or non-processed mRNA a band 350bp larger (the size of 
intron 1) is visible on a gel. If contamination following RTPCR with GAPDH trans- 
intronic primers was d e tec ted  the  sample was not used for RNA analysis.
5.2 Correlation of Méthylation at the HS3ST2 and HS3ST4 
CpG Islands with Transcription in Celi Culture and In 
Vivo
A screen for méthylation a t  the  HS3ST2 and HS3ST4 loci was carried out on 7 
different cell lines: MCF7, A2780, SVCT, HeLa, MCF-8, SUM149PT and SUM 102PT, 
using MSPCR. MCF7, the  breast derived tumour cell line was found to be 
m ethylated a t the  HS3ST2 CpG island and A2780, an ovarian cell-line (gifted by 
Prof. Bob Brown) was found to be m ethylated a t  the  HS3ST4 CpG island. These 
two cell lines w ere  used as in vitro tools, to study the  relationship between 
méthylation a t  the  CpG island and RNA expression from the  respective gene.
Méthylation status of the  CpG islands of both genes was determ ined using 
MSPCR. RNA expression was d e tec ted  using RTPCR, as described previously. We 
also t re a ted  cells with 5-aza-2-deoxycytidine to  reverse the  méthylation of the  
CpG islands.
A2780 cells and MCF 7 cells w ere  seeded a t  a density of 6x10^ c e l ls /10 cm plate 
on day 0, and exposed to 0, 0.1, 0.2, 0.5, 1 or 2mM 5-aza-2-deoxycytidine (5- 
aza-dC; Sigma) for 24 hrs on days 1 and 3. The cells w ere  cultured in fresh media 
a f te r  each tre a tm en t,  and harvested on day 4 using Tri-reagent, as described in 
Materials and Methods.
On harvesting the  cells both DNA and RNA was ex trac ted , méthylation status was 
determ ined  by MSPCR. The RNA was harvested and used for RTPCR as described 
previously.
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5.3 Correlation of Méthylation at the HS3ST2 and HS3ST4 
Loci with Transcription in Breast Tumour Samples
Méthylation and transcriptional correlation is apparen t in the  cell lines analysed. 
However, cell culture is an artificial environment and the  observations made in 
these  models do not always hold true  in vivo.
Carrying out RTPCR in a non-quantatitive fashion is a reasonable approach in a 
cell culture system as it gives a positive or negative result in a sample th a t  is 
believed to contain a homogeneous population of cells. Tumour extracts , from 
any site, contain an admixture of marrow-derived cells, fibroblasts, endothelial 
cells, and in the  case of breast tissue adipocytes, myoepithelial cells and 
possibly normal ad jacen t epithelial cells. Carrying out non-quantitative RTPCR 
on breast tumours requires th a t  the  sample is almost exclusively breast tumour, 
containing no, or as little as possible 'contam ination ' from normal cells.
Two approaches w ere  used to overcome this difficulty: in samples th a t  the re  
was enough tissue tumours w ere examined by naked eye and if breast tumour 
m aterial was clearly identified it was dissected using a scalpel from the  
surrounding normal tissue. Margins were taken within the  tumour mass and 
normal tissue was never present a t  the  margins. In o ther samples micro­
dissection was carried out using the  Arcturus Laser Capture Microscope and the  
associated RNA Extraction kit, as described in Materials and Methods.
The two approaches were not used side by side, use of the  gross dissection 
process was m ade first of all as a means of deciding w hether micro-dissection 
needed to be used in this instance.
53J  Micro-dissection of Tumour Samples
Breast tumour samples w ere  collected and stored as described previously. 
Samples were prepared as described in Materials and Methods. Micro-dissection 
of samples was undertaken using the  Arcturus Laser Capture System and the  
associated RNA extraction kit was used for harvesting RNA.
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5.4 Results
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5.4.1 Expression of HS3ST2 and HS3ST4 in Normal Breast Tissue
RNA expression of HS3ST2 and HS3ST4 was dem onstra ted  in 14/14 cases (100%) 
of cases of normal tissue. Figure 5-1 and Figure 5-4 show representative  results 
for RTPCR carried out on normal breast tissue specimens and these  results are  
summarised in Table 5-3 RTPCR for HS3ST2 and HS3ST4 in Normal Tissue. The 
figures show two reactions for each sample, one contains a cDNA tem pla te  th a t  
was constructed using the  reverse transcriptase enzyme superscript II (+) and the  
o ther lane contains tem p la te  constructed w ithout the  addition of the  SSI! 
reverse transcriptase (-). The la tte r  is a negative control for the  RTPCR reaction 
and would only be positive if th e re  was contamination by DNA. In all cases 
examined no such contamination was seen.
5.4.2 Expression of HS3ST2 and HS3ST4 in Ceil Culture
5.4.2.1 HS3ST2 and Cell Line WICF7
Figure 5-2 shows a number of MSPCR reactions for HS3ST2 th a t  were carried out 
on the  cell line MCF7. The figure shows six groups of two cell culture samples. 
Cell cultures for increasing concentrations of 2-deoxy-5-azacytidine w ere set up 
(Untreated-2.0uM) and a parallel culture  was se t up for each dose, but this 
culture was not t re a ted  with the  demethylating agent. This parallel culture 
should retain the  m ethylated s ta te  of the  HS3ST2 gene as it is not t re a ted  with
2-deoxy-5-azacytidine. The figure shows th a t  the  HS3ST2 locus remains 
m ethylated when un trea ted  and the re  is com plete  loss of méthylation a t  a 
concentration of 0.2uM and above.
Figure 5-3 shows the  corresponding HS3ST2 RTPCR results for the  cell cultures 
th a t  a re  detailed  in the  associated MSPCR reactions. The negative control for 
each RTPCR reaction is a tem p la te  which was constructed without addition of 
the  superscript II enzyme, as detailed  above. In this figure it can be seen th a t 
th e re  is a product just visible a t  the  0.1 uM concentration, however, com plete  
déméthylation of the  MSPCR primer sites does not occur until 0.2uM. This
Craig Peter Charles Dick Page 154 3/13/2007
indicates the re  may be partial déméthylation a t  this locus, e ither  between cells, 
or within the  CpG island and expression takes place. In order to address this 
question HS3ST2 MSPCR for the  unmethylated form of the  island would have to 
be carried out.
The association of HS3ST2 méthylation status and expression in MCF7 is 
summarised in Table 5-4 Correlation of Méthylation and Transcription of the 
HS3ST2 Locus in the  Cell Line MCF7.
5.4.2.2 HS3ST4 and Cell Line A2780
Figure 5-5 and Figure 5-6 show the  equivalent reactions detailed  in 5.4.2.1 for 
FIS3ST4 in the  setting of the  cell line A2780. In this case re-expression of FIS3ST4 
does not take place until the  0.2uM concentration, which corresponds with the  
loss of HS3ST4 méthylation.
The relationship of HS3ST2 méthylation status and expression in A2780 is 
summarised in Table 5-5.
5.4.2.3 Expression of HS3ST2 and HS3T4 in Grossly Dissected Tumour 
Samples
In to ta l  ten  samples w ere used from the  tumour bank to  assess méthylation and 
associated RNA expression in HS3ST2 and FIS3ST4. The details of the  tumours 
used and their  results are  given in Table 5-6 and the  statistical analysis of these  
results is shown in the  tables below.
Table 5-1 HS3ST2 Méthylation and Transcription in Grossly Dissected Tumour Samples
HS3ST2 RTPCR 
RTPCR (+ve) 
RTPCR ( - V 0 )  
Total
HS3ST2 M éthylation "Significance
M ethylated U nm ethylated
4  (57%) 
3 (43%) 
7 (100%)
2 (67%) 
1 (33%)
3 (100% ) P = 1 .0 0
^Significance calcul ated  Fisher’s ex a c t te s t .
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Table 5-2HS3ST4 Méthylation and Transcription in Grossly Dissected Tumour Samples
HS3ST4 RTPCR
RTPCR (+ve) 
RTPCR ( - V 0 )
Total
HS3ST4 M éthylation "Significance
M ethylated U nm ethylated
2 (40% )
3 (60% ) 
5 (100% )
4  80%)
1 (20% ) 
5 (100% ) P = 0 .5 2
"Significance ca lcu la ted  Fisher's exact te s t .
The tables above indicate th a t  the re  is no significant correlation betw een 
méthylation status of these  two genes and expression in the  case of the  grossly 
dissected tumour specimens. Reasons for this are  most probably due to  the  
admixture of cell types th a t  constitu te  a breast tum our sample. While 
méthylation can be found in tumour samples the  quantification of méthylation 
was not assessed in these  samples. It may be th a t  méthylation does not occur in 
all tum our cells, or also th a t  a sample is not a homogeneous sample of tumour 
alone but includes normal b reast epithelial cells. Samples will undoubtedly 
contain normal cells of some type be they endothelial or ad jacen t fibroblasts. 
Previously in this chap te r  it has been shown th a t  the  two genes HS3ST2 and 
HS3ST4 w ere expressed in normal breast tissue. It is expected  it is unlikely th a t  
a single breast tumour sample will contain a pure tum our cell sample and 
therefore  a t  least some RNA from normal cells will be present.
5.4.2.4 Micro-dissection
Micro-dissection and RNA extraction was largely unsuccessful in contrast to 
micro-dissection and DNA extraction. Samples did not produce the  quality of 
RNA th a t  was required to amplify GAPDH, our control mRNA. Various a ttem pts  
w ere  made a t  modifying the  cutting, staining, handling and extraction process to 
prevent RNA degradation.
In the  first instance the  sample was frozen immediately in liquid nitrogen, took a 
section and fixed this immediately in alcohol. The tim e from patien t to  fixation 
was less than an hour in some circumstances. This method in itself was not 
enough to prevent degradation. Time from fixation, through staining and 
eventual micro-dissection and harvesting was fu rther reduced. The machinery 
was cleaned and prepared with RNase Zap as was all the  glassware and DEPC
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t re a ted  w a ter  was used to  dilute staining medium and ethanol. In summary, this 
technique was ham pered by technical difficulties.
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300b 
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Figure 5.1 RTPCR for HS3ST2 in normal breast tissue taken from mastectomy specimens.
L=ladder, num bers re la te  to  th e  sp ec im en  that th e  tissu e w as taken  from , - is th e  n egative  
control (th e RNA extraction  w ithout th e  addition o f superscript!I a t th e  reverse transcriptase  
sta g e), + in d ica tes th at reverse tran scriptase w as added to  th e  RNA extraction . Marker sizes  
are given in base pairs.
2.0 Controls
Figure 5.2
5-azacytidine
R for H 12 in the M F7 cell line treate
300bp
200bp
100bp
with 2-deoxy-
Follow ing e ith er  no tre a tm en t (U) w ith  th e  d em eth y la tin g  drug 2 -d eoxy  5 -azacy tid in e or 
treatm ent with 0.1 uM, 0.2uM, 0.5uM, luM or 2uM. (-) is the negative control for each treatm ent; 
ce lls  w ere grown in p arallel, but not trea ted  w ith 2 -d exy-5-azacytid in e. (+) in d icates that 
th e ce ll line w as treated  with th e associated  dose of 2-deoxy-5-azacytidine. L is the m olecular 
ladder and s izes  are given in base pairs. This gel d em onstrates d ém éth y la tion  of HS3ST2 in 
th e MCF7 ce ll line follow ing treatm en t w ith O.ZuM 2-deoxy-5-azacytid in e, or concentrations  
above this. The postive control reaction is uses a plasmid tem plate that is artificially m ethylated  
and tre a te d  w ith  sodium  b isu lph ite and th e  n egative  con tro l con ta in s norm al unm odified  
genom ic DNA.
300bq&
200bp
100b(j
Figure 5.3 RTPCR for HS3ST2 in the MCF7 cell line treated with 2-deoxy- 
5-azacytidine
Follow ing e ith er  no tre a tm en t (U) w ith  th e  d em eth y la tin g  drug 2 -d eo x y -5 -a za cy tid in e  or 
treatm ent with 0.1 uM, 0.2uM, 0.5uM, luM or 2uM. (-) is the negative control for each treatm ent; 
reverse transcriptase w as not added to  th e RNA extraction m ixture. (+) indicates that reverse 
transcriptase w as added to  th e  RNA extraction  m ixture. L is th e  m olecular ladder and sizes  
are given in base pairs. This gel d em onstrates re expression  of HS3ST2 in th e MCF7 ce ll line 
follow ing trea tm en t w ith  0.1 uM 2-d eoxy-5 -azacy tid in e, or con cen tra tion s ab ove this. The 
n egative  controls remain blank dem onstrating that any signal is due to  th e  p resen ce of RNA 
and DNA contam ination  is not an issue.
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Figure 5.4 RTPCR for HS3ST2 in normal breast tissue taken from mastectomy specimens.
L=ladder, num bers re la te  to  th e  sp ec im en  that th e  tissu e w as taken  from , - is th e  n egative  
control (th e RNA extraction  w ithout th e  addition of superscript!! a t th e  reverse transcriptase  
sta g e), + in d ica tes th a t reverse tran scriptase w as added to  th e  RNA ex traction . Marker s izes  
are given in base pairs.
Figure 5.5 MSP 5-azacytidine for H in the M
2.0 Controls
300bp 
200bp
100bp
F7 cell line treated with 2-deoxy
Follow ing e ith er  no tre a tm en t (U) w ith  th e  d em eth y la tin g  drug 2 -d eoxy  5 -azacytid in e or 
treatm ent with 0.1 uM, 0.2uM, 0.5uM, 1uM or 2uM. (-) is the negative control for each treatm ent; 
ce lls  w ere  grown in p aralle l, but not trea ted  w ith 2 -d exy-5-azacytid in e. (+) in d icates that 
the ce ll line w as treated  with th e associated  dose of 2-deoxy-5-azacytidine. L is the m olecular 
ladder and s izes  are given in b ase pairs. This gel d em onstrates d ém éth y la tion  o f HS3ST2 in 
th e  MCF7 ce ll line follow ing treatm en t with 0.2uM 2-deoxy-5-azacytid in e, or concentrations  
above this. The postive control reaction is uses a plasmid tem plate that is artificially m ethylated  
and trea ted  w ith  sodium  b isu lph ite and th e  n ega tive  control con ta in s norm al unm odified  
genom ic DNA.
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200b
100b
Figure 5.6 RTPCR for HS3ST2 in the MCF7 cell line treated with 2-deoxy- 5-azacytidine
Follow ing e ith er  no tre a tm en t (U) w ith  th e  d em eth y la tin g  drug 2 -d eo x y -5 -a za cy tid in e  or 
treatm ent with 0.1 uM, 0.2uM, 0.5uM, 1uM or 2uM. (-) is the negative control for each treatm ent; 
reverse transcriptase w as not added to  the RNA extraction m ixture. (+) indicates that reverse 
transcriptase w as added to  th e  RNA extraction  m ixture. L is th e  m olecular ladder and sizes  
are given in base pairs. This gel dem onstrates re expression  of HS3ST2 in th e  MCF7 ce ll line  
follow ing trea tm en t w ith  0.1 uM 2-d eoxy-5 -azacy tid in e, or con cen tra tion s above this. The 
n egative  controls rem ain blank dem onstrating that any signal is due to  th e  p resen ce of RNA 
and DNA contam ination  is not an issue.
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Table 5-3 RTPCR for HS3ST2 and HS3ST4 in Normal Tissue.
T issue
N um ber
GAPDH HS3ST2 HS3ST4
1 ++ ++ ++
2 ++ ++ ++
3 ++ ++
4 ++ ++ ++
5 *f*+ ++ ++
6 ++ ++ ++
7 ++ ++ ++
8 ++ ++ ++
9 ++ ++ ++
10 ++ ++ ++
11 ++ ++ ++
12 ++ ++ ++
13 ++ ++ ++
14 ++ ++ ++
(+)=positive, (-)=negative. 1 4 /1 4  sam ples w ere p ositive for HS3ST2 expression and 1 4 /1 4  sam ples 
w ere positive for HS3ST4 expression  in normal breast tissu e (100%) in th e  ca se  of each  g en e.
Table 5-4 Correlation of Méthylation and Transcription of the HS3ST2 Locus in the Cell Line 
MCF7
[5-aza-2-deoxycytidine] HS3ST2 M éthylation Status HS3ST2 RTPCR
0 Methylated Negative
0.1 uM Methylated Positive
0.2uM Unmethylated Positive
0.5uM Unmethylated Positive
liiM Unmethylated Positive
2uM Unmethylated Positive
Table 5-5 Méthylation and Transcription of the HS3ST4 Locus in the Cell Line A2780
[g-aza-a-deoxycytidlne] HS3ST4 Méthylation Status HS3ST4
RTPCR
0 M ethylated Negative
O.luM Unmethylated Positive
0.2uM Unmethylated Positive
0.5iiM Unmethylated Positive
luM Unmethylated Positive
2uM Unmethylated Positive
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Table 5-6 Grossly Dissected Tumours and HS3ST2 and HS3ST4 Méthylation Status and 
RTPCR Results
Tum our  
D atabase ID.
HS3ST2M RTPCR
HS3ST2
HS3ST4M RTPCR
HS3ST4
Source
CDTDRP4 (+) (+) (+) F
CDTDA64 (+) (+) (+) F
CDTD101 (+) (+) F
CDTDW90 (+) (+) (+) TB
CDTDFS2 (+) (+) (+) F
CDTDHD1 (+) (+) F
CDTD4FT (+) (+) TB
CDTDWB6 (+) (+) F
CDTDFF5 (+) (+) F
CDTD123 (+) (+) TB
(+) in d icates a p ositive result, (-) ind icates a n egative result. TB=tumour bank, F=fresh
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5.5 Discussion
The association of méthylation a t  the  HS3ST2 and HS3ST4 CpG islands with 
silencing of transcription is in keeping with the  general consensus in the  
lite ra ture  - dense méthylation of a CpG island correla tes  with transcriptional 
silencing of th a t  gene (Esteller 2005; Esteller 2005; Esteller 2005).
Removing méthylation from these  CpG islands restored transcription from the  
respective genes in v i t ro  and this supports the  idea th a t  méthylation directly 
inhibits transcription. However, as with all demethylating agents, the  e ffec t  is 
not specific to the  gene th a t  is being studied. It is always possible th a t  
déméthylation and re-expression of o ther genes, such as transcription factors, is 
responsible for the  re-expression of HS35T2 and HS3ST4. This is a universal 
confounding factor in this type of experim ent and is not particular to the  HS3ST 
loci.
This chapter, and the  investigation of the  expression profile of this family of 
genes is limited. Essentially a relationship betw een méthylation a t  the  HS3ST2 
and HS3ST4 loci and transcriptional silencing of the  respective gene is supported 
by these  results. Of more importance is the  e ffec t th a t  non-expression has - 
does lack of 3-0-sulphation in specific molecules offer a means of acquiring one 
of the  six novel capabilities proposed by Weinberg and Hanahan?: limitless 
replicative potential, self-sufficiency in growth signals, insensitivity to  growth- 
inhibitory signals, evasion of programmed cell death , sustained angiogenesis and 
tissue invasion and metastasis(Hanahan and Weinberg 2000). Certainly heparan 
sulphate molecules are  involved in almost all of these  processes, as can be seen 
from the  tab le  a t  the  end of this chapter.
3-0-Sulphation is the  rarest modification of a heparan sulphate 
molecule(Danishefsky, Steiner e t  al. 1969) and therefore  it is ideally suited to 
selectively regulate  biological activities. Individual isoforms of heparan sulphate 
D-glucosaminyl 3-0-sulphotransferase (HS3ST) exhibit sequence-specific 
action(Raman, Myette e t  al. 2002), which crea tes  heparan sulphate structures 
with distinct biological functions. For example, HS3ST1 preferentially generates  
binding sites for anti-thrombin III (Zhang, Lawrence e t  al. 2001), w hereas HS3ST3
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isoforms c rea te  binding sites for the  gD envelope protein of herpes simplex virus 
1 (HSV-1), which enables viral entry  to cells(Liu, Shriver e t  al. 2002).
HS3ST enzymes comprise a presumptive sulphotransferase domain and a 
divergent N-terminal region. Domain swaps betw een cDNA species were  carried 
out in an a t te m p t  to localize the  domain or motif th a t  determ ines a family 
m em ber’s substrate  specificity(Yabe, Shukla e t  al. 2001). In this experim ent the  
N-terminal region of HS3ST1 was fused with the  sulphotransferase domain of 
HS3ST3A to  generate  N1-ST3(A). Similarly, the  N-terminal region of HS3ST3A was 
fused to  the  sulphotransferase domain of HS3ST1 to genera te  N3(A)-ST1. Wild- 
type and chimaeric enzymes w ere transiently expressed in COS-7 cells and 
ex tracts  w ere  analysed for selective generation of binding sites for an ti­
thrombin. HS3ST1 was 270-fold more efficient a t  forming anti-thrombin-binding 
sites than HS3ST3A, indicating its significantly g rea te r  selectivity for substrates 
th a t  can be 3-0-sulphated to  yield such sites, N3(A)-ST1 was as active as HS3ST1, 
w hereas the  activity of N1-ST3(A) was as low as th a t  of HS3ST3A. Analysis of 
Chinese ham ster ovary cell transfectan ts  revealed th a t  only HS3ST3A and N1- 
ST3(A) generated  gD-binding sites and conveyed susceptibility to infection by 
HSV-1.
This experim ent dem onstrates  th a t  the  substrate-specific properties of HS3STs 
are  defined by the self-contained sulphotransferase domain and are not directly 
influenced by the  divergent N-terminal region. This finding re-emphasises the  
specificity of each family m em ber of the  HS3ST family and shows th a t  they have 
definite  functions th a t  are  not redundant.
Heparan sulphate molecules can be sequenced. The technique is akin to  the  
Maxam and Gilbert technique for sequencing DNA molecules - the  terminal sugar 
is covalently linked to  a chemical reagent, cleaved from the  end of the  heparan 
sulphate and sent through a mass spectrom eter. The mass-profile of this 
term inal monomer reveals the  sugar’s identity and its sulphation pattern . 
Unfortunately, this technique is reliant on a pure sample of a heparan sulphate 
and, as can be imagined, sequencing an in v i t ro  sample th a t  is composed of 
many differentially modified heparan sulphates may prove to be impossible. The 
reason for mentioning this issue is th a t  currently the  function of HS3ST enzymes 
is assayed using tertia ry  assessments of their enzymatic activity e.g. the  ability
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to  produce functioning anti-thrombin Ilia, or the  internalisation of HSV-1 
particles into cells in cell culture. There is no technique to  directly d e tec t  3-0- 
sulphation of heparan sulphate molecules and this is a major hurdle in 
understanding how each family m em ber confers a d ifferent functional domain.
Heparan-sulphate glycosaminoglycans (HSGAGs) ac t a t  the  cell-extracellular- 
matrix (ECM) interface to  modulate cell signaling, thereby  regulating how a cell 
perceives its environment(Perrimon and Bernfield 2000). HSGAGs also in teract 
with various extracellular signaling molecules: growth factors, morphogens, 
enzymes and chemokines(DiGabriele, Lax e t  al. 1998; Sasisekharan, Shriver e t  al. 
2002). The specificity of these  interactions is dependen t on HSGAG sequence, 
spacing of binding sites and the  three-dimensional s tructure  of the  HSGAG chain 
(Gallagher 1995; Vives, Pye e t  al. 1999). HSGAGs, depending on location and 
sequence, impinge on tumour onset and progression in various ways, some of 
which are pro-tumourogenic and others of which are  anti-tumourogenic(Berry, 
Kwan e t  al. 2001; Liu, Shriver e t  al. 2002; Liu, Shriver e t  al. 2002; Liu, Shriver e t  
al. 2002; Shriver, Liu e t  al. 2002). HSGAGs a t  the  tumour-cell surface actively 
modulate the  tumourogenic process by regulating autocrine signaling loops th a t  
lead to unregulated cell growth(Sasisekharan and Venkataraman 2000; Liu, 
Shriver e t  al. 2002; Sasisekharan, Shriver e t  al. 2002). HSGAGs impinge on how 
an organism responds to  a growing tumour, including the  recruitm ent of cells of 
the  immune system to the  tumour site(Esko, Rostand e t  al. 1988), formation of a 
fibrin shell around the  tumour th a t  acts as a protective barrier(Stringer and 
Gallagher 1997; Rao and Pendurthi 1998; HajMohammadi, Enjyoji e t  al. 2003) 
and developm ent of new blood vessels to the  site of the  growing 
tumour(Vlodavsky, Goldshmidt e t  al. 2002; Blackball, Merry e t  al. 2003; Chen, 
Adenekan e t  al. 2004; Reiland, Sanderson e t  al. 2004). Compelling clinical 
evidence indicates th a t  pharmacological doses of heparin, a highly sulphated 
HSGAG, can have a marked e ffec t on tumour metastasis. Clinical trials have 
been designed to determ ine the  exact benefits of heparin therapy in 
cancer(Borsig, Wong e t  al. 2001; Borsig 2003; Borsig 2004). With all this in terest 
cen te red  around the  very substrate  th a t  the  HS3ST enzymes ac t on it would be 
surprising if 3-0-sulphation, or lack of it, did not in some way modulate the  
function of heparan sulphate.
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5.6 Conclusions
The findings in this chap te r  can be summarised as follows:
Méthylation of the  CpG islands of HS3ST2 and HS3ST4 is corre la ted  with gene 
silencing.
Déméthylation of the  CpG islands a t  these  loci is corre la ted  with re-expression 
of the  associated gene
The analysis of expression in the  gross tumour samples is uninformative as is the  
analysis using micro-dissected material.
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6 Materials and Methods
6.1 General Materials
6.1.1 Chemicals and Reagents
AnalaR and molecular biology grade chemicals were obtained from Fisher 
Scientific, Merck Ltd. (BDH Laboratory Supplies), Riedel-de Haën or Sigma 
Chemical Company Ltd. Other reagents obtained from alternative sources 
are mentioned in Table 6.1.
Table 6.1 Chemicals and reagents
Chemicals and reagents Supplier
[a-^^P]dCTP (3000 Ci/nmol) Amersham Pharmacia
Biotech
30% (w/v) acrylamide/bis 29:1 (3.3% C) BioRad
Acetic acid Fisher Scientific U.K. Ltd.
Agar Difco Laboratories
Agarose Boehringer Mannheim
Bacto® tryptone Difco Laboratories
Bacto® yeast extract (without amino Difco Laboratories
acids)
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Boric acid Fisher Scientific U.K. Ltd.
Chloroform Fisher Scientific U.K. Ltd.
Ethanol, absolute 100%, analytical Bamford Laboratories 
reagent
ExpressHyb hybridization solution 
Hydrochloric acid 
I PTC 
PMSF
Sephadex® G-50
Sepharose Cation Exchange Matrix
Sodium dodecyl sulphate 
X-gal
Clontech
Fisher Scientific U.K. Ltd.
Boehringer Mannheim
Boehringer Mannheim
Amersham Pharmacia
Biotech
Amersham Pharmacia
Biotech
Anachem
Boehringer Mannheim
6.2 General Disposable Plasticware
General disposable plasticware materials used during the  course of this project 
are listed in Table 6.2 below.
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Table 6.2. Plastic materials and suppliers.
Plastic Materials Supplier
0.2 ml micro-tubes ABgene®
5ml Chromatography Columns Novagen
15 ml centrifuge tubes, gamma Sterilin 
irradiated
20 pi, 200 pi and 1 ml filter pipette  Rainin Instrument Co.
tips Inc. and Greiner
Labortechnik
200 pi and 1 ml p ipette  tips Sarstedt
50 ml centrifuge tubes Sterilin
90 mm Petri dishes Philip Harris Scientific
Thin-wall polycarbonate 96-well Costar
plates and thermosealers
6.2.1 Tissue Culture Disposable Materials
Tissue culture disposable plastic materials are listed in Table 6.3 below.
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Table 6.3. Tissue culture materials and suppliers. 
Disposable Materials Supplier
100 X 20 mm polystyrene tissue culture dishes Corning
25 cm^ tissue culture flasks Costar and Iwaki
5, 10 and 25 ml pipettes Corning
6-, 12- and 96-well tissue culture microplates Iwaki
60 X 15 mm polystyrene tissue culture dishes Corning
75 and 150 cm^ tissue culture flasks Iwaki
Cell scrapers
Cryo 1 °C freezing container
Sigma
Nalgene
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6.2.2 Enzymes
The enzymes used for DNA analysis are listed in Table 6.4, together with their 
suppliers, from where their reaction buffers were also obtained.
Table 6.4. Enzymes and suppliers.
Enzyme Supplier
Taq DNA polymerase Bioline
T4 DNA ligase GibcoBRL Life Technologies
EcoRI GibcoBRL Life Technologies
Msel New England Biolabs
Mspll New England Biolabs
Hhal New England Biolabs
Hpall New England Biolabs
SssMethyltransferase New England Biolabs
HbaMethyltransferase New England Biolabs
Proteinase K Boehringer Mannheim
Superscript 11 Invitrogen
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6.3 Nucleic Acids Size markers and Mass Ladders
Following gel electrophoresis, DNA and RNA samples were sized and /or 
quantified using the  following size markers or mass ladders listed in Table 2.5.
Table 6.5. Nucleic acid size markers and/or mass ladders and their suppliers.
Size marker and /or mass ladder Supplier
1 kb^ ruler GibcoBRL Life Technologies
2.5 kb molecular ruler BioRad
HaelW digested <^ X174 DNA New England Biolabs
High MW mass ladder GibcoBRL Life Technologies
Hindi 11 digested X DNA New England Biolabs
Low DNA mass ladder GibcoBRL Life Technologies
RNA ladder GibcoBRL Life Technologies
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6.3.1 Kits
The kits used during the  course of this project are listed in Table 6.6.
Table 6.6. Kits and suppliers.
Kit
CpG Modification Kit (S7820)
Supplier
Chemicon Serologicals
International
Nucleon® BACC kit Nucleon
PGEM®“Teasy vector system
QIAprep® miniprep kit
Promega
Qiagen
QIAquick® spin kit Qiagen
Ready-to-go DNA labelling beads (- Amersham Pharmacia Biotech 
dCTP)
6.3.2 Membranes and Paper
Hybond™-N'^ and Hybond™-N nylon membranes were obtained from Amersham 
Pharmacia Biotech.
Schleicher & Schuell supplied gel blotting paper. Saran wrap was obtained from 
Dow.
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6.3.3 Photography and Autoradiography
Agarose gels were photographed using a UVP gel documentation system 7500. 
Konica X-ray film and autoradiography cassettes were obtained from Genetic 
Research Instrumentation Ltd. Films were developed using an X-Ograph 
Compact X2 system (X-Ograph Ltd.). Both fixing and developer solutions were 
supplied by Kodak.
Micro-dissection photographs were taken with a Nikon coolpix digital camera.
6.3.4 Microscopes
An Arcturus laser dissection microscope was used during the  course of this 
project for micro-dissection of patient samples. Cells were collected on an 
CapSure® LCM Caps.
6.3.5 Spectrophotometer
A Shimadzu UV-1201 UV-Vis spectrophotom eter was used to determine purity 
and concentration of nucleic acids in aqueous solution.
6.3.6 DNA Crossiinker
A Stratagene® UV crosslinker 2400 was used during the  course of this project, 
to fix DNA onto nylon membranes.
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6.4 Experimental Materials
6.4.1 Bacterial Host Strains
Escherichia coli TOP10 strain was obtained from Invitrogen, Dh 5 alpha strain 
from Invitrogen, XL1-Blue Supercompetent and XL2-Blue Ultracompetent strains 
were obtained from Stratagene. E.Coli strain BL21 (DE3) pLys was obtained 
from a communal laboratory stock.
6.4.2 Vectors
pGEM®T-Easy bacterial vector was obtained from Promega and pCR2.1 vector 
was purchased from Invitrogen.
6.4.3 DNA Sources
pET6HMB, a modified form of pET11D (Novagen), containing the  Rat MecP2 HMB 
domain coding region, was gifted from Dr R. Brock.
6.4.4 Oligonucleotides
The oligonucleotide primers used in this project were obtained from Genosys. 
The primer sequences are listed in Table 2.7.
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Table 6.7. Oligonucleotides.
Name, 5'-3' sequ en ce, m elting tem perature (Tm) and target sequence.
Oligonucleotide Sequence 5 '-3’ Tm (°C) Product CpGs Cs
HS3ST1UMF
HS3ST1UMR
HS3ST1MF
HS3ST1MR
HS3ST1F
HS3ST1R
GGTTGTGTTGTTTTTGGGTGTGGT 64 X  102bp 4 9
TCCCCACTTTCCACAAAAACTCCT 64 X
CTTACGCACGCCGATAATAA
ATTGATCTGC GGCGACAGCT
CCCTAGTAAT TGAAGGCCTG
65 X
64 X 723bp na na
64 X na na
HS3ST2UMF
HS3ST2UMR
HS3ST2MF
HS3ST2MR
HS3ST2F
HS3ST2F
TGGGAGTGTTTGAGTTGTTTG
TCCATAAACCCACACCAAAA
CGTAAGAGTTTGGGAGCGTTCG
ATAAACCCGCGCCGAAAATC
GGCATTTCCCGAAGAGCCAGA
CTTGGGTGAGCCGGAGTGGTT
59 X 278bp 4 9
59 X
65 X 285bp 3 7
65 X 10
64 X 713bp na na
64 X na na
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HS3T3AUMF
HS35T3AUMR
HS3ST3AMF
HS3ST3AMR
HS3ST3AF
HS3ST3AR
TTTGAGTGGGAGATAGGAGGTTTGTG 66 X  114bp 3 7
CCAACCCAACCCAACCACAC
TTCGTTTGGGCGCGTTTT
ATGGGGGACA CTGGGGAAGG
GGTCTTGGCA GCGGTGTCG
66 X
62 X  252bp 3 8
AAAACAACCGATAAACGCCTACGA 62 X 1 10
59 X  663bp na na
59 X na na
HS3ST3BUMF
HS3ST3BUMR-
HS3ST3BMF
HS3ST3BMR
HS3ST3BF
HS3ST3BR
AGTTTTGGGTTGGATTTATTTGG
AGTTAAGTTTCGGGTCGGATTT
TTCACGACACAACCTACGACTC
Cloned from GB library
Cloned from GB library
60 X  264bp 3 10
ACACATAAAAATTTCACAAC ACAACC 60 X
60 X  222bp 2 8
60 X
875bp na na
na na
HS3ST3BE1.1UMF.1 TGGTTGTGGGTATATGGGGGTAA 65 X  242bp 4 8
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HS35T3BE1.1 UMR. 1 ACAACACMACTTCCTCCTCACCA 65 X
HS3ST3BE1MF TGTTCGGCGGGATTTACGTT
HS3ST3BE1 MR CTCACCGACGACGAAAACGA
65 X  149bp 3 10
65 X 11
HS3ST3BE1F TTCCTGCGCA GTTCGCCTCT 59 X  654bp na na
HS3ST3BE1R CGGCCATCTC CTTGCCTGAA 59 X na na
HS3ST4UMF
HS3ST4UMR
HS3ST4MF
HS3ST4MR
HS3ST4F
HS3ST4R
TTTATTTAAGGAGGTGTTGTTTGA 57 X  223bp 0 6
TAAATTCCAACCACACAAATACA
CCAACCACGCAAATACGTTTA
TTCCACGCCCTTCGAGCATC
CGGAGGTGGGAGGCATCCTT
57 X
TTTTGTTTTGTTTTTCGCGTTT 59 X  240bp 2 14
59 X
62 X  778bp na na
62 X na na
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6.5 Solutions
6.5.1 General Solutions
X DNA X Hind\\\ and (|)x174 DNA x HaeWl size ladders
25 ng/pl X DNA digested with Hmdlll and 25 ng/pl (j)x174 DNA digested with 
Hae\\\, 1X TE, 1X DNA loading dye.
0.5M EDTApH 8.0
0.5M EDTA with NaOH to pH 8.0.
1 kb+ ladder
60 ng/pl 1 kb ladder, 1X DNA loading dye in 1X TBE.
10% (w/v) SDS
10 % (w/v) SDS in HzO.
100X Denhardt’s solution
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1% (w /v) FicoU®400, 2% (w /v) polyvinylpyrolidone, 2% (w /v) BSA.
100X Ethidium brom ide-acridine orange stock solution
2.75 mM ethidium bromide, 1.25 mM acridine orange, 2% (v/v) ethanol in H2O.
IMTris.HCl pH 8.0 
1 M Trizma base and HCl to  pH 8.0.
IX TBE
90 mM Trizma base, 90 mM orthoboric acid, 2 mM EDTA.
2.5 kb molecular ruler
333 ng/pl of 2.5 kb molecular ruler in IX TE, 1X Orange G loading dye.
20X 5SC
3.0 M NaCl, 0.3 M sodium citra te .
Craig Peter Charles Dick Page 179 3/13/2007
20X SSPE
3.0 M NaCl, 0 .2  M NaHzP0 4 , 20 mM EDTA, pH 8 .0 .
3 M Sodium ace ta te  pH 7.5 
3 M sodium ace ta te  with NH3 to pH 7.5.
5X DNA loading dye
0.5% (w/v) SDS, 0.25% (w/v) xylene cyanol, 0.25% (w/v) bromophenol blue, 
1.5% (w/v) Ficoll®400, in 3XTBE.
5X Orange G loading dye
0.06 % (w/v) Orange G, 50 % (v/v) glycerol in H2O.
75% (v/v) Ethanol
75% (v/v) absolute ethanol in H2O.
80% (v/v) Ethanol
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80 % (v /v ) absolute eth anol in H2O.
Amplisize molecular ruler
333 ng/pl of amplisize molecular ruler in 1XTE, 1X Orange G loading dye.
Denaturing solution
0.5 M NaOH, 1.5 M NaCl in H2O.
Ethidium bromide
Stock solution: 25 mM in H2O.
Working concentration: 500 nM.
Lysis buffer
50 mM Tris.HCl pH 8.0, 100 mM EDTA pH 8.0, 0.5% (w/v) SDS in HzO.
Neutralising solution
1.5 M NaCl, 0.5M Trizma base and HCl to  pH 7.5.
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PCR buffer
45 mM Tris'HCl pH 8.8, 11 mM ammonium sulphate, 4.5 mM MgClz, 6.7 mM 2- 
m ercaptoethanol, 4.4 pM EDTA, 1 mM dATP, 1 mM dCTP, 1 mM dGTP, 1 mM 
dTTP and 113 pg/ml BSA.
Phenol
Phenol satu rated  in 10 mM Tris pH 8.0, 1 mM EDTA.
Phenol : ch lorof orm : isomayl alcohol, 25:24:1
Phenol:chloroform:isomayl alcohol, 25:24:1, saturated  in 10 mM Tris pH 8.0, 1 
mM EDTA.
Proteinase K
Stock solution: 20 mg/ml proteinase K in filter sterilised 50 mM Tris#HCl pH 
8 .0 .
TAE
40 mM Tris#acetate, 1 mM EDTA in HzO.
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TE
10 mM Tris.HCl pH 8.0, 1 mM EDTA pH 8.0 in HzO.
6.5.2 Bacterial Solutions, Media and Antibiotics
Ampicillin
Stock solution: 50 mg/ml in HzO (stored a t -20°C).
Working concentration: 100 pg/m l.
Chloramphenicol
Stock solution: 50 mg/ml in HzO (stored at -20“C), 
Working concentration: 20ug/ml.
IPTG
Stock solution: 100 mg/ml in HzO (stored a t -20°C).
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Working concentration: 10 pg /m l.
Luria-Bertani (LB) medium
3% (w/v) Bacto® tryptone, 0.5% (w/v) Bacto® yeast ex tract, 1% (w/v) NaCl. 
LB agar contained 1,5% (w/v) agar.
SOB medium
2% (w/v) Bacto® tryptone, 0.5% (w/v) Bacto® yeast ex tract, 0.85 mM NaCl, 0.25 
mM KCl pH 7.0 with NaOH. Sterilized 10 mM MgS04 added prior to  use.
SOC medium
0.04% (w/v) glucose in SOB medium.
X-gal
Stock solution: 50 mg/ml in dimethylformam ide (stored a t -20“C). 
Working concentration: 50 pg/m l.
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6.5.3 Tissue Culture Solutions, Media and Antibiotics
Tissue culture media, serum, antibiotics and solutions w ere obtained from 
GibcoBRL Life Technologies or Sigma.
Dulbecco’s modified Eagle medium (DMEM)
DMEM with 862 m g/l L-alanyl-L-glutamine (GlutaMax’), 4 m g/l pyrodoxine.HCl, 
4500 m g/l glucose, 110 m g/l sodium pyruvate.
Trypsin/EDTA solution
Stock solution: 5.0 g/l trypsin, 2.0 g /l EDTA, 8.5 g /l NaCl (stored a t -20“C). 
Working concentration: 0.5 g trypsin, 0.2 g EDTA«4Na/l in PBS.
Penicillin and streptomycin solution
Stock solution: 10,000 U/ml penicillin, 10,000 pg/m l streptom ycin. Utilising 
penicillin G (sodium salt) and streptom ycin sulphate: prepared in normal saline 
(stored a t -20“C).
Working concentration: 100 U/ml penicillin, 100 pg/m l streptom ycin.
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10X Dulbecco’s phosphate buffered saline (PBS)
8 g /l NaCl, 0.2 g /l KCl, 2 g /l KH2PO4, 2.16 g /l N a z H P 0 4 * 7 H 2 0 .
Foetal bovine serum (FBS)
Origin B.C. Virus and mycoplasma tested .
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6.6 Tissue Culture Methods
6.6.1 Feeding Cultured Cells
Cells w ere grown in a 5% CO2 incubator a t 37°C. Initially cells w ere cultured in 
25 cm^ flasks during the  first 5-10 passages. All solutions (cell growth medium, 
PBS and trypsin/EDTA) w ere warmed to  37° C. The old medium (5 ml) was 
removed carefully, avoiding scratching the  surface of the  cells. Cells w ere 
washed gently with 3 ml of PBS, and 5 ml of fresh culture medium was added. 
The sam e standard protocol was adapted for cells growing in 6-well clusters: 
each well was washed with 2 ml of PBS and th e  cells grown in 3 ml of cultured 
medium.
6 .6 .2  Subculturing Cultured Cells
Cells growing in 25 cm^ flasks w ere washed in PBS as described before: 2 ml of 
trypsin/EDTA solution added and th e  cells incubated a t 37°C, 5% CO2 for 5 
minutes. The cells w ere observed under th e  microscope to  check if they had 
rounded up and lifted off th e  surface of the  culture flask. The flask was tapped 
gently against the  bench to  help th e  cells dissipate from th e  surface of the  
flask. If necessary, the  cells w ere incubated for an extra two minutes and a cell 
scraper used to  make sure th a t nearly every cell was floating. Trypsin digestion 
was stopped by the  addition of 3 ml of fresh culture medium. The cell 
suspension was pippetted  up and down repeatedly to  dissociate cell clumps, 
and transferred into a 15 ml falcon tube. The cells w ere collected by 
centrifugation a t 200 g for 5 minutes, the  supernatant removed and the  cell 
pellet resuspended in 5 ml of fresh culture medium. A variable am ount of the 
cell suspension, dependent on the  split ratio (1:5 or 1:10), was collected and 
mixed with fresh growth medium, up to  a final volume of 5 ml. For the  higher 
split ratios cells w ere not collected by centrifugation a fte r trypsin digestion
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prior to seeding. Instead, a small aliquot of the cell suspension (usually 100 pi 
or 125 pi for split ratios of 1:50 or 1:40, respectively) was mixed with 5 ml of 
fresh medium and plated in a fresh 25 cm^ tissue culture flask. Cells were 
finally returned to the 37°C, 5% CO2 incubator. At every passage the number of 
population doublings was determ ined based on the cell number.
6 .6 .3  Measuring Cell Counts and Determining Population 
Doubling Times
Following trypsin digestion and neutralisation with standard growth medium, 
cells w ere counted on a haem ocytom eter, using a phase contrast microscope. 
The haem ocytom eter was covered with the coverslip and a drop of cell 
suspension was dropped a t the edge of the coverslip on both sides of the 
cham ber. At least 100 cells w ere counted, and the number of cells/m l 
calculated. The number of population doublings (PD) was determ ined, based on 
the  cell num ber for two consecutive passages as follows:
Equation 1
PD = log2 cell number a t passage n+1 x split ratio 
_cell number a t passage n
Finally, the population doubling times were calculated by dividing the number 
of population doublings, by the tim e over which they had occurred:
PDT = PD / tim e
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6.6.4 Freezing Cultured Human Cells In Liquid Nitrogen
A single cell suspension was obtained following trypsin digestion as described 
before (section 6.6.2). Cells w ere precipitated  by centrifugation a t 200 g for 5 
minutes, resuspended in fresh culture medium a t a concentration of -1.3-3 x 
10^ cells/m l and transferred  into 2 ml cryovials. Dymethylsulphoxide (DMSO) 
was added to  a final concentration of 10% (v/v), and then mixed well by gently 
inverting the  tubes.
The vials w ere transferred into a freezing container with isopropanol a t room 
tem peratu re , and cooled to  -70°C for a t least 4 hours. Finally the  frozen 
samples w ere moved to  liquid nitrogen (-190°C) until needed.
6.6.5 Thawing Cultured Human Cells
Frozen cell samples stored in liquid nitrogen w ere quickly thaw ed by immersion 
of th e  cryovials in a w ater bath a t 37°C. Five ml of fresh warm medium w ere 
added to  the  cells, and mixed gently by repeated  pipetting. The cells w ere 
then collected by centrifugation a t 200 g for 5 minutes, resuspended in fresh 
culture medium, and finally plated on a tissue culture flask or p late.
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6.7 Preparation, purification and analysis of DNA
6.7.1 Preparation of Plasmid DNA
Qiagen kits w ere used in order to obtain high yields of good quality plasmid 
DNA. DNA was purified from 5-ml bacterial cultures by alkaline lysis followed 
by anion-exchange columns, according to  th e  m anufacturer’s protocol.
6.7.2 DNA Extraction from Human Tissues
A 10mg to 20 mg piece of breast tissue was milled and placed in a 1.5 ml screw 
top Eppendorf tube with 550 pi of lysis buffer and 15 pi of 20 m g/m l of 
proteinase K to a final concentration of 530 pg/m l of proteinase K. The tissue 
was incubated overnight a t 60°C. The lysate was briefly centrifuged a t 21,000 g 
to  precip ita te  the  debris. Two hundred and fifty pi of supernatant was 
transferred  into a fresh tube, an equal volume of phenol was added and mixed 
vigorously by vortexing for 5 seconds to  emulsify the  two phases. The mixture 
was centrifuged for 5 minutes a t 21,000 g to  separate  th e  two phases. The 
upper phase was placed in a clean tube, 250 pi of phenol:chloroform:isoamyl 
alcohol (25:24:1) added and mixed vigorously by vortexing for 5 seconds. The 
upper phase was removed and transferred to  a clean tube. To remove any 
remaining traces of phenol, 250 pi of chloroform was emulsified with the 
aqueous phase by vortexing for 5 seconds.
The upper aqueous phase was transferred  to  a clean tube along with 25 pi of 
3M sodium ace ta te , pH 7.5 and mixed briefly by inverting th e  tube 5 to  10 
tim es. The DNA was finally precipitated  by the  addition of 500 pi of ice-cold 
absolute ethanol, incubated a t -20°C for a t least 1 hour, and spun a t 21,000 g 
in a bench top centrifuge. Supernatant was decanted, the  pelle t rinsed with 1 
ml of ice-cold 80% (v/v) ethanol and precipitated  by centrifugation a t 21,000 g
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in a top bench centrifuge. The DNA pellet was e ither air dried a t room 
tem peratu re  for 30 to 60 minutes, or a t 4 “C overnight. Once dried the  DNA 
pellet was dissolved in 100 to  200 pi of TE and heated to  60“C for 30 minutes, 
or a t 37“C overnight.
6 .7 .3  DNA Extraction from Cultured Human Cells
Cell culture DNA samples w ere ex tracted  using a Nucleon DNA extraction kit for 
blood and tissue culture, following the m anufacturer’s protocol. Briefly, cells 
w ere collected by centrifugation a t 800 g for 5 m inutes, resuspended in 
washing “Buffer MA”‘ and left on ice for 5 minutes. Cells w ere collected by 
centrifugation a t 1,300 g and subsequently lysed in “Reagent B”  ^ by gently 
pipetting up and down, followed by a 30-minute incubation a t 37“C. Proteins 
w ere precipitated  by the  addition of 5M sodium perchlorate and subsequently 
ex tracted  by the  addition of chloroform. Nucleon resin and centrifugation at 
370 g for 2 minutes. The upper aqueous phase was removed and transferred 
into a fresh 1.5 ml Eppendorf tube, w ithout disturbing the resin layer or the 
chloroform phase. An extra centrifugation step  a t 5,000 g for 2 minutes was 
perform ed to  pellet down any resin th a t might have been carried over. The 
supernatant was collected and transferred into a fresh 1.5 ml Eppendorf tube. 
DNA was precipitated by the  addition of ice-cold absolute ethanol and 
centrifugation a t 21,000 g for 10 m inutes. The supernatant was discarded and 
th e  DNA pellet washed in ice-cold 80% (v/v) ethanol and e ither air-dried a t 
room tem peratu re  for 30 m inutes, or a t 4°C overnight. Once dried, th e  DNA 
pelle t was dissolved in 100 pi of TE a t 60“C for 30-60 minutes, or a t 37“C 
overnight, and finally stored a t -20“C.
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6.7.4 Determination of DNA Concentration
When necessary, the  concentration and purity of DNA in aqueous solution was 
established by measuring th e  UV absorbance of the  solution a t wavelengths 
ranging from 200-300 nm. Pure double-stranded DNA solutions have an 
absorbance maximum a t 260 nm, a t which an optical density of 1 corresponds 
to  50 m g/m l of DNA in th e  solution. The purity of DNA samples was calculated 
by comparing the  ratio of the  OD a t 260 nm (OD260) to 280 nm (OD280), a t which 
wavelength proteins have an absorbance maximum. An OD260/OD280 ratio of 1.8 
or g rea ter is taken as an acceptable level of purity. DNA samples w ere diluted 
1:100 in H2O and the  spectrophotom eter baseline corrected with H2O. The OD 
was measured and the concentration calculated as 100 x 50 x OD260 mg/ml.
Alternatively, DNA concentrations w ere determ ined by electrophoresis on 
agarose gels, followed by densitom etry analysis against low molecular weight 
DNA mass ladder (GibcoBRL, Life Technologies), using Kodak Digital Science ID 
softw are (Kodak).
6.7.5 Polymerase Chain Reaction (PCR)
All PCR amplifications w ere carried out in e ither a Biometra Uno therm al cycler 
or a Biometra T3 therm al cycler, in e ither ABgene 96 well plates or ABGene 
thin walled 200 pi tubes. Each reaction was overlaid with w hite light mineral 
oil and then sealed. The therm al cycler lid was preheated to  105°C.
PCR amplifications w ere perform ed with 1 pM of each prim er, IX PCR buffer 
and 0.5 U Taq DNA polymerase in a to ta l volume of 10 pi. The annealing 
tem peratu re  varied according to  th e  primers selected  to  carry out the 
amplification, but in general fell within a range from 55“C to  68“C. Reactions 
w ere therm al cycled under th e  following conditions:
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Table 6.8 Generic PCR Cycle 
96“C for 1 minute
55-68“C for 1 minute
70“C for 1 minute
1 step: 60-68 ° C
for 1 m inute
1 step: 72° C for
10 minutes
20-35 cycles
6 .7 .6  DNA Cloning Techniques
6.7.6.1 Restriction Endonuclease Digestion of Plasmid DNA
Restriction digests were carried out with 1-5 pg of purified plasmid DNA, 5-10 
units of restriction endonuclease and 1X m anufacturer's restriction 
endonuclease reaction buffer in a to ta l of 10 pi with HzO w ere incubated a t 
37°C for 90-120 minutes.
6.7.6.2 DNA Ligation
Bacteriophage T4 DNA ligase was used to catalyse the  formation of 
phosphodiester bonds betw een the  3'-hydroxyl groups and the  5 '-phosphate 
groups of the DNA inserts and vectors. A recom binant plasmid with 2 single­
stranded nicks results owing to the removal of the 5 '-phosphate groups from
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the  digested vector. The nicks are repaired a fte r the recom binant plasmids 
have been introduced into com petent bacteria.
Ligations of vector and insert DNA w ere incubated a t 4 “C overnight with 1 U of 
bacteriophage T4 DNA ligase and 1X T4 DNA ligase buffer in a to ta l volume of 
10 pi. Generally, DNA molecules w ere ligated a t vector:insert molar ratio of 
1:3. Control ligations, with one com ponent missing, w ere also incubated a t 4°C 
overnight.
6.7.6.3 Transformation of Competent Bacterial Cells
Fifty pi aliquots of com petent cells w ere thaw ed on ice for 10 minutes. One pi 
of the  ligation mixture or 10 ng of control plasmid w ere added and a fte r gentle 
mixing, the  bacteria w ere incubated on ice for 30 minutes. The cells w ere 
heat-shocked a t 42°C for 45 seconds and cooled on ice for 2 minutes. Pre­
warmed SOC medium (450 pi) was added to the cells and the  samples 
incubated, with shaking (225rpm), a t 37°C for 1 hour. The transform ed cells 
w ere split into two aliquots of 50 pi and 450 pi, which w here subsequently 
spread on a Luria-Bertani (LB) p late  containing 100 pg/m l ampicillin, 50 pg/m l 
5-bromo-4-chloro-3-indolyl-B-D-galactoside (X-gal) and 10 pg/m l isopropylthyo- 
B-D-galactoside (IPTG), dried for up to  30 m inutes, and incubated a t 37°C 
overnight. Ampicillin, X-gal and IPTG are used to  positively select transform ed 
bacteria , which are resistant to  th e  antibiotic ampicillin, and are w hite 
because of the  insertional inactivation of the l a d  gene of the  recom binant 
plasmid. As a result (3-galactosidase is not synthesised and the  bacterial 
colonies are white ra ther than blue.
6.7.6.4 Generation of Plasmid Stocks
Stocks of bacteria transform ed with recom binant plasmids w ere prepared for 
long-term storage. A colony from an agar p late was used to  inoculate 5 ml of
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LB medium, containing 100 pg/m l of ampicillin and Incubated a t 37°C 
overnight. An aliquot of overnight culture (usually 500 pi) v^as mixed with an 
equal volume of 2% (w/v) peptone, 40% (v/v) glycerol, by repeated  inversion. 
The stocks w ere stored a t -70“C until needed.
6.7.6.5 Gel Electrophoresis
6 .7 .6.5.1 Agarose gel electrophoresis
DNA molecules w ere separated  according to  their size by agarose gel 
electrophoresis. Solutions of 0.8-2% (w/v) of agarose in 0.5X TBE w ere prepared 
in a microwave, the  solution was cooled to  approximately 50“C, ethidium 
bromide was added to  a final concentration of 500 nM and the  gel was cast in a 
horizontal tray. DNA samples w ere mixed with IX DNA loading dye and 
electrophoresed in 0.5X TBE for periods of tim e varying from 2-16 hours. An 
aliquot of a DNA size ladder (usually 100-200 ng) was also electrophoresed and 
used as a size m arker. Separated DNA samples w ere visualised using an UV 
transillum inator (wavelength 254 nm) and photographed.
6.7.6.6 Southern Blotting
DNA transfer from agarose gels onto a nylon mem brane by Southern “squash” 
blotting
Once th e  gels had run sufficient distance, a scalpel and a stainless steel ruler 
w ere used to  cut off excess gel not required. Gels w ere rinsed in deionised 
w ater, incubated in depurinating solution for 10 minutes, denaturing solution 
for 30 minutes and neutralising solution for 30 minutes and rinsed in deionised 
w ater betw een incubations, incubations w ere perform ed with gentle shaking.
A piece of Magna nylon m em brane the  same size as th e  gel was w et in 
deionised w ater first, and then in neutralising solution. A piece of Saran Wrap, 
som ewhat larger in size than the  gel, was placed on the  bench, with a piece of
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gel blotting paper, the  sam e size as the  gel and w et in neutralising solution, 
layered on top. The gel was placed on the  Saran Wrap, and th e  membrane 
layered on top of the  gel. Any air bubbles trapped under th e  membrane w ere 
carefully removed. Two sheets of gel blotting paper w ere rinsed in neutralising 
solution and layered onto the  membrane. The blot was topped with a thick 
layer of paper towels, a glass p la te  and a weight (500 g for a small gel, 1 kg 
for a large gel). The DNA was transferred  from the  gel onto the  m em brane by 
capillary action for 3 up to  16 hours. The blot was dismantled in reverse order 
and th e  mem brane placed on a piece of dry gel blotting paper, th e  DNA side 
up. The mem brane was baked for a t least 20 minutes in an 80“C oven and the 
DNA fixed to th e  mem brane by exposure to  1,200 J/m ^ in a UV cross linker.
6 .7 .7  Preparation of Radioiabeiied Doubie-Stranded Probes
Double-stranded DNA probes w ere radiolabelled using a-^^P-labelled 2 '- 
deoxycitidine-5’-triphosphate ([a-^^P]dCTP) and the  Ready-to-go kit, following 
the  m anufacturer's instructions. Briefly, 30 ng of DNA double-stranded probe, 5 
ng of DNA size m arker and HzO to  a final volume of 45 pi w ere denatured a t 
100“C for 5 minutes and quenched on ice for 3 minutes. The lyophilised 
reaction mix was resuspended in the  DNA solution. Five pi of [a-^^P]dCTP (3,000 
Ci/nmol) w ere added and th e  mixture incubated a t 37“C.After 1 hour the 
reaction was term inated by the  addition of 250ul of ddH20
Double-stranded DNA probes w ere purified using a 1.0 ml Sephadex® G-50 
column, prepared in a 1.0 ml plastic syringe. The Sephadex® was com pacted 
by centrifugation a t 1,800 g for 2 minutes. The probe was added to  the  column 
and centrifuged a t 2,000 g for 3 minutes. The e luate  was collected and the 
percentage of incorporation calculated by taking counts per minute (cpm) 
readings before and a fte r purification.
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6.7.8 Bisulphite Modification of DNA
Depending on the sample used the  DNÂ was modified with a Chemicon CpG 
modification kit, according to  th e  m anufacturer’s protocol, or using the 
following protocol.
6.7.8.1 Dénaturation.
1ug of DNA was digested using either Msel or Bglll in a to ta l volume of 25ul, the  
reaction was incubated a t 36“C for 3 hours. Dénaturation of the  DNA was 
carried out by adding 2.77ul of 3M NaOH to give a final concentration of 0.3M 
NaOH. This solution was incubated for 15minutes a t 37°C.
6.7.8.2 Deamination.
A solution of 4M sodium bisulphite and 6.25M urea was made up freshly for 
each reaction, pH was adjusted  to  5 using concentrated NaOH. 22ul of the  
digestion reaction was added to  208ul of th e  sodium bisulphite reaction and 
hydroquinone was added to  a final concentration of 0.5mM. The final 
concentrations of urea and sodium bisulphite w ere 5.36M and 3.44M 
respectively. This reaction was overlaid with mineral oil and subjected  to  the 
following program, using th e  Biometra therm al cycler: 55°C for ISminutes 
followed by 30 seconds a t 95 °C for 25 cycles - this reaction takes 
approximately 6-8hours depending on the  machine.
6.7.8.3 Desulphonation.
The reaction was then cleaned using a Quiagen PCR purification column and 
e lu ted  in 50ul of TE (Tris-EDTA), 5.5ul of 3M NaOH was added to  th e  e luent 
and incubated for 20minutes a t 36°C.
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6.7.S.4 Neutralisation and Desalting.
65ul of 5M NH40AC, 2uL of 20mg.ml'^ glycogen solution, and 360ul of 100% 
ethanol w ere added to  each reaction. The mixture was stored a t -20°C 
overnight and centrifuged a t 16Krpm on a benchtop centrifuge a t 4°C and the 
supernatant removed. The pellet was then washed twice with 70% ethanol and 
allowed to  air dry for 20mins before being dissolved in 30ul of TE pH8 and 
aliquoted into lOul volumes, before being stored a t -20“C,
lu l of each reaction was used as a tem plate  for MSPCR.
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6.8 Preparation, Purification and Analysis of RNA
6.8.1 RNA Extraction from Cultured Human Celis and Human 
Tissue
RNA is vulnerable to  degradation from nucleases, to  optimise the  successful 
handling of RNA, the  following precautions were taken 1) RNA work was 
restricted  to  a dedicated bench. 2) Dedicated equipm ent and stock reagents 
w ere used w herever possible and gloves w ere worn a t all tim es. 3) All solutions 
required for RNA related techniques w ere made using diethylpyrocarbonate 
(DEPC) trea ted  w ater. 4) DEPC was added to  a concentration 0.1% (v/v) to 
deionised w ater, mixed and allowed to  stand overnight before the  inactivation 
of th e  DEPC by autoclaving. 5) All plasticw are was soaked in active DEPC- 
trea ted  w ater before autoclaving, all glassware was soaked in active DEPC 
w ater before baking.
Cells w ere grown on a 75cm^ tissue culture flask until confluence was achieved. 
Approximately 6 x 1 0 ^  cells w ere collected a fte r trypsin digestion (see section 
6.6.2), washed once in IX PBS and lysed in 1 ml of Tri Reagent™ by repeated  
pipetting. The lysate was allowed to  stand for 5 minutes, to  ensure com plete 
dissociation of nucleoprotein complexes. Following cell lysis, 200 pi of 
chloroform w ere added, th e  mixture was shaken vigorously for 15 seconds and 
allowed to  stand for 15 minutes a t room tem perature. The mixture was then 
separated  into th ree  phases by centrifugation a t 12,000 # for 15 minutes a t 
4°C. The aqueous phase was transferred  into a fresh tube, 500 pi of 
isopropanol w ere added and th e  mixture was allowed to  stand for 10 minutes 
a t room tem peratu re. The RNA was precipitated  by centrifugation a t 12,000 g 
for 10 minutes a t 4°C. The supernatant was removed, the  RNA pelle t washed in 
1 ml of 75% (v/v) ethanol and collected by centrifugation a t 7,500 g for 5 
m inutes a t 4°C. The RNA pellet was let to  air-dried for 10-30 minutes and
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finally resuspended in 40 pi of DEPC trea ted  ddHzO. Repeated pipetting a t 60°C 
for 15 minutes facilitated RNA solubilisation.
6.8.2 Determination of RNA Concentration
The concentration and purity of RNA in aqueous solution was quantified by 
measuring the  UV absorbance of th e  solution a t wavelengths ranging from 200- 
300 nm. Pure RNA solutions have an absorbance maximum a t 260 nm, a t which 
a solution containing 40 m g/m l of RNA gives rise to an absorbance of 1. The 
purity of the  DNA samples was estim ated by comparing the  ratio of the OD a t 
260 nm to 280 nm, a t which wavelength proteins have an absorbance 
maximum. An ODzôo/ODzso ratio of 1.65 or g reater is taken as an acceptable 
level of purity. RNA samples w ere diluted 1:80 in HzO and the 
spectrophotom eter baseline corrected with HzO. The OD was m easured and the 
concentration calculated as 80 x 40 x ODz6o mg/ml.
6.8.3 RNA Visualisation by Agarose Gel Electrophoresis
In order to  assess RNA integrity and quality, RNA samples w ere electrophoresed 
through a 1% (w/v) agarose gel containing 0.1% (w/v) SDS, 500 nM ethidium 
bromide, and prepared in IX TAE. Five pg of RNA w ere diluted in DNA loading 
buffer to  a final volume of 10 pi, heated  a t 65°C for 5 minutes and immediately 
cooled on ice. The samples w ere electrophoresed a t 100 V for 1 hour, 100-200 
ng of 1 kb^ DNA size m arker was also electrophoresed. Separated RNA 
molecules w ere visualised using a UV transillum inator (wavelength 254 nm) and 
photographed.
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6.9 Slide Preparation for Laser Capture Micro-dissection
The sections w ere placed in the  following solutions for the annotated times.
1. 100% ethanol 15 
seconds
2. 95% ethanol - 15 
seconds
3. 70% ethanol - 15 
seconds
4. Deionized w ater - 
15 seconds
5, Mayer’s
Hematoxylin - 30 
seconds
6. Deionized w ater - 
rinse (x 2) - 15 
seconds
7. 70% ethanol - 15 
seconds
8. Eosin Y - 5 
seconds
9. 95% ethanol - 15 
seconds
10. 95% ethanol - 15 
seconds
11. 100% ethanol - 15 
seconds
12. 100% ethanol - 15 
seconds
13. Xylenes (to ensure 
dehydration of 
th e  section) - 60 
seconds
14. Air-dry for 
approximately 2 
minutes.
Table 6.9 Slide Preparation for LCM
This protocol was adapted from th e  NCI protocols database. The critical issue 
in micro-dissection appears to  be the  elimination of all w ater from the  slides 
th a t are to  be harvested. We only used tissue th a t had been frozen in liquid
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nitrogen. This was then fixed in 100% ethanol following cryosectioning. Myer’s 
haemotoxylin solution (Sigma), in varying concentrations was used for staining, 
along with Eosin Y solution (Sigma). The tissue is now ready for LCM.
The sections w ere then microdissected on an Arcturus LCM using th e  Capsure™ 
lids. DNA was harvested from the  m aterial by overnight digestion with 
proteinase K solution. RNA was collected using the  Picopure™ RNA kit from 
Arcturus, as per th e  m anufacturer’s instructions.
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6.10 Patient Samples
Breast tum our samples used in this study, obtained from patients undergoing 
m astectom ies or lumpectomies, w ere classified as infiltrating ductal 
carcinomas or lobular carcinomas. Adjacent normal parenchyma was obtained 
to  serve as a control. DNA (5 pg) was ex tracted  from a m atched pair of samples 
(36 w ere derived from tum our and 36 from the  ad jacent normal tissue) using 
standard techniques then digested with Msel, 10 U (NEB) for 3-4 h. The 
digested DNA from th e  normal sample was fractionated using an MBD column as 
described. This was followed by washing with 20 ml of buffer containing 1.0 M 
NaCl to  remove any remaining bound DNA. The column was then equilibrated 
by washing with 20 ml of buffer containing 0.1 M NaCl followed by the 
fractionation of samples derived from tum our DNA. Samples eluting from the 
MBD column betw een 0.75 and 0.85 M NaCl w ere precipitated and used in this 
analysis.
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6.11 ICEAMP
6.11.1 Manufacture of HMBD Column
The recom binant, His-tagged MBD (HMBD) from Rattus norvégiens  MeCP2 was 
expressed in Escherichia co li BL21 (DE3)LysS using the  plasmid pET6HMBD, 
kindly donated by Dr. Graham Brock and used previously(Brock, Huang e t al. 
2001) . The HMBD sequence is based on a previous study th a t defined the 
minimal protein fragm ent required to  recognize doulble stranded m ethylated- 
CpG. The poly-His tag does not in terfere  with binding. An overnight culture was 
diluted 100 tim es and incubated a t 37 °C to  A600 = 0.3, before induction with 
isopropyl -thiogalactoside. Cells w ere grown in defined medium enriched with 
4.g.l.-1 glucose and 5g.l.-1 (NH4)2S04. Harvested cells w ere resuspended in 
buffer A (50 mM sodium phosphate (pH 7.0), 50 mM NaCl), combined with five 
volumes of Buffer MA plus 5 M urea (due to  the  protein being expressed in an 
insoluble form), sonicated and pelleted . The supernatant was loaded onto a 
sepharose cation-exchange column and was washed sequentially with Buffer MA 
plus 5 M urea, Buffer MA plus 0.25 M NaCl and 3.75 M urea, and Buffer MA plus 
0.4 M NaCl and 3 M urea. The protein was eluted in Buffer MA plus 1 M NaCl. 
The m aterial was purified further on a nickel-agarose column. The purity of the 
protein was -98 % (as judged by SDS-polyacrylamide gel electrophoresis) and 
the  yield was 10 - 40 mg 1-1 of culture. Prior to using the  HMBD column it was 
washed in lOOmls of BufferA (All operations w ere perform ed a t 4 °C.
6.11.2 DIG Labelling of COT-1 DNA
COT-1 DNA was purchased from Roche, as was the  High Prime DIG labelling Kit. 
COT-1 DNA was used as a tem pla te  for the DIG labelling reaction. Labelling 
was carried out as per the  m anufacturer's instruction.
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In brief 10ug of COT-1 DNA was used as a tem plate, to  which one vial with 20 pi 
5x conc. labeling mixture containing: random hexam er prim er mixture, 1 
un it/p l Klenow enzyme, labeling grade, 1 mM dATP, dCTP, dGTP, each, 0.65 M 
dTTP, 0.35 mM DIG-11-dUTP, alkali-labile 5x reaction buffer with 50% glycerol 
(v/v) was added plus ddH20 to  a final volume of 100ul. The reaction was 
Incubated overnight a t 36oC and stored a t -20oC as per th e  m anufacturer's 
instructions.
6 -11.3 Subtractive Hybridisation
Linker-adaptors (10 mM) LA2.1 5 -TAGTTAACGCGCTGCATGAGTA-3' and LA2.11 
5'-TACTCATGCAGCGCGTTAAC)-3‘ w ere added to  the  driver DNA (-150 ng) along 
with T4 ligase (400 U) and lOx Ugase buffer (NEB) in a to ta l volume of 20 pi, 
then incubated overnight a t 4°C. This was followed by incubation for 30 min a t 
37°C with 1 U of T4 DNA polymerase (NEB) and dNTPs (100 pM). Driver and 
te s te r, mixed in a ratio of 3:1-10:1, w ere cleaned using a Qiagen PCR 
Purification Kit column (Qiagen Ltd, UK) and resuspended in 20 pi of distilled 
H20 with 50 mM HEPES (pH 7.5), 100 mM NaCl, 50 mM EDTA (pH 8) and 0.1% 
w /v SDS, to ta l volume 50 pi, based on a method described previously . 
Following a 5 min incubation a t 95°C th e  solution was held a t 68°C for 48 h, 
placed immediately on ice for 10 min and cleaned using a Qiagen PCR clean-up 
column. After resuspending in 20 pi of Tris-HCl pH 8.0, linker adaptors (20 mM) 
LA2.4 5-TACTTCTTGCGCCAAGACGTT-3' and LA2.44 5'-
AACGTClTGGCGCAAGAAG-3', T4 ligase (800 U) and lOx ligase buffer (NEB) were 
added, to ta l volume 30 pi, followed by overnight incubation a t 4°C. A Qiagen 
column was used to  clean the  mixture, and an aliquot (1 pi) used in a PCR 
reaction with linker LA2.44 as primer.
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6.12 Statistical Methods
Méthylation a t each single locus was correlated with the  clinicopathological 
param eters listed in Table 4-6. Fisher's exact te s t was used to  calculate 
significance of méthylation a t a locus with respect to  ER/PR positivity and 
lymphovascular invasion. The chi-squared te s t for trend was used to  calculate 
significance for NPI, nodal status, grade, tumour and age. Where the  
continuous variables; age, tum our size and NPI w ere concerned a Mann Whitney 
te s t was also perform ed to  te s t for significance. The association betw een 
m éthylation a t d ifferent loci was assessed using Fisher's exact test. 
Méthylation of more than one locus and relationship to  clinicopathological 
variables was assessed using the chi-squared te s t for trend.
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7 Appendices
7.1 Ethics Approval
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7.2 Tumour Database
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78 CDTDPLY (+) 0 .00 1.00 0 .00 0.00 1.00 1.00 X X X X X X
79 CDTDFTA (-) (+) 0 .00 0 .00 0 .00 0.00 0 .00 0 .00  X X X X X X
8 0 CDTDBIG {+) 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00  X X X X X X
81 CDTDBXX (-) (■) {-) X X X X X X X X X X X X
82 CDTD4Y4 (-) (-) (-) X X X X X X X X X X X X
83 CDTD2X2 (-) (-) {-) X X X X X X X X X X X X
84 CDTD7A6 {-) (-) (■) X X X X X X X X X X X X
85  CDTD6JQ (-) (■) (-) X X X X X X X X X X X X
86 CDTD0J6 {-) {-) (') X X X X X X X X X X X X
8 7  CDTDGD {-) (“) (') X X X X X X X X X X X X
88 CDTD1DC {-) (■) (■) X X X X X X X X X X X X
89  CDTDD2C (-) (-) (-) X X X X X X X X X X X X
9 0  CDTD333 (-) (-) (-) X X X X X X X X X X X X
0.00  4 5 .0 0  0 .00  30 .00  15.00 34.00
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0 .00 0.00 1 3.26 GRI 2002 F
1.00 1.00 3 7 .60 GRI 2003 F
0.00 1.00 3 5.58 WIG 2003 F
0.00 0 .00 2 4 .60 WIG 2002 F
1.00 1.00 1 3.50 WIG 2003 F
0.00 0.00 2 4 .20 WIG 2003 F
X X 1 3.44 WIG 2002 F
1.00 1.00 3 6 .80 WIG 2002 F
X X X X GRI 1989 TB
0.00 0 .00 1 3 .60 WIG 2003 F
0 .00 0.00 1 4 .60 GRI 1999 TB
X X X X GRI 1995 TB
0.00 0.00 1 4 .70 WIG 2003 F
0.00 0.00 1 4 .48 WIG 2003 F
X X X X GRI 1999 TB
0.00 0.00 2 5.70 GRI 1989 TB
0.00 0.00 2 5.56 GRI 1992 TB
1.00 1.00 3 6 .52 GRI 1996 TB
0.00 0.00 2 5.92 GRI 1999 TB
X X 1 4 .70 GRI 1997 TB
0.00 0 .00  X X WIG 2003 F
1.00 1.00 2 5.68 GRI 1998 TB
0.00 1.00 2 4 .50 GRI 1998 TB
1.00 1.00 3 5.60 GRI 1998 TB
X X 1 3.34 GRI 1999 TB
X X 2 5.94 GRI 1999 TB
0.00 0 .00 1 4 .80 GRI 1999 TB
0.00 0,00 1 5 .90 GRI 1998 TB
1.00 1.00 3 6 .72 GRI 1998 TB
0.00 0.00 1 4 .52 GRI 1998 TB
0.00 1.00 3 5 .24 GRI 1999 TB
1.00 1.00 2 5.40 GRI 1999 TB
0.00 0.00 2 4 .22 GRI 1999 TB
0.00 0 .00 1 4 .50 GRI 1999 TB
0.00 0.00 1 2 .44 WIG 2003 F
0.00 1.00 3 4 .30 WIG 2003 F
0.00 0.00 1 4 .50 WIG 2003 F
0.00 1.00 2 5.48 WIG 2003 F
0 .00 0.00 2 5.00 WIG 2003 F
0 .00 0.00 2 6 .60 GRI 1998 TB
0 .00 1.00 3 6 .94 GRI 1999 TB
0.00 0.00 1 4 .04 GRI 1999 TB
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0.00 0 .00 2 4 .34 WIG 2002 F
1.00 1.00 3 6.76 WIG 2002 F
1.00 1.00 3 6 .60 WIG 2003 F
0.00 0 .00  X X WIG 2003 F
0.00 1.00 2 3.50 WIG 2003 F
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0.00 0,00 2 4 .90 WIG 2002 F
1.00 1.00 3 4.76 WIG 2002 F
1.00 1.00 3 5.36 WIG 2002 F
X X X X GRI 1993 TB
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0.00 0 .00  X X WIG 2002 F
0.00 0.00 2 3.26 GRI 2002 F
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X X X X GRI 2000 TB
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X X X X GRI 2000 TB
0.00 0 .00 2 4 .60 WIG 2002 F
1,00 1.00 3 6.70 WIG 2002 F
X X X X GRI 1999 TB
X X X X GRI 1999 TB
X X X X GRI 1999 TB
0.00 0.00 3 6 .60 GRI 2000 TB
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X X X X GRI 1989 TB
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X X X X GRI 1984 TB
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GRI
WIG
55
35
F
TB
39
51
lO•o
I
Tumour could not be linked back to  a patient.  
Tumour could not be linked back to  a patient.
ER and PR immuno not reported.
0
(U(8
1o
3OE
H
CDTDSS2
CDTDRP4
CDTDH19
CDTDB03
CDTDP30
CDTDGG1
CDTDRS40
CDTDA64
CDTDB66
CDTD101
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CDTDQ11
CDTDLH8
CDTDL09
CDTDBS1
CDTDE10
CDTDHG5
CDTDAA1
CDTDFR2
CDTDRF3
CDTDBB8
CDTDJKL
CDTDNQ2
CDTDQWE
CDTDHD1
Axillary clearance not carried out
No clinical details w ere  entered  in the tumour database.
No clinical details w ere  entered  in the tumour database.  
No clinical details w ere  entered  in th e  tumour database.  
No clinical details w ere  entered  in th e  tumour database.  
No clinical details w ere  entered  in th e  tumour database.
Age only entered in the tumour database
No clinical details w ere entered  in th e  tumour database.
Grade, size and age only entered  in database.
Age only entered  in the tumour database  
Age only entered  in the tumour database
Axillary clearance not carried out  
No clinical details w ere  entered  in th e  tumour database.  
No clinical details w ere  entered  in the tumour database.  
No clinical details w ere entered  in th e  tumour database.  
DNA degraded during storeage.
DNA degraded during storeage.
DNA degraded during storeage.
DNA degraded during storeage.
CDTDLOQ
CDTDJD1
CDTDFRD
CDTD6MH
CDTDB04
CDTDG41
CDTD4FT
CDTDBB7
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CDTDNL2
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CDTDTT2
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CDTD42Y
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CDTDPLY
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CDTD4Y4
CDTD2X2
CDTD7A6
DNA degraded during storeage. CDTD6JQ
DNA degraded during storeage. CDTD0J6
DNA degraded during storeage.  CDTDCID
DNA degraded during storeage. CDTD1DC
DNA degraded during storeage.  CDTDD2C
DNA degraded during storeage.  CDTD333
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